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1.1. Duchenne Muscular Dystrophy  
 
1.1.1. Clinical phenotype 
 
Edward Meryon, an English physician, was the first to publish on an inherited disorder we now 
refer to as Duchenne muscular dystrophy (DMD). In 1852, he described the clinical 
manifestations of eight affected boys from three families in great detail (Meryon 1852). At the 
time, Meryon already observed that the progressive muscle wasting and weakness was restricted 
to muscle and did not affect the nervous system. The disorder was later named after Guillaume 
Benjamin Amand Duchenne who was the first to study DMD patient biopsies (Duchenne 1868). 
Muscle fibers of DMD patients are vulnerable to exercised-induced damage and despite 
efforts to regenerate, muscle mass is gradually lost resulting in progressive muscle weakness. In 
DMD patients, the first symptoms become apparent between the age of two and five years and 
consist of pseudohypertrophy of the calf muscles and difficulties in running, jumping and 
climbing stairs. Eventually, patients lose muscle coordination, have difficulties walking and rise 
from the ground by using their arms to climb up their body, which is known as Gower’s sign 
(Gowers 1879). Early in the second decade, patients become wheelchair dependent due to loss of 
strength in the lower limb muscles. Subsequently, progressive weakness of the shoulder girdle 
and arms results in loss of function in all extremities (Blake et al. 2002).  
 Also the heart is affected in more than 90% of the DMD patients. Cardiac involvement 
is already found in 25% of patients under the age of six. This is recognizable by minor 
electrocardiographic (ECG) and echocardiographic signs, in the absence of symptoms. Clinical 
cardiomyopathy is observed from the age of 10 onwards and is first characterized by myocardial 
hypertrophy in which the interventricular septum is thickened followed by dysrhythmias. 
Infiltration of fibrotic tissue starts at the left ventricular wall and progressively spreads 
throughout both ventricles. It eventually results in cardiomyopathy in which chambers are 
dilated and ventricles have poor contractility resulting in a decreased ejection fraction. The left 
ventricular posterobasal and lateral walls are predominantly affected (Finsterer and Stollberger 
2003).  
Patients also develop thoracolumbar scoliosis, for which they can undergo spinal 
stabilisation surgery (Eagle et al. 2007;Kohler et al. 2005). This deformity of the spinal cord is 
thought to result from asymmetric weakening of the muscles that support the spinal column (Oda 
et al. 1993). In the late teens, they develop respiratory impairment and need assisted ventilation 
first primarily at night, but in more advanced stages in a chronic manner (Lo Mauro et al. 2010). 
With smooth muscles being affected as well, DMD patients often suffer from bloating, feeling of 
fullness and constipation (Borrelli et al. 2005). Also cases of acute gastric dilatation and intestinal 
pseudo-obstruction have been reported. As a consequence of their immobility, body composition 
is altered with a low bone mineral density, lower lean tissue and higher fat mass compared to 
healthy age-matched boys. At the age of 13, 44-54% of DMD patients become obese, but the same 
percentage of boys is underfed when they are 18 years old, primarily resulting from swallowing 
difficulties (Martigne et al. 2011).  
The function of the retina is affected as well. Especially boys that lack the dystrophin 
isoform Dp260 (see below) often have difficulties in red-green discrimination (Pillers et al. 
1999;Costa et al. 2007). The average IQ is one standard deviation below the mean and 20% of the 
patients have an IQ of less than 70. Learning disabilities, involving dyslexia and dyscalculia are 
common. However these non-muscle related symptoms are not of a progressive nature (Billard et 




Although improved health care has increased the life expectancy in the Western world, 
most DMD patients die in their third or fourth decade due to heart or respiratory problems (Eagle 
et al. 2007).  
 
1.1.2. The DMD gene and dystrophin  
 
With an incidence of 1 in 3500 newborn boys, DMD is the most common inherited 
neuromuscular disorder. It is caused by mutations in the DMD gene which is located on the short 
arm of the X-chromosome (Xp21). It is the biggest known human gene (2.4 Mb) and is also 
extremely large in other organisms like the mouse, zebra fish and drosophila. The majority of the 
gene consists of intronic regions, since the coding sequence, ~14 kb spread over 79 exons, only 
accounts for 0.6% in man (Koenig et al. 1987;Muntoni et al. 2003;Roberts et al. 1993).  
 
 
Figure 1. Schematic overview of the different dystrophin isoforms. 
A. Five different promoters spread throughout the DMD gene ensure transcription of seven dystrophin isoforms; 
three full-length and four shorter proteins. B. Full-length dystrophin is composed of an actin-binding domain, four 
hinge sites (H1-4), a central rod domain, a WW domain, a cysteine-rich domain (consisting of 15 cysteines, two EF 
hand motifs and a ZZ domain) and a C-terminal domain (consisting of two coiled coil-domains). None of the smaller 
isoforms contains the N-terminal actin-binding domain and most lack great parts of the central rod domain. Dp71 
even lacks the central rod domain entirely (Figure is based on Willmann et al. NMD 2009).  
 
The DMD gene codes for the protein dystrophin of which different isoforms are expressed in 
several tissues. The isoforms originate from seven promoters spread along the gene (Figure 1). 
Full-length dystrophin is synthesized from three promoters located before the common exon 2. 
The isoforms are named after the molecular weight of the protein and the tissue of origin. The 
Dp427m isoform is synthesized in skeletal and cardiac muscle (Gorecki et al. 1992;Muntoni et al. 
2003). The cortical neurons and the hippocampus of the brain synthesize Dp427c, while Dp427p 
is found in cerebellar Purkinje cells and in lower levels in skeletal muscle. Full-length 427m 
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dystrophin consists of 3685 amino acids. It takes approximately 12 hours to transcribe 1,770 kb, 
extrapolating to a transcription time of ~16 hours for the entire gene (Tennyson et al. 1995). It is 
expressed in very low levels in muscle (0.002% of total muscle protein). Full-length dystrophin 
contains four domains (Koenig et al. 1988). The N-terminal actin-binding domain is the first 
distinctive domain. This domain contains two actin-binding sites and facilitates binding of 
dystrophin to filamentous actin (F-actin) in the subsarcolemmal cytoskeleton. This domain is 
followed by the central rod domain which consists of 24 triple-helical repeats making it the 
largest domain. These repeats are interspersed by 4 proline-rich hinge regions (H1-4) (Koenig and 
Kunkel 1990). The rod domain provides flexibility and elasticity to the protein.  
An additional actin-binding domain is located between repeat unit 11-17 (Rybakova et 
al. 1996) and a neuronal nitric oxide synthase (nNOS) binding domain is present in repeat unit 
16-17 (Lai et al. 2009).  
      
 
 
Figure 2. Dystrophin-glycoprotein complex in skeletal muscle. 
Dystrophin binds with the N-terminus to the F-actin skeleton of the cell and with the C-terminus to the DGC which 
is linked to the extracellular matrix. The DGC consists of multiple proteins. Several muscular disorders are caused by 
the absence of some of these proteins.  
 
The last two domains are the cysteine-rich domain, which includes 15 cysteines, two EF hand 
motifs and a ZZ domain, and the C-terminal domain that consists of two stretches that form X-
helical coiled coil-domains (Koenig et al. 1988). The cysteine-rich domain promotes binding to 
and localization of the dystrophin-glycoprotein complex (DGC) and contains the domain that 
binds to β-dystroglycan. 
Internal promoters allow the production of four smaller isoforms called Dp260 (retina), 
Dp140 (brain, kidney, blood vessels and retina), Dp116 (Schwann cells of the peripheral nerves) 
and Dp71 (most non-muscle tissues). Those proteins lack the actin-binding domain and part of 




the N-terminus binds the intracellular F-actin of the cytoskeleton while the C-terminus connects 
with the transmembranal DGC that is in turn connected to the extracellular matrix (ECM) 
(Figure 2). In this way, dystrophin provides stability to muscle fibers during contractions, but it 
also plays a role in cell signaling. The DGC is a large protein complex that contains, amongst 
others, sarcoglycans, sarcospan, dystroglycans, syntrophins and dystrobrevins (Ehmsen et al. 
2002). Various muscle disorders have been linked to the absence of some of these proteins, where 
the absence of sarcoglycans or the improper glycosylation of dystroglycans result in various types 
of Limb girdle muscular dystrophy (Sciandra et al. 2003;Muntoni et al. 2008). In the absence of 
dystrophin, expression of these proteins is largely reduced and localization at the sarcolemma is 
lost.  
 
1.1.2.1. The UTRN gene and utrophin 
In addition to the dystrophin isoforms, also three dystrophin homologues have been described. 
These share homology with large proportions of dystrophin and are called utrophin (first referred 
to as dystrophin related protein 1), dystrophin related protein 2 and dystrobrevin. Utrophin is 
most similar to dystrophin and is the most relevant homologue for the DMD field (Love et al. 
1989b). It is transcribed from the UTRN gene (0.9Mb) located on chromosome 6 and contains 74 
exons. The full length protein is 395kDa and consists of an N-terminal actin-binding domain, a 
central rod domain, a cysteine-rich and C-terminal domain (Figure 3). Compared to dystrophin, 
utrophin lacks repeat units 15 and 19 and hinge regions 1 and 3 (Blake et al. 2002;Winder et al. 
1995).  
 
Figure 3. Utrophin isoforms.  
A. Representation of the UTRN gene with two different promoters giving rise to full-length utrophin  A and B, 
which are expressed at the neuromuscular junction and in vascular endothelial cells respectively. Downstream of the 
gene, three additional promoters synthesize shorter isoforms. B. Schematic representation of full-length utrophin and 
the three shorter isoforms. The protein structure of full-length utrophin is largely identical to that of dystrophin 
(Figure design is based on Willmann et al. NMD 2009). 
 
Full-length utrophin is transcribed from two independent promoters; Utrn-A and Utrn-B, 
resulting in distinct proteins that differ at the initial 5’ ends and in localization as utrophin A is 
expressed at the neuromuscular junction (NMJ) while utrophin B is expressed at the vascular 
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endothelium. Like dystrophin, utrophin also has three shorter isoforms; Up140, Up113 (G 
utrophin) and Up71 (Perronnet and Vaillend 2010;Burton et al. 1999;Dennis et al. 1996;Wilson et 
al. 1999). Similar to how dystrophin links actin to the DGC complex in muscles, utrophin links 
actin to a DGC-like complex present at the synaptic membrane, which contains agrin, rapsin and 
acetylcholine receptors (AChRs) in addition to proteins found in the DGC complex found for 
dystrophin (Figure 4) (Apel et al. 1995;Haenggi and Fritschy 2006). The expression of utrophin 
and dystrophin at the synaptic membrane does not overlap. 
 
 
Figure 4. Utrophin-glycoprotein complex at the synaptic membrane. 
Utrophin binds with the N-terminus to the F-actin skeleton and with the C-terminus to the DGC. The composition 
of the synaptic DGC is slightly different from that found at the muscular sarcolemma, e.g. at the synapse, laminin α4 
and 5, syntrophin β1 and 2 are expressed whereas laminin α2 and syntrophin α1 and β1 are found at the muscular 
sarcolemma. Also additional proteins like agrin, rapsyn and the acetylcholine receptors are present at the synaptic 
membrane. 
 
In heart, utrophin is localized at intercalated discs and microvasculature smooth muscle 
(Hainsey et al. 2003). During development, in both healthy and DMD foetuses, utrophin A is 
expressed in developing and regenerating muscle fibers along the entire sarcolemma. In maturing 
fibers, it is replaced by dystrophin at the sarcolemma and is then solely expressed at the NMJ 
where it colocalizes with AChRs. It participates in postsynaptic membrane maintenance and 
AChR clustering (Nguyen et al. 1991;Clerk et al. 1993). In DMD patients and the mdx mouse 
however, overexpression of utrophin A is observed at the sarcolemma in mature muscle fibers 
compensating for the absence of dystrophin. Although this, to some extent, partially rescues the 
dystrophic phenotype in mice, overexpression is too low to prevent muscle degeneration in DMD 
patients. However, the degree in which utrophin is expressed, correlates with disease severity 
(Kleopa et al. 2006). Mice that lack utrophin (utrn -/-) but express dystrophin appear healthy and 





1.1.3. Muscle pathology 
 
In DMD patients, the absence of functional dystrophin leads to a series of events, which finally 
result in replacement of muscle fibers by fibrotic and fat tissue. The exact cause of initiation of 
this pathological cascade is not fully understood, but several hypotheses have been proposed to 
explain why the absence of dystrophin results in vulnerable fibers and degeneration (Figure 5).  
As mentioned before, dystrophin links the actin filaments to the DGC, maintains fiber 
integrity during eccentric contractions and plays a role in signaling. In the absence of dystrophin, 
muscle contractions result in disruptions of the membrane and thereby increased membrane 
permeability. The presence of these membrane tears is evident by elevated serum creatine kinase 
(CK) levels. CK is an enzyme that catalyses the conversion of creatine into phosphocreatine 
turning adenosine triphosphate (ATP) into adenosine diphosphate (ADP). Muscles consume ATP 
in large amounts and CK is mainly found in this tissue. Upon fiber damage, CK leaks through 
tears in the membrane into the bloodstream resulting in very high levels of 20,000 to 50,000 U/L 
(normal human values <200 U/L) (Emery and Muntoni 2003). This process is known to be 
exacerbated by exercise. Even in healthy individuals, CK levels are elevated after a bout of 
strenuous exercise as a consequence of membrane disruptions.  
Through the same membrane tears from which CK leaks out of the fibers, extracellular 
Ca2+ passively enters. In addition, Ca2+ enters the fibers actively through mechanosensitive 
stretch-activated (SAC) channels. DMD patients have increased numbers of SAC channels and 
they are also more active than those in healthy individuals. The increased Ca2+ level causes a 
disruption of the intracellular Ca2+ homeostasis (Allen et al. 2010;Deconinck and Dan 2007). The 
Ca2+ also activates proteases like calpain, which degrade a wide range of skeletal muscle proteins, 
causing more membrane damage and also activate the SAC channels further, enabling more Ca2+ 
to enter and thereby creating a feedback loop of Ca2+ entering the fiber, eventually resulting in 
fiber death. To some extent, excessive intracellular Ca2+ will be taken up by mitochondria (Blake 
et al. 2002;Chen et al. 2000). However, due to the chronic nature of the disease, mitochondria get 
structurally damaged, inducing the downregulation of several important genes. This results in 
malfunction of mitochondria, leading to impaired oxidative phosphorylation and thereby a loss of 
energy. In addition, damaged mitochondria cause reactive oxygen species (ROS), produced by 
inflammatory cells like neutrophils and macrophages (Whitehead et al. 2006). ROS promote 
activation of transcription factor nuclear factor NF-κB, which regulates the expression of pro-
inflammatory cytokines like TNF-α and Interleukine (IL)-1B. NF-κB itself inhibits muscle cell 
differentiation and thus the regeneration process. ROS levels are further increased via a positive 
feedback loop in which TNF-α exacerbates inflammation. The elevated ROS levels can be 
scavenged by nitric oxide (NO). NO is formed by nNOS and functions as an endogenous 
messenger molecule and induces vaso-dilatation. In healthy individuals nNOS is recruited to the 
membrane by dystrophin. In DMD patients, the absence of dystrophin results in de-localization 
of nNOS, forcing it to freely float in the cytoplasm (Lai et al. 2009). Since nNOS levels are 
decreased in DMD patients, NO levels are also largely reduced which disallows fibers to decrease 
ROS levels and thereby exacerbates continuous fiber damage by ROS.  
The pathological cascade initiated by disrupted calcium homeostasis eventually results 
in fiber necrosis, which induces a chronic inflammatory response that triggers fibrosis. The 
immune response consists of numerous components including leukocyte adhesion, chemokine 
signaling, diapedesis, invasive cell type specific markers and complement system activation. The 
inflammatory cells produce cytokines and other toxins that further damage the muscle fibers. 




Figure 5. Schematic overview of pathogenesis in skeletal muscles of DMD patients.  
In absence of dystrophin an extensive cascade of pathological events is chronically triggered that eventually results in 
the replacement of muscle fibers by connective and fat tissue leading to loss of muscle function.   
 
Blood vessel abnormalities, including impaired vasodilatation resulting from low NO levels, have 
been reported in DMD patients. Especially during exercise, when the need of oxygen is higher, 
muscle ischemia may occur (Miike et al. 1987;Saito et al. 2005;Sander et al. 2000). In skeletal 
muscle, degenerated fibers are replaced through regeneration. This does not occur in heart as 




Regenerated fibers are characterized by central nucleation which originates from the 
differentiation and fusion process of myoblasts into myotubes. Additionally, to compensate for 
the loss of force-generating capacity, muscles increase in mass by undergoing hypertrophy 
(Karpati et al. 1988;Narita and Yorifuji 1999). Upon exhaustion of the regenerative capacity, fibers 
are gradually replaced by connective and adipose tissue. With decreased numbers of muscle fibers 
from which CK leaks out, serum CK levels drop. The described pathological hallmarks are clearly 
visible in DMD patient biopsies, which contain groups of necrotic or degenerated fibers, fibrotic 
and fatty tissue.  
Although muscle sections of DMD patients are essentially dystrophin negative, in about 
50% of patients ~1-10% of the fibers express some dystrophin. Those so-called ‘revertant’ fibers 
express dystrophins that can lack up to 30 exons of the rod-domain in mice. Revertant fibers 
originate most probably from secondary mutations which re-frame the transcript enabling 
synthesis of truncated but functional dystrophin (somatic reversion). It is hypothesized that this 
happens in a specific subset of myogenic stem cells that proliferate in response to degeneration. 
Revertant fibers are most often found in small clusters and have the same deletion within a 
cluster, while this often differs per cluster. This indicates that fibers within a cluster inherit the 
secondary mutation from the same myogenic stem cells (Hoffman et al. 1990;Thanh et al. 
1995;Klein et al. 1992). 
The degree in which individual skeletal muscles and the heart are affected differs. Some 
muscles like the diaphragm are severely affected, while others like the soleus are partly spared. 
Extraocular muscles even appear to entirely escape from the pathological events. Also the order in 
which muscles are affected and fibrosis and fatty tissue infiltrations are observed is chronological 
(Torriani et al. 2011;Marden et al. 2005). The exact cause(s) for both phenomena are unclear, 
however several hypotheses exists. Most often, severely affected muscles are the ones that are 
constantly used and therefore undergo more stress than those which are rarely used. As exercise 
exacerbates disruption of the intracellular Ca2+ homeostasis this might underlie differences in 
severity. However, although the soleus is often used during movements, it is largely protected 
from pathology. It has been hypothesized that this muscle is spared until late in the disease 
because it mainly consists of slow muscle fibers.  
Individual fibers contain functionally distinct isoforms of myosin heavy chain (MyHC) 
(Gregorevic et al. 2008). Based on the different MyHC isoforms, several fiber types have been 
identified, which differ in their functional properties. There are two types of muscle fibers. Slow 
twitch (type I) fibers are efficient at using oxygen (aerobic) and therefore stand muscle 
contraction over a long time. Fast twitch (type II) fibers use glycogen (anaerobic) and are better at 
generating short bursts of strength than slow muscles, however they fatigue quicker. Type II 
fibers can be further grouped into type IIa, IIb and IId/x fibers (Schiaffino et al. 1989). Type IIa 
fibers are intermediate fast twitch fibers that can use both an aerobic and anaerobic metabolism 
for energy supply, making them more a combination of type I and II fibers. Type IIb and IId/x 
fibers only use an anaerobic metabolism. Type II fibers have a larger diameter than type I fibers 
and are subjected to the greatest mechanical stress during muscle contraction. Most often muscles 
containing primarily fast fibers are more vulnerable to mechanical damage and earlier affected 
than muscles that mainly consist of slow fibers (Table 1). Muscles can primarily consist of slow or 
fast fibers or of a mixture of both types. Depending on the demand of muscles, fiber type 
compositions can change over time, which happens in a distinct order: type IIb → type IId/x → 
type IIa → type I. Exercise-induced fiber type switches have been described in mice, as well as 
differences in composition between mouse strains that differed in disease severity.  
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Muscle Fiber type composition Severity pathology 
Quadriceps Mixed Moderate 
Gastrocnemius Mixed Moderate 
Tibialis anterior Fast Moderate 
Soleus Slow Mild 
EDL Fast Moderate 
Triceps Mixed Moderate 
Biceps Mixed Moderate 
Diaphragm Fast Severe 
 
Table 1. Overview of fiber type composition and the degree of histopathology. 
The table is based on several studies in mdx mice of which fiber type composition of several muscles was determined. 
Fiber types and the timing of onset of pathological symptoms closely correlate, however multiple other factors play a 
role as well (Table is adapted from Willmann et al NMD 2012). 
 
In healthy muscle, individual fibers express only one MyHC isoform. Expression of multiple 
different MyHC isoforms is found in dystrophin negative fibers (Willmann et al. 2011;Emery and 
Muntoni 2003;Johnson et al. 1973;Webster et al. 1988).  
However, fiber type composition is not the only factor that influences the order of 
initiation of muscle pathology (Emery and Muntoni 2003). Other factors are the number of SAC 
channels per muscles, differences in regeneration capacity, muscle fiber diameter and length, 
mitochondrial content, growth rate during development and expression levels of utrophin and 
members of the DGC (Lewis and Ohlendieck 2010;Porter 1998;Grounds and Shavlakadze 2011). 
Differences in embryonic origin might play a role as well as muscles derived from the somatic 
mesoderm are more severely affected than those derived from the paraxial mesoderm. It has also 
been speculated that some muscles have improved ability to regulate Ca2+ homeostasis and that 
they possess mechanical properties that make them more resistant to damage (Khurana et al. 
1995;Wiesen et al. 2007). For example the functional properties of extraocular muscles are more 
advanced as they display faster peak contraction rates, higher fatigue resistance profiles and have 
smaller motor units which are less prone to damage (Thomas et al. 2008).  
 
1.1.4. Antisense-mediated exon skipping 
 
In order to synthesize dystrophin protein, a pre-mRNA transcript is generated from the DMD 
gene. During splicing, all introns are spliced out and exons joined so that mRNA is formed. This 
mRNA is used as a template for protein synthesis, where every three consecutive nucleotides 
contain the information for one amino acid. DMD patients have mutations that disrupt the 
reading frame, e.g. a deletion of an exon that contains a number of base pairs that is not divisible 
by three. This leads to a shift in the reading frame, inclusion of aberrant amino acids and 
generally a premature stop codon (UAA, UGA or UAG) and untimely truncation of protein 
translation. Since dystrophin forms a flexible bridge-like connection between the intracellular F-
actin filaments and the ECM, and only one bridge-head remains in DMD patients, this function is 
lost, resulting in the previously described pathogenesis.  
 Mutations that maintain the reading frame in the DMD gene lead to Becker muscular 
dystrophy (BMD) which affects 1:20,000 men (section 1.3.2). In these patients, a shorter, 
internally deleted, but partly functional protein is synthesized. The bridge-like connection is 




are expressed to some extent. These fibers are supposed to be less vulnerable to exercise-induced 
damage which leads to a less pronounced pathology and better life expectancy. Some of these 
patients even lack over two thirds of the central rod domain, indicating that large parts of this 
domain can be missed (England et al. 1990;Love et al. 1989a).  
 
1.1.4.1. The concept of exon skipping 
With no causal treatment available for DMD, effort has been put into attempting to restore the 
disrupted reading frame (Aartsma-Rus 2010). With the use of antisense oligonucleotides (AONs), 
which are modified, small pieces of DNA or RNA (~6-8 kDa), signals that are required for 
inclusion of an exon can be hided from the splicing machinery, so that this exon and its flanking 
introns are spliced out during pre-mRNA splicing. In this way, the reading frame is restored and 
internally deleted BMD-like dystrophin proteins are synthesized. As shown in the example of 
Figure 6, a deletion of exon 52 disrupts the reading frame and causes protein synthesis to stop 
prematurely. With AONs directed to exon 51, this exon will be skipped, thereby restoring the 
reading frame enabling the synthesis of a BMD like dystrophin protein. 
 
Figure 6. Antisensense oligonucleotide mediated exon 51 skipping.  
A. In DMD out-of-frame deletions lead to premature stop codons and truncated, non-functional dystrophins.  
B. Using AONs, an exon can be hidden from the splicing machinery, restoring the open reading frame and allowing 
the production of internally deleted, partly functional dystrophins. The synthesized protein has an unnatural 
transition (represented by the grey bar) resulting from the lack of the skipped exon (From van Putten et al. Expert 
Opin. Biol. Ther.). 
 
Mutations found in DMD patients can occur anywhere across the entire gene, but a 
major hotspot is present between exon 45 and 53 (den Dunnen et al. 1989). Exon skipping is a 
mutation specific approach, as for different mutations different exons have to be skipped to 
restore the reading frame. However, skipping of some exons benefits larger groups of patients 
with different mutations. Exon skipping can be applied to all reading frame disrupting exons of 
the central rod domain and theoretically might benefit over 90% of the DMD patients. Only a 
small proportion of all mutations (5-10%) cannot be addressed with this approach. These consist 
of mutations in the two outer exons; 1 and 79 as these exons cannot be skipped, and mutations 
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that also result in DMD while they maintain the open reading frame, e.g. mutations that remove 
either all actin-binding domains or the cysteine-rich domain (Aartsma-Rus et al. 2009). 
In the majority (65%) of DMD patients one or more exons are deleted. Here, often skipping one 
or two flanking exons corrects the reading frame. Skipping two exons, so-called double exon 
skipping, is feasible by using a combination (cocktail) of AONs targeting the two exons. In vitro 
transfection of patient-derived cell cultures using an AON cocktail to induce double exon 
skipping results in only slightly lower amounts of dystrophin expressing cells compared to single 
exon skipping (Aartsma-Rus et al. 2004a).  
 
Figure 7. Overview of the exons of the DMD gene.  
Light grey bars represent in-frame exons, which can be deleted without disrupting the reading frame. Black exons 
represent out-of-frame exons and deletions of these exons disrupt the reading frame resulting in DMD. For these 
exons one or multiple neighbouring exons need to be skipped to restore the reading frame. (Based on Aartsma-Rus et 
al. Hum. Mut 2008 used with kind permission of John Wiley and Sons).  
 
 Small mutations (nonsense mutations, small deletions or insertions and splice site 
mutations) are found in 28% of the patients. For these patients the reading frame can generally be 
corrected by only skipping the mutated exon when this is an in-frame exon, or together with an 
adjacent exon in case of an out-of-frame exon (Figure 7). Duplications, found in 7% of the 
patients, are more challenging to address with exon skipping (Aartsma-Rus et al. 2007). AONs are 
sequence specific and cannot distinguish between the original and duplicated exon as they both 
contain the same sequence. In case of single exon duplications either that exon or the original 
exon can be skipped to restore the reading frame. However, when skipping efficiency it too high 
(i.e. close to 100%), both the original and duplicated exon are skipped, which is reading frame 
disrupting. By skipping an additional exon in addition to the duplication this can sometimes be 
remedied. The duplication of exon 2 is the most common and makes up 12.7% of all duplications. 
When the duplication consists of multiple exons, exon skipping becomes very complex and 
restoration of the reading frame has not been feasible to date for these mutations. Based on data of 
the Leiden Open Variation Database, it is known that the largest group of patient (13%) would 
benefit from exon 51 skipping. Therefore skipping this exon is the current focus of clinical 
development (Aartsma-Rus et al. 2009). As shown in Table 2, 41% of the patients will benefit 















1 51 13.0% 19.1% 0.3% 3.0% 
2 45 8.1% 11.8% 0.2% 2.2% 
3 53 7.7% 11.4% 0.1% 1.5% 
4 44 6.2% 8.8% 0.4% 2.7% 
5 46 4.3% 6.2% 0.2% 1.6% 
6 52 4.1% 5.7% 0.5% 2.3% 
7 50 4.0% 5.6% 0.2% 1.9% 
8 43 3.8% 5.3% 0.2% 2.6% 
9 6 and 7 3.0% 3.6% 0.1% 6.3% 
10 8 2.3% 2.3%  8.0% 
11 55 2.0% 2.7% 0.8% 0.2% 
12 2 1.9% 1.3%  12.7% 
13 69 and 70 1.4%  5.6%  
14 19 and 20 1.1%  4.6%  
15 45 and 51 1.1% 1.7%   
16 58 and 59 1.1%  4.5%  
17 17 1.0% 1.1% 0.1% 3.1% 
18 7 1.0% 1.4%  0.8% 
19 65 and 66 1.0%  3.9%  
20 43 and 44 0.9%  3.5%  
21 12 0.8% 1.0% 0.3% 1.4% 
22 23 0.8%  3.1%  
23 18 0.9% 1.0% 0.1% 2.5% 
24 20 0.8% 1.0% 0.2% 1.2% 
25 21 0.8% 0.5% 1.2% 1.6% 
26 17 and 18 0.8%  3.1%  
27 11 and 12 0.7%  2.9%  
28 68 and 69 0.7%  2.9%  
29 19 0.6% 0.5% 0.4% 1.8% 
30 22 0.6% 0.6% 0.1% 1.8% 
31 45 and 53 0.6% 0.9%   
32 41 0.6%  2.3%  
33 14 0.6%  2.2%  
34 54 and 55 0.6%  2.2%  
35 20 and 21 0.5%  2.1%  
36 35 0.5%  2.1%  
37 54 0.5% 0.6%  1.0% 
38 24 0.5%  2.0%  
39 40 0.5%  2.0%  
40 34 0.4%  1.8%  
41 56 0.4% 0.6%  0.5% 
42 11 0.4% 0.3% 0.2% 2.3% 
43 16 0.4%  1.7%  
44 39 0.4%  1.7%  
45 62 and 63 0.4%  1.5%  
46 64 0.4%  1.6%  
47 7 and 8 0.4% 0.4% 0.5% 0.2% 
48 26 0.4%  1.5%  
49 10 0.4%  1.4%  
50 51 and 52 0.4%  1.4%  
51 6 0.4% 0.3%  1.6% 
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52 52 and 53 0.3%  1.4%  
53 74 0.3%  1.4%  
54 3 0.3%  1.2% 0.5% 
55 13 0.3%  1.3%  
56 21 and 22 0.3%  1.3%  
57 32 0.3%  1.3%  
58 48 0.3%  1.3%  
59 55 and 56 0.3%  1.3%  
60 69 0.3%  1.3%  
61 30 0.3%  1.3%  
62 44 and 45 0.3%  1.3%  
63 47 0.3%  1.1% 0.3% 
64 25 0.3%  1.1%  
65 60 0.3%  1.0% 0.3% 
66 75 and 76 0.3%  1.2%  
67 5 0.3%  1.0%  
68 27 0.3%  1.0%  
69 50 and 51 0.3%  1.0%  
70 50 and 55 0.3% 0.4%   
71 56 and 57 0.3%  1.0%  
72 57 0.3% 0.2% 0.2% 0.9% 
73 28 0.2%  1.0%  
74 4 0.2%  0.9%  
75 29 0.2%  0.9%  
76 38 0.2%  0.7% 0.5% 
77 52 and 55 0.2% 0.3%   
78 33 0.2%  0.8%  
79 36 0.2%  0.8%  
80 37 0.2%  0.8%  
81 68 0.2%  0.7%  
82 70 0.2%  0.7%  
83 9 0.2%  0.7%  
84 61 0.2% 0.03%  1.6% 
85 15 0.2%    
86 43 and 53 0.2% 0.2%   
87 63 0.1% 0.1% 0.3% 0.2% 
88 43 and 51 0.1% 0.2%   
89 59 and 60 0.1% 0.2%   
90 65 0.1%  0.5%  
91 66 0.1% 0.03% 0.4%  
92 6 and 8 0.1% 0.1% 0.2%  
93 45 and 46 0.1%  0.4%  
94 58 0.1% 0.1% 0.1% 0.5% 
95 61 and 62 0.1%   1.1% 
96 2 and 11 0.1%   0.9% 
97 8 and 11 0.1%   0.9% 
98 31 0.1%  0.3%  
99 62 0.1% 0.03% 0.2% 0.3% 
100 2 and 7 0.1% 0.1%   
101 68 and 69 0.1% 0.1%   













103 17 and 22 0.04% 0.1%   
104 42 0.04%  0.2%  
105 53 and 54 0.04% 0.03%  0.2% 
106 57 and 58 0.04% 0.1%   
107 59 0.04% 0.03% 0.1%  
108 59 and 63 0.04% 0.1%   
109 67 0.04%   0.5% 
110 73 0.04%  0.2%  
111 2 and 6 0.02%   0.2% 
112 2 and 17 0.02%   0.2% 
113 8 and 17 0.02%   0.2% 
114 11 and 22 0.02% 0.03%   
115 17 and 20 0.02% 0.03%   
116 18 and 46 0.02%   0.2% 
117 21 and 44 0.02% 0.03%   
118 22 and 43 0.02%   0.2% 
119 44 and 52 0.02%   0.2% 
120 46 and 52 0.02%   0.2% 
121 49 0.02%  0.1%  
122 52 and 57 0.02% 0.03%   
123 58 and 62 0.02%   0.2% 
124 62 and 68 0.02% 0.03%   
125 66 and 68 0.02%  0.1%  
126 71 0.02%  0.1%  
127 72 0.02%  0.1%  
128 75 0.02% 0.03%   
129 77 0.02%  0.1%  
130 78 0.02%   0.2% 
 
Table 2. Applicability of the exon skip approach.  
This table gives an overview of the proportions of patients that benefit from single or double exon skipping (From 
Aartsma-Rus et al. Hum. Mut 2008, reprinted with kind permission of John Wiley and Sons). 
 
 Several different AON chemistries are available to induce exon skipping, but only the 
2’O-methyl phosphorothioate (2OMePS) and phosphorodiamidate morpholino oligomers (PMO) 
have so far been tested in clinical trials for DMD. These specific chemistries are favoured above 
others for their specificity and good safety profile in humans. The structure of 2OMePS AONs is 
similar to that of RNA, but contains two modifications. Instead of the non-bridging oxygen atom 
found in RNA, 2OMePS AONs contain a sulphur (atom) in the phosphate backbone, thereby 
forming a phosphorothioate (PS) backbone. This enhances stability by inhibiting breakdown by 
endo- and exonucleases. The PS backbone also facilitates low affinity binding to serum proteins, 
thereby preventing rapid clearance by liver and kidney upon systemic injection. This leads to a 
relatively long serum half-life of approximately 29 days (Goemans et al. 2011). The second 
modification consists of a methyl group at the 2’-OH position of the ribose sugar which renders 
2OMePS AONs resistant against RNase-H mediated knockdown, and also results in higher 
affinity to the target RNA (Aartsma-Rus et al. 2004b).  
PMOs contain six-membered morpholine rings that are connected through 
phosphorodiamidate linkages (Summerton and Weller 1997). They have a non-ionic backbone at 
physiological pH, which minimizes protein interactions and non-specific antisense effects, and 
increases binding capacity to mRNA. Unfortunately, their uncharged nature makes them hard to 
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transfect in tissue culture and results in a short half-life of ~1.6-3.6 hours upon systemic injection 
as they are rapidly filtered out by the kidney (Amantana and Iversen 2005;Cirak et al. 2011).  
The first in vitro proof of concept studies were performed with 2OMePS AONs on patient-
derived cell cultures carrying a variety of different mutations throughout the DMD gene. AON 
transfections resulted in the skip of the targeted exon, subsequent restoration of the reading frame 
and synthesis of dystrophin (Takeshima et al. 2001;van Deutekom et al. 2001;Aartsma-Rus et al. 
2003). Both chemistries have also been locally administered in the mdx mouse where a skip of 
exon 23 restores the murine Dmd reading frame (Dunckley et al. 1998;Wilton et al. 1999). These 
experiments showed that also in the mouse model restoration of the reading frame resulted in 
dystrophin synthesis. Systemic administration revealed that dystrophic muscle is an easier AON 
target than healthy muscle, since 10-fold higher AON levels were detected in dystrophic 
compared to healthy muscles (Heemskerk et al. 2010). This is thought to results from the 
damaged membranes that facilitate AONs to enter the target tissue. Treated mdx mice had 
improved muscle pathology and function in the absence of toxicological side effects (Lu et al. 
2003;Alter et al. 2006). PMOs were also successfully tested in some GRMD-dogs, where a double 
skip of exon 6 and 8 results in the correction of the reading frame and consequent dystrophin 
synthesis (Yokota et al. 2009).  
 
1.1.4.2. Clinical trials 
With these encouraging data, AONs targeting exon 51, which would benefit the largest group of 
patients, have been tested in clinical trials for both chemistries. Trials with 2OMePS AONs 
(PRO051/GSK2402968) were initiated by Prosensa Therapeutics, later joined by GlaxoSmithKline 
(GSK), while those with PMOs (AVI-4658) were undertaken by AVI-BioPharma in collaboration 
with the MDEX consortium. The first-in-man trial involved a single local intramuscular injection 
with 0.8 mg PRO051/GSK2402968 in the tibialis anterior of four DMD patients (NTR712). 
Biopsies taken one month later revealed that targeted exon 51 skipping resulted in 67-97% 
dystrophin positive fibers at levels of 17-35% of wild type (van Deutekom et al. 2007).   
 Later, intramuscular injections in the extensor digitorum brevis (EDL) of DMD patients 
with 0.09 mg (n = 2) and 0.9 mg (n = 5) AVI-4658 were performed by AVI-BioPharma and the 
MDEX consortium (NCT00159250) (Kinali et al. 2009). Biopsies were taken three and four weeks 
after administration. In all patients receiving the high dose, dystrophin restoration was found in 
44-79% of the fibers at intensities ranging from 22-32% of wild type. The low dose only resulted 
in specific exon 51 skipping but no dystrophin synthesis. These trials showed that AON-mediated 
exon skipping with both chemistries was effective and safe. 
 The human body consists of 434 different muscles which account for 30-40% of its 
content. Since all these should be targeted, systemic AON delivery is crucial. Thus, after the 
encouraging results obtained with local administration for both chemistries and optimization of 
systemic treatment in animal models (Alter et al. 2006;Heemskerk et al. 2009;Heemskerk et al. 
2010;Lu et al. 2005;Malerba et al. 2009), systemic trials were initiated. An open-label Phase I/II 
trial was undertaken for PRO051/GSK2402968 (NTR1241). Four cohorts, each consisting of three 
patients, received five weekly subcutaneous injections of either 0.5, 2, 4 or 6 mg/kg (Goemans et 
al. 2011). Biopsies revealed a dose-dependent recovery of dystrophin expression in almost all 
patients, of up to >80% of the fibers in patients receiving the highest dose. Maximum dystrophin 
signal intensity compared to wild type was 15.6% after treatment, while no adverse effects were 
reported. Thereupon, at the beginning of 2010, all patients enrolled in a still ongoing open label 
extension study (NCT01480245), receiving weekly injections of the highest (6mg/kg) dose. No 




reactions at the injection site, proteinuria and increased urinary α1-microglobulin levels. After 12 
weeks, this resulted in a trend of functional improvement in the 6-minute walk test in most of 
the patients, contrasting the anticipated decline. Results should be interpreted with caution due 
to the open-labelled nature of the trial and the lack of a placebo group. Therefore, to elucidate the 
effectiveness of the compound, as well as long term safety and tolerability, a double-blind 
placebo-controlled Phase III trial has been initiated involving weekly GSK2402968 
administration of 6 mg/kg in 180 patients (NCT01254019). Another double-blind placebo-
controlled trial, undertaken for the same compound is a Phase II trial elucidating the effects of 
different dosing regimens (once versus twice weekly 6 mg/kg) (NCT01153932). In addition, a 
Phase I trial assessing the pharmacodynamic profile of a single injection of different doses (3, 6, 9 
and 12 mg/kg) in non-ambulant patients has been initiated (NCT01128855). Finally, a phase II, 
placebo controlled study has been initiated assessing two doses (3 and 6 mg/kg/week) in ambulant 
patients (NCT01462292).  
 AVI-BioPharma performed an open-label dose escalation Phase Ib/II trial, in which 19 
DMD patients received weekly intravenous injections with 0.5, 1, 2, 4, 10 or 20 mg/kg AVI-4658 
for a period of 12 weeks (NCT00844597). Exon 51 skipping was detected in biopsies from all 
patients, leading to a variably dose-dependent dystrophin synthesis in patients receiving 2 mg/kg 
or more. The maximum proportion of dystrophin positive fibers found was 55% obtained in a 
patient of the highest dosing cohort, while maximum fiber intensity compared to wild type levels 
was 27% post-treatment. As AVI-4658 also appeared to be well tolerated, a double blind placebo-
controlled Phase II study has been undertaken to assess efficacy, pharmacokinetics, safety and 
tolerability (Cirak et al. 2011). Patients received a 60-minute intravenous infusion of 30 mg/kg (n 
= 4), 50 mg/kg (n = 4) or placebo (n = 4) once weekly (NTC01396239). Exon 51 skipping was 
detected in all patients receiving 30 mg/kg for 24 weeks, resulting in increased dystrophin levels. 
In biopsies from patients receiving 50 mg/kg for 12 weeks exon 51 skipping did not result in 
increment of dystrophin synthesis (www.avibio.com). Clinical outcome measures (6-minute walk 
test, Gower’s maneuver, 10 meter run) did not change in any of the treatment groups. As no 
serious side-effects were reported, all patients enrolled in an open-label extension study. Patients 
belonging to the placebo group are now also receiving AVI-4658.  
Although no apparent differences in efficiencies regarding both proportion of dystrophin positive 
fibers and their expression levels were observed between the two chemistries upon intramuscular 
injection, these were observed upon systemic administration. Compared to the 
PRO051/GSK2402968 trial where doses dependent dystrophin expression (in up to 80% of the 
fibers) was observed in roughly all (10 out of 12) patients, the AVI-4658 trial reported to observe 
restored dystrophin expression in 55% of the fibers or less in only a few (7 out of 19) patients. 
This might be due to technical differences in immuno-histochemical protocols, reference samples 
and analysis methods used in the two studies. On the other hand, biological factors might 
underlie this difference. As previously mentioned, the serum half-life of 2OMePS (<4 to 28 days) 
and PMOs (1.6 to 3.6 hours) differs significantly. Since PMOs are quickly cleared by the liver and 
kidney, the chances of being taken up by muscle are lower for PMO than for 2OMePS AONs. 
Possibly, and consistent with the greater variability observed for PMO, the much lower effective 
muscle exposure with PMO leads to variable uptake of AONs dependent on the physical integrity 
of specific fibers, with recently disrupted/repaired fibers taking up more AON. Further studies are 
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Effort is also put in the development of AONs targeting other exons. Currently, Prosensa 
Therapeutics conducts a dose escalation trial with 2OMePS AON targeting exon 44 (PRO044) 
which would apply to 6% of patients (NCT01037309). This open-label Phase I/IIa trial consists of 
weekly subcutaneous injections of 0.5, 1.5, 5, 8, 10 and 12 mg/kg PRO044 for 5 weeks. Pre-
clinical investigations for AONs targeting exon 45, 53, 52 and 55 are ongoing and it is anticipated 
that exon Phase I/IIa trials for exon 45 and 53 will be initiated in 2012. 
 
1.1.4.3. Hurdles to overcome 
Even though AON-mediated exon skipping results in restoration of dystrophin expression and is 
well tolerated, there are still several hurdles to overcome. As previously mentioned, skeletal 
muscle fibers of DMD patients have an uptake advantage as AONs can easily enter the fibers 
through disruptions of the membrane. However, mouse studies indicate that large amounts are 
still taken up by liver and kidney. To improve delivery to muscle, AONs may be bound to sugar 
groups or cell-penetrating peptides. The efficiency of the latter has been investigated to enhance 
uptake of PMOs in mouse models. Cell-penetrating, arginine-rich peptides were conjugated to 
PMOs (PPMO) and injected in mdx and mdx/utrn -/- mice. This resulted in increased intracellular 
PPMO levels and very efficient dystrophin restoration, leading to improved functional 
performance and life span in the severely affected mdx/utrn -/- mouse. No adverse effects were 
observed in both models (Goyenvalle et al. 2010;Yin et al. 2008;Moulton et al. 2009). Based on 
these encouraging results, PPMOs targeting exon 50 (AVI-5038) were further tested in primates 
in preparation for a clinical trial. Unfortunately, the toxicity observed after systemic 
administration has precluded further development of this specific compound (Sazani et al. 2009). 
As differences in chemistry might resolve the toxicity issue, pre-clinical investigations aim at 
identification of non-toxic peptides that enable targeted AON uptake (Yin et al. 2009;Yin et al. 
2010;Yin et al. 2011).  
 Additionally, also the heart is more challenging to target (Heemskerk et al. 2010). This 
is probably due to differences in architecture of cardiomyocytes, which are not as permeable as 
skeletal muscle fibers and thus have a more limited AON uptake. The consequences of AON-
induced dystrophin expression in skeletal muscle in the absence of expression in heart are 
unknown. It is speculated that as dystrophin expression in skeletal muscle will result in increased 
activity levels, a higher workload will be projected to the heart, which might worsen heart 
disease progression (Malerba et al. 2011a;Townsend et al. 2008). Other reports indicate that 
dystrophin correction of diaphragm itself is already beneficial for heart function in dystrophic 
animal models (Crisp et al. 2011). As more than 90% of DMD patients develop dilated 
cardiomyopathy, applying some form of cardiac therapy is essential. In principle, heart 
transplantation is an option but this may not always be a viable approach dependent on organ 
availability, condition and histocompatibility status. Thus preferably also the heart would need to 
be targeted. 
As yet, it remains unknown which levels of dystrophin are needed to protect muscles 
against damage and prevent or delay disease progression. From case reports, and studies in BMD 
and DMD patients and BMD carriers it has been speculated that ~20% already results in a mild 
phenotype (Hoffman et al. 1988;Hoffman et al. 1989;Neri et al. 2007). With new mouse models 
expressing variable, low dystrophin levels more insight in this issue has been gained (Chapters 4, 
5 and 6). 
 As AON-mediated exon skipping is a personalized approach leading to the production of 
dystrophins that internally lack different sequences, it can only be speculated whether these 




ability to protect against fiber damage, protein stability or secondary pathology (eg. brain 
involvement). Additional factors might also play a role as differences in severity within BMD 
families have been reported (Melis et al. 1998). Upcoming clinical trials will probably give more 
insight in these issues.  
 Finally, DMD is a rare disease affecting only 1:3500 newborn boys and mutations are 
present throughout the entire gene. To treat all patients that might theoretically benefit from this 
approach 130 combinations of single and double exon skipping are needed targeting more than 50 
different exons (Aartsma-Rus et al. 2009) (Table 2).  
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1.2. Mouse models for DMD 
 
1.2.1. The mdx mouse 
 
The most commonly used mouse strain in DMD research is the mdx mouse. This is a natural 
model which arose from the C57BL/10ScSnJ (wild type) strain. It was first described in 1984 
under the official name C57BL/10ScSn-Dmdmdx/J (Bulfield et al. 1984), where mdx stands for: X-
linked muscular dystrophy. Mdx mice have a point mutation in exon 23 of the Dmd gene (A>T at 
base 3185 replacing a glutamine codon (CAA) with a termination codon (TAA)). This premature 
stop codon prevents synthesis of full-length dystrophin (Sicinski et al. 1989). Even though only 
15% of the DMD patients have a nonsense mutation, this model has been of great importance for 
proof of concept studies of potential therapeutic approaches like exon skipping and compounds 
targeting premature stop codons. 
Although both DMD patients and mdx mice lack full-length dystrophin, the pathology 
of mdx mice is less severe (see below), enabling them to almost live as long as wild type mice and 
making homozygous breeding possible. The mean age of wild type mice is 27 and 26.5 months for 
females and males respectively, whereas this is 22.5 and 21.5 months for female and male mdx 
mice respectively (a reduction of 17% for females and 19% for males) (Chamberlain et al. 2007). 
In addition, slightly higher (~3.5 fold) mortality levels have been observed in mdx pups. Also the 
number of young mdx mice that die before the age of seven days is 45% higher than wild type 
mice (Torres and Duchen 1987). These rates seem to be independent of litter size, but as mdx 
mice are very susceptible to stress, mortality can be reduced by reducing animal handling and 
regular cage cleaning. 
 
1.2.1.1. Skeletal muscle histopathology  
The initiation of muscle pathology in mdx mice is essentially identical to that in DMD patients. 
However, in mdx mice, pathogenesis occurs in waves and is not a continuum like in DMD 
patients. Until weaning, only minor pathological changes have been reported (Grounds et al. 
2008). From the age of 3-4 weeks onwards, an acute onset of degeneration followed by 
regeneration is present, which lasts for five weeks and then subsides (Bulfield et al. 1984). The 
cause for the acute onset instead of a more gradual one is unknown. As a result, loss of muscle 
fibers is slow in adult mdx mice, with regenerated fibers being more resistant to necrosis. More 
severe muscle weakness is only found in old mdx mice with the diaphragm being the most 
severely affected muscle. Replacement of fibers by fat tissue is rare (Chamberlain et al. 
2007;Stedman et al. 1991;Bulfield et al. 1984;Deconinck et al. 1998;Karpati et al. 1988;Weller et 
al. 1990).  
For obvious reasons, pathological events in mice can be studied in more detail than in 
DMD patients, where generally only biopsies are available (Figure 8). Histopathology is 
characterized by increased numbers of small, newly regenerated fibers, as well as big 
hypertrophic fibers and by large patches of fibrosis and necrosis (Marshall et al. 1989). Like DMD 
patients, mdx mice also have revertant fibers and these increase in number with age from ~11 
fibers in one month old to >100 in one year old mice. Mdx mice that are irradiated with 18 Gy 
have significantly reduced muscle regeneration and consequently a reduced expansion of their 
revertant fibers. Revertant fibers in heart do not increase in number over time (Yokota et al. 





Figure 8. Cross sections of the quadriceps of an mdx and a C57BL/10ScSnJ (wild type) mouse. 
A. The mdx mouse section shows a lot of variation in fiber size, with small, newly regenerated fibers and enlarged 
hypertrophic fibers. Most fibers have centralized nuclei, indicating recent regeneration events. Newly regenerated 
fibers are indicated with an arrow. B. Pathology in an mdx mouse involving an area with fibrosis and infiltration of 
inflammatory cells. C. Fibers undergoing necrosis in a section of an mdx mouse. D. C57BL/10ScSnJ mouse reveals 
muscle fibers that are evenly sized and with nuclei at the membrane. No pathological features are evident. E. 
Revertant fiber in an mdx cross section. F. Dystrophin expression of a C57BL/10ScSnJ mouse. 
 
Muscle fibers of mdx mice also have an abnormal architecture as they can have one or 
multiple branches (Head et al. 1992;Lovering et al. 2009). Different types of branches have been 
found; fibers being totally split in two (Y-shape), having one or multiple small branches on the 
side (╣ shape), or having a small split in the middle while remaining intact at either side. It is 
hypothesized that branches originate from imperfect fusion of myogenic cells during 
regeneration. Branched fibers are more susceptible to exercise-induced damage. The number and 
complexity of the branches increases with age as in young mdx mice (6-8 weeks old) 17% of the 
fibers have branches, while this increases to 89% in old (27-31 weeks old) mice. Only in old mdx 
mice these branches result in a significantly increased drop in maximum tetanic force upon 
repeated eccentric contractions of 58% in mdx compared to 25% in wild type mice. Fibers of wild 
type mice rarely have branches (Chan et al. 2007;Chan and Head 2011). 
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1.2.1.2. Neuromuscular junction and skeletal muscle pathology 
Mdx mice have abnormalities in the anatomy of the NMJ and show functional deficits in muscle. 
To better appreciate the significance of these abnormalities and those observed in other DMD 
mouse models, the situation in wild type mice is discussed first, followed by that in mdx mice. 
Muscle contractions are coordinated by the central nervous system, from which nerve pulses are 
sent to the NMJ (Figure 9). When these reach the synaptic end bulb, acetylcholine (ACh) is 
released from vesicles and diffuses across the synaptic cleft to bind ACh receptors (AChR) at the 
motor end plate of the muscle. This causes ion channels to open which allow entrance of Na+ into 
the muscle fiber resulting in an action potential. The action potential travels across the 
sarcolemma and initiates the muscle to contract (see below). ACh is then broken down by 
acetylcholinesterase (AChE) in choline and acetate in the synaptic cleft. Dystrophin and utrophin 
colocalize with the Na+ channels at the base of the folds and with the AChRs respectively. 
Although utrophin compensates for the lack of dystrophin in the muscular sarcolemma, 
compensation for each others absence does not happen in the NMJ. The DGC is involved in the 
maturation and cluster formation of AChRs, in the regulation of ACh release and maintenance 
during NMJ differentiation (Deconinck et al. 1997a;Grady et al. 1997a;Miike et al. 1989;Pilgram 
et al. 2010;Grady et al. 2000).  
 
 
Figure 9. The neuromuscular junction. 
Nerve pulses excited by the central nervous system ensure release of ACh in the synaptic cleft. Uptake of ACh by 
AChR results in an influx of Na+ in the motor end plate of the muscle provoking an action potential which eventually 




In comparison to wild type mice, the NMJ motor end plate of mdx mice displays varying decrease 
of postsynaptic folding, whith ~30% of the area completely lacking folding. Additionally, AChRs 
and AChEs are abnormally distributed from the age of 4-6 weeks onwards. α-Bungarotoxin 
staining (visualizing AChRs) reveals that synapses of mdx mice consist of distinct boutons 
whereas continuous branches are present in wild type mice (Lyons and Slater 1991;Ferretti et al. 
2011). Electrophysiological properties of the NMJ are not impaired as the total number of AChRs 
and AChEs remains similar. Interestingly, all these pathological hallmarks are only observed in 
regenerated fibers, indicating that the lack of dystrophin itself has minor direct consequences. 
However, during regeneration in the absence of dystrophin, utrophin clustering is altered which 
results in remodelling of the pre- and postsynaptic components (Lyons and Slater 1991;Ferretti et 
al. 2011).  
 
Figure 10.  Molecular mechanisms of a muscle contraction. 
1. Upon arrival of the action potential in the T-tubules, Ca2+ is released from the sarcoplasmic reticulum and binds to 
Troponin C in the myofibril. 2. This ensures a conformational change of tropomyosin exposing the myosin head 
binding sites. 3-5. Cycles of ATP triggered binding and release of the myosin head to actin, bring them in close 
proximity of each other resulting in contraction of the muscle. 6. Upon depletion of Ca2+, the conformational change 
of actin will be reversed, making myosin head binding sites inaccessible. Thereupon, actin slides back in its original 
position resulting in muscle relaxation.   
 
The action potential from the NMJ is transported over the sarcolemma and ends up in 
the T-tubules located in the core of the muscle fibers. This triggers opening of voltage sensitive 
proteins and thereby release of Ca2+ from the sarcoplasmic reticulum in the cytosol. Within the 
myofibril, Ca2+ binds to Troponin C in the actin filaments of the sarcomere, changing the 
conformation of tropomyosin ensuring exposure of myosin head binding sites (Figure 10 step 1). 
Contractions start with the binding of ATP to the myosin head (step 2), which contains the 
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enzyme adenosine triphosphatase (ATPase) which splits ATP into ADP, phosphate and energy 
(step 3). This triggers the myosin head to bind to the actin filament. This initial binding is 
tightened by release of the phosphate molecule (step 4). Conformation of proteins in the myosin 
head lead to their repositioning and thereby pulls the actin filament along the myosin. Upon 
binding of another ATP molecule to the myosin head it moves back to starting position and the 
ATP is broken down into ADP and phosphate (step 5). Binding of a new ATP molecule will 
repeat this procedure, but leads to a more proximal binding so that the myosin and actin filaments 
are brought towards each other resulting in muscle contraction. In the absence of new Ca2+, 
tropomyosin will move back in its original conformation. This depletes the number of myosin 
head binding sites, forcing actin to slide back in its previous location leading to muscle relaxation 
(step 6) (Holmes 1996).  
The myotendinous junction (MTJ) is located at the distal sides of a muscle where it is 
connected to the tendon. In wild type mice, the MTJs are extensive finger-like projections of the 
sarcolemmal membrane, which serve to increase the area of attachment between the muscle fiber 
and the tendon. They also ensure force transmission between muscle and tendon. Like the NMJ, 
also in the MTJ a marked reduction in the number of foldings is observed in mdx mice (Law and 
Tidball 1993;Deconinck et al. 1997b).  
There are three main types of muscle contractions; isotonic (muscle shortens as force 
generated is greater than the load), isometric (load is greater than force generated, muscle length 
remains similar) and isokinetic (same speed) contractions. Isotonic contractions can be divided 
into two groups; concentric and eccentric contractions. During concentric contractions muscle 
contract and shorten in length, eccentric contractions result in lengthening of the muscle. In the 
latter case, muscles not only contract to build force but also slide alongside each other to 
lengthen. Muscle contractions in mdx mice have been studied in individual fibers and whole 
muscles. The most often used outcome measures are twitch force (force generated upon a single 
stimulation), tetanic force (force generated upon summation of individual twitches) and muscle 
fatigue initiated by multiple eccentric contractions.  
Acute weakness of the proximal followed by the distal muscles is observed in young 
mdx mice during the cycles of degeneration and regeneration (Muntoni et al. 1993). Although 
hypertrophic fibers generate higher twitch force than wild type mice, the relative force 
normalized for cross sectional area is significantly decreased in both young and old mdx mice. 
Force generating capacity of 21 months old mdx mice differs between fast and slow muscles. Fast 
muscles have significantly decreased twitch and tetanic force as well as decreased resistance to 
eccentric contractions, whereas slow muscles only have a significant decreased tetanic force 
compared to wild type muscle (Bobet et al. 1998;Lynch et al. 2001;Raymackers et al. 2003). 
Muscle force also differs between male and female mice as in females tetanic force is significantly 
less impaired at the age of six months (Hakim and Duan 2012). Impaired muscle function of mdx 
mice results in significantly reduced voluntary activities and bad overall motor performance 
(section 1.4.1.5.) (Hara et al. 2002;van Putten et al. 2012). However, chronic voluntary wheel 
running activities improve tetanic force of the EDL by 28% (Call et al. 2010). On the other hand, 
muscle pathology can also be negatively influenced by chronic horizontal treadmill running, 
which puts increased strain on the muscles. Especially downhill running in which muscles are 








1.2.1.3. Pathology of the heart 
Like DMD patients, mdx mice also develop dilated cardiomyopathy resulting from an identical 
pathological cascade. Heart function has been primarily studied by ECG and MRI (section 1.4.2.). 
In mice, the first pathological hallmarks are observed from the age of 2-3 months onwards. These 
involve uptake of Evans blue dye by cardiomyocytes, lower levels of nNOS and increased strain 
and tension (van Erp et al. 2010;Bia et al. 1999). In a proportion of mdx mice abnormal S-waves 
are observed. Mice aged 6 months have significantly higher levels of fibrosis and macrophage 
infiltrations than wild type mice, and these increase in proportion with age. Fibrosis is not 
restricted to a particular region, but is distributed in a patchy manner over both ventricles (Li et 
al. 2009). In parallel, elevated levels of markers involved in ECM remodeling and fibrosis 
(amongst others; CTGF, TIMP-1, MMP-9 and TGF-β1) are found as well (Au et al. 2011). 
Additionally, hypertrophy of the heart involving in particular the left ventricle has been 
described. ECGs of these mice are characterized by polyphasic R-waves and decreased S/R ratios. 
More extensive impairment of heart function is present from the age of 7-8 months onwards. First 
a decrease in right ventricular ejection fraction is observed accompanied by a decreased end 
diastolic volume and increased end systolic volume. In slightly older mice, a decreased left 
ventricular ejection fraction is observed as well (Figure 11). Some articles have reported a 
decreased cardiac output of both ventricles in 9-10 months old mice. A decreased S and R wave 
amplitude and increased heart rate is present at the age of 12 months.  
Discrepancy exists in literature regarding the age of onset of dilated cardiomyopathy, as 
some studies report these changes at an early age (Verhaart et al. 2011;Zhang et al. 2008;Crisp et 
al. 2011) while others do not observe major functional abnormalities in 10 months old mdx mice 
(Li et al. 2009).  
 
Figure 11. MRI scans of the heart of a C57BL/10ScSnJ and mdx mouse. 
MRI scans of the systolic and diastolic phase of the heart contraction from a wild type and mdx mouse aged 10 
months. At this age, mdx mice show severe dilatation of both the left and right ventricles, involving decreased stroke 
volume and ejection fraction.  
 
The exact cause for this is unknown, but it might be due to differences in the wild type strains 
used (C57BL/10ScSnJ versus C57BL/6). Also gender is known to influence heart function as this is 
more severely impaired in 22 months old female compared to male mdx mice (Bostick et al. 
2010).Forced treadmill exercise or voluntary wheel running has been found to negatively 
influence heart function most likely by putting an increased workload and strain on the heart 
(Costas et al. 2010;Nakamura et al. 2002).    
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1.2.1.4. Limitations of the mdx mouse 
Although mdx mice and DMD patients share the genetic defect that hampers the expression of 
functional dystrophin, pathology is less severe in mice. In contrast to DMD patients, motor 
function of mdx mice is only slightly reduced, they do not lose the ability to walk and life span is 
only slightly shorter. These differences can primarily be explained by differences in body size and 
architecture. The time-scale in which mice grow and mature is much shorter than that of 
humans, as mice directly go from childhood into adulthood, while humans spend a significant 
period of their life in puberty. This means that only 5% of a mouse's total life span has passed 
before they become sexually mature, while this is 20% for humans. Developmental milestones of 
DMD patients have been compared with mdx mice based on hormonal and physiological changes 
(Table 3) (Grounds et al. 2008). This clearly showed that the time-frame in which mdx mice 
undergo major pathological changes is extremely short in comparison to DMD patients. Mice also 
have a much smaller body size and distribute their body weight over four limbs instead of two. 
Taken together, this reduces the workload and stress on the muscles, preventing damage. 
 
Human Mouse 
Newborn 1 week 
~3 months 2 weeks 
~6 months 3 weeks 
~10 months 4 weeks 
~16-18 years 6 weeks 
~20 years 8 weeks 
~25 years 12 weeks 
 
Table 3: Developmental comparison between human and mdx mouse.  
Based on hormonal and physiological changes, Grounds et al. published this comparison between DMD patients and 
the mdx mouse. It can be appreciated from the table that most of the DMD pathology falls within the first eight 
weeks of the mouse’s live (From Grounds et al. Neurobiol. Dis. 2008; reprinted with permission of Elsevier)  
 
The less severe pathology observed in mdx mice results from multiple additional factors. 
Mdx mice have an incredible regeneration capacity for exceeding that of DMD patients. 
Furthermore, expression of transcription factors like Myod is upregulated, which enhances 
regeneration. Muscles of mdx mice are also better protected against damage since they are more 
efficient in overexpressing the dystrophin homologue utrophin that can functionally compensate 
for the loss of dystrophin. Also in DMD patients, utrophin is overexpressed between 2 and 10-fold 
compared to healthy controls, and these levels do positively correlate with disease severity 
(Kleopa et al. 2006). However, compensation in mice is more effective than that in human. This 
might be caused by differences in fiber diameter between human and mouse. As the surface-to-
volume ratio is smaller in human, the sarcolemma of these fibers experiences more stress and 
therefore they might require more utrophin (Grady et al. 1997b). It is not known whether the 
compensatory mechanisms of mice will generate similar protective effects in human, as overall 








1.2.2. The mdx2-5cv mouse models 
 
In addition to the naturally occurring mdx mouse, several other mice with mutations in the Dmd 
gene have been generated to make more extensive studies possible (Chapman et al. 1989). Male 
C3H.X25 x C57BL/6Ros mice were intraperitoneally treated with the chemical N-ethylnitrosourea 
(ENU). This chemical is a powerful mutagen inducing point mutations to progeny at a frequency 
of 1 mutation per 700 loci. Crossings of ENU treated males with C57BL/10 x mdx females resulted 
in female progeny which were selected according to their CK level. This resulted in four mdx 
models with mutations throughout the Dmd gene, called mdx2cv, mdx3cv, mdx4cv and mdx5cv. 
Mutations of these mice, consisting of one nonsense and three affecting mRNA splicing were 
found to be spread over the gene, making these mice an ideal object to study the effect of 
mutation position on pathology (Cox et al. 1993;Im et al. 1996).  
 
Figure 12. Dystrophin isoforms in different mdx mouse models. 
A. Representation of the Dmd gene in which the induced or natural mutations of the mdxcv, mdx52 and mdx mouse 
models are indicated by a cross. B. This schematic overview summarizes which isoforms are expressed in the mdxcv, 
mdx52 and mdx models. (Figure is based on Willmann et al. NMD 2009).  
 
The mdx2cv mouse has a single base mutation (A>T) in the acceptor splice site of exon 43 
(which lies in intron 42) of the Dmd gene. This mutation results in a complex pattern of aberrant 
splicing that generates multiple transcripts, of which none has an intact reading frame, so that the 
synthesis of functional full-length dystrophin synthesis is prevented. The smaller isoforms Dp140, 
Dp116 and Dp71 are normally expressed in these mice (Figure 12). The mdx3cv mouse carries a 
T>A mutation in intron 65 (14 base pairs proximal to exon 66), which introduces a cryptic splice 
site and frame-shift that prevents completion of all dystrophin isoforms. This makes mdx3cv mice 
exceptional since all other known mdx substrains express Dp71 and one or multiple additional 
short dystrophin isoforms. Mdx4cv mice have a C>T transition (CAA to TAA) at position 7916 in 
exon 53, which results in a premature stop codon, preventing dystrophin synthesis. These mice 
express only the dystrophin isoforms Dp116 and Dp71 (Im et al. 1996). Mdx5cv mice have an A>T 
mutation at position 1324 of exon 10. This mutation introduces a cryptic splice donor site 
(GTGAG) that generates a frame shift and prevents the synthesis of dystrophin (Im et al. 1996). 
As this mutation is close to the N-terminus of the protein, these mice only lack full-length 
dystrophin and express all the short dystrophin isoforms, like mdx mice. 
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Initially, it was thought that pathology of the mdx2-5cv mice greatly corresponded with 
that of mdx mice, therefore only mice younger than six months were studied. However, detailed 
investigations carried out in non-muscle tissues revealed phenotypical differences resulting from 
the absence of specific dystrophin isoforms. As the mdx3cv mouse does not express any dystrophin 
isoform, this model has been most intensively studied. Mdx3cv mice appeared hard to breed and 
survival chances of pups were smaller than that of mdx mice. Also the litter size is much smaller, 
which is not the case for the other mdxcv models (Cox et al. 1993). Mouse spermatozoa contain 
Dp71. Spermatozoa lacking Dp71 have abnormally shaped flagella and altered distribution of ion 
channels and signalling proteins. Although the short utrophin isoform Up71 is upregulated and 
redistributed and levels of α-syntrophin and voltage dependent Na+ and K+ channels are increased 
in mdx3cv mice, this does not prevent the phenotype (Hernandez-Gonzalez et al. 2005).  
Besides differences in fertility, mdx3cv mice also differ on a histological level from the 
other mdxcv mice. Danko et al. compared the number of revertant fibers between the mdxcv and 
mdx mice (Danko et al. 1992). He observed that mdx3cv mice do not express revertant fibers while 
mdx mice and the other three mdxcv strains do. In contrast, mdx3cv express a nearly full-length 
dystrophin (415kDa) at very low levels (~5% of normal levels) in all skeletal muscle fibers, but not 
in heart. These dystrophin proteins result from alternative splicing of the transcript, and lack the 
cysteine-rich domain sequences encoded by exon 65 and 66. Among the other mdxcv mice 
differences in the number of revertant fibers and the amount of increment of fiber numbers over 
time are found. Mdx2cv mice express 10 times more revertant fibers in skeletal muscle at the age of 
two and six months in comparison to mdx4cv and mdx5cv mice. With age, the number of revertant 
fibers increases 7.4 times, while increases of 4 and 4.6 times are found in mdx4cv and mdx5cv mice 
respectively. In this perspective, mdx2cv mice are most comparable to mdx mice. Also in heart, the 
highest numbers and biggest clusters of revertant fibers are found in mdx2cv mice. Mdx3cv mice 
express revertant fibers in heart at the age of six but not two months. 
Muscle function of the majority of the mdxcv models is indistinguishable from mdx mice. 
The mdx5cv mouse is an exception as a recent publication showed that they have functional 
deficits exceeding those observed in mdx mice. Mdx5cv mice perform significantly worse on the 
rotarod and have more severe strength deficits in the diaphragm. No differences in force 
generation have been observed for the EDL and histopathology is also comparable between the 
two strains (Beastrom et al. 2011). Differences in genetic background probably underlie these 
findings, as differences in e.g. functional tests have been described before between different wild 
type strains (Connolly et al. 2001).   
More distinct phenotypes have been observed in non-muscle tissues. The dystrophin 
isoforms Dp427, Dp260, Dp140 and Dp71 are expressed in the retina of both mouse and human. 
The function of the retina can be measured with an electroretinogram (ERG) which measures the 
electrophysiological response of the retina to light stimulation. DMD and BMD patients have 
abnormal ERG waveforms characterized by a reduced scoptopic b-wave. Severity of ERG 
abnormality is mutation specific; patients with mutations 3’ have abnormal ERGs while these are 
normal in most patients with 5’ mutations (Pillers et al. 1999;Pillers et al. 1995). To elucidate the 
correlation between position of the mutation and ERG severity, mdxcv mice have been intensively 
studied. Mdx5cv and mdx mice lacking only Dp427 have ERG waves comparable to those of wild 
type mice. All other strains that lack the retina isoform Dp260 have a phenotype, which differs in 
severity between them. Mdx2cv and mdx4cv mice show increased b-wave and oscillatory potential 
implicit times. Mdx3cv mice are most severely affected and show in addition to increased b-wave 
and oscillatory potential implicit times also reduced b-wave amplitudes (Pillers et al. 1995). The 




and Dp140 are expressed at the outer plexiform layer of the retina, while Dp71 is expressed at 
retinal blood vessels and the inner limiting membrane (Howard et al. 1998). In addition, cones 
also have a higher Dp427 to Dp260 ratio than rods (Wersinger et al. 2011). As colour blindness is 
caused by non-functional rods, this nicely correlates to the finding that DMD patients who lack 
Dp260 more often present a deficit in red-green discrimination (Costa et al. 2007).  
Also in brain, several dystrophin isoforms are expressed. Primarily mdx3cv mice have 
been used to study the consequences of additional loss of all the other dystrophin isoforms. It was 
hypothesized that especially the loss of Dp140 and Dp71 might result in subtle abnormalities 
during brain development because these proteins are highly expressed in foetal brains (Lidov 
1996). Studies investigating spatial learning abilities showed no differences in acquisition rates 
between mdx3cv, mdx and wild type mice (Vaillend et al. 1995;Vaillend et al. 1998). Like in mdx 
mice, the retrieval of long term memory and synaptic transmission is unaltered in mdx3cv mice, 
however differences in strategies to learn the task have been observed between these mice. In 
contrast to mdx mice, anxiety-related behaviour of mdx3cv mice is enhanced, whereas locomotion 
is reduced compared to wild type mice (Vaillend and Ungerer 1999). Strangely, the ability of 
mdx3cv mice to learn to press a bar is in the acquisition phase almost comparable to that of wild 
type, while mdx mice perform much worse. Performance in the extinction phase however is 
similar between all mice. The differences observed between mdx and mdx3cv mice might be 
caused by the expression of low dystrophin levels in mdx3cv mice and/or the different genetic 
backgrounds. However, more extensive research is needed to elucidate the exact mechanisms.  
 
1.2.3. The mdx52 mouse 
 
As only a limited number of DMD patients carry point mutations, the mdx52 mouse was 
generated to mimic a frequently found deletion in humans (Araki et al. 1997). In this mouse exon 
52 of the Dmd gene was disrupted by means of homologous recombination on a C57BL/6J 
background. These mice lack, similar to mdx4cv mice, full-length dystrophin and the shorter 
isoforms Dp260 and Dp140. Pathology and muscle function is similar to that of mdx mice. 
Hypertrophy of limb muscles is present in four months old mice along with variation in fiber size 
and central nucleation in 90% of the fibers. At this age also the diaphragm is more severely 
affected than the tibialis anterior and EDL. Revertant fibers are occasionally observed. There are 
no pathological changes in the heart and brain nor have behavioural changes been identified in 
18 months old mice.  
 These mice have also been used to explore the applicability of exon 51 skipping. PMOs 
targeting exon 51 induced exon skipping resulted in synthesis of truncated but functional 
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1.2.4. The mdx/utrn -/- mouse 
 
Disease pathology of mdx, mdxcv and mdx52 mice is relatively mild in contrast to that of DMD 
patients, which is partly caused by functional compensation for dystrophin through the 
upregulation of utrophin. It was hypothesized that absence of both proteins would result in a 
more severe model, which would accelerate research. Therefore, effort was put into making a 
utrophin knockout mouse (utrn -/-) to be used to generate a dystrophin and utrophin knockout 
mouse. However, as spontaneous mutations in the utrophin gene had never been found, it was 
believed that mice lacking this protein would not be viable (Grady et al. 1997a;Pearce et al. 1993). 
Despite these speculations, two independent groups successfully generated utrn -/- mice 
(Deconinck et al. 1997a;Grady et al. 1997a).  
 In 1997, Deconinck et al. made a construct in which an NH2 terminal exon of the Utrn 
gene, which is located in the actin-binding domain, was missing. They transfected embryonic 
stem (ES) cells with this construct and generated utrn +/- mice which were crossed to obtain utrn -
/- mice. The mutation led to the complete loss of full-length utrophin (Deconinck et al. 1997a). 
Simultaneously, Grady et al. generated utrn -/- mice in which the COOH-terminal cysteine-rich 
region of the Utrn gene was removed, which is needed for binding to the DGC (Grady et al. 
1997a). To do so, ES cells with this mutation generated by homologous recombination were 
implanted and resulted in germ line chimeras. Utrn -/- mice were again produced from crossings of 
utrn +/- mice. Despite the slight difference in the way utrophin expression was abolished, both 
models were phenotypically normal. Therefore, phenotypes of both mice will be discussed 
together, without making any distinctions.  
 Despite expectations, utrn -/- mice appeared to be viable and able to produce normal 
litter sizes. They did not develop any dystrophic phenotype or behavioural abnormalities and 
even two year old mice were indistinguishable from age-matched wild type mice in prospect of 
muscle function. As utrophin normally clusters with AChRs of the NMJ, a subtle phenotype was 
expected. Although synapses of utrn -/- mice had a normal architecture, AChRs density was 30% 
lower than that of utrn +/- mice, postsynaptic currents were altered and the number of 
postsynaptic folds of the NMJ was lower in utrn -/- mice than these of mdx and utrn +/-  or +/+ mice. 
Although utrophin was missing from the synaptic sites, the synaptic DGC complex was 
maintained and no decrease in levels of any of the proteins was observed, probably as a 
consequence of dystrophin somehow making up for the utrophin absence. As discussed in section 
1.1.2.1, the distribution of utrophin and dystrophin does not overlap in the NMJ. It was assumed 
that the DGC complex would be unaffected in the utrn -/- mice as a result of replacement of 
utrophin by dystrophin. Investigations however revealed that this was not the case as dystrophin 
was evenly distributed with no synaptic enrichment. Dystrophin did also compensate for 
utrophin in several other organs like brain, kidney and heart (Deconinck et al. 1997a;Grady et al. 
1997a).  
 As utrn -/- mice were viable and free from any dystrophic phenotype, both research 
groups crossed them with mdx mice to obtain mice lacking both dystrophin and utrophin. These 
mice were called mdx/utrn -/- or double knockout (dko) mice (Deconinck et al. 1997b;Grady et al. 
1997b). Extensive studies have been carried out, elucidating the consequences of the lack of both 
proteins in mice. In accordance with the two utrn -/- mouse models, no phenotypical differences 
have been described for the two mdx/utrn -/- strains. Therefore no distinction will be made 
between the two from now on.  
 Mdx/utrn -/- mice are much more severely affected than mdx mice and closely mimic the 




wild type pups. However, from weaning onwards, mdx/utrn -/- mice are significantly smaller than 
mdx mice and develop joint contractures and kyphosis leading to abnormal breathing patterns. 
They show difficulties walking and have an abnormal posture of the hindlimbs as they are not 
able to spread them like mdx or wild type mice (Figure 13). Mice die prematurely between 4 and 
20 weeks. Only 50% is still alive at the age of eight weeks, and they rarely survive 12 weeks. Life 
span can be slightly extended by feeding the mice wet food or sunflower seeds, but it never 
exceeds 20 weeks. The primary cause of death is unknown, but is most often related to respiratory 
and heart failure combined with swallowing difficulties, so it might be generalised weakness and 
conditional loss.  
Even though mdx/utrn -/- mice have a significantly reduced life span, muscle pathology 
does not dramatically differ from that observed in mdx mice. It is hypothesized that the absence 
of severe histopathology is caused by the lack of time for pathology to develop due to their short 
life span. The most dramatic difference in histopathology is seen in the extraocular muscles which 
are spared from pathology in mdx mice, but are severely affected in the mdx/utrn -/- mice, 
indicating that the upregulation of utrophin in particular prevents pathogenesis in mdx mice 
(Porter et al. 1998).  
 
Figure 13. Phenotypical characteristics of mdx/utrn -/- mice.  
A. Pictures of a C57BL/10ScSnJ mouse which is able to spread its hindlimbs upon handling by the tail and which does 
not show any malformations of the back. B. The mdx/utrn -/- mouse is unable to spread it hindlimbs normally as they 
contract upon handling. In addition, severe kyphosis is visible.  
 
Subtle differences are seen in the onset of degeneration and development of necrosis 
which is already observed in six day old mdx/utrn -/- mice whereas at that time this is not yet 
observed in mdx mice. At the age of three weeks, when repeated cycles of degeneration and 
regeneration start in mdx mice, both strains have similar amounts of fibrosis, necrosis and 
inflammation. Although pathology in skeletal muscle but not diaphragm subsides in older mdx 
mice, this does not occur in mdx/utrn -/- mice, resulting in more intensive fibrosis and necrosis in 
10 week old mice. Nevertheless, severity of histopathology at time of death is significantly less 
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compared to that seen in 18 months old mdx mice. Contrastingly, severity of the diaphragm is 
indistinguishable between the two models. In several muscles of mdx/utrn -/- mice fiber types 
tend to shift towards type I fibers. Although mdx/utrn -/- mice are much smaller than mdx mice, 
relative body weight to muscle mass does not significantly differ. Muscles of mdx/utrn -/- mice 
also seem to have problems to mature. Normally, only regenerating and immature fibers express 
developmental proteins like embryonic myosin heavy chains (eMHC) and neural cell adhesion 
molecule (N-CAM) and lose this expression upon maturing. Surprisingly, in a substantial group of 
large calibre fibers in mdx/utrn -/- mice eMHC and N-CAM expression remains present in contrast 
to mdx and wild type mice (Deconinck et al. 1997b;Deconinck et al. 1998;Grady et al. 
1997b;Rafael et al. 1998).  
With minor pathological changes of the NMJ in utrn -/- mice, extensive research has 
been carried out on the NMJ of mdx/utrn -/- mice. The axon of the synaptic terminal of the NMJ is 
similar to that of mdx mice, however, it almost completely lacks folding in the postsynaptic motor 
end plate regions. As previously mentioned, the synapse end plate of utrn -/- mice is identical to 
wild type mice, whereas a proportion of those seen in mdx mice are broken up to some extent and 
not as continuous. All synapses of mdx/utrn -/- mice are broken up into multiple boutons. No 
differences have been observed in intensities of AChRs detected by α-bungarotoxin staining 
between mdx and mdx/utrn -/- mice (Deconinck et al. 1997b;Grady et al. 1997b;van Putten et al. 
2012). Like in the NMJ of mdx/utrn -/- mice the MTJ has significantly less foldings compared to 
mdx mice, which might be detrimental to force transmission. This causes marked increases in 
forces placed on individual contact areas between fiber membrane and the connective tissue 
matrix of the tendon resulting in membrane damage in these regions. A causative defect from 
nerves or synapses was ruled out after an experiment demonstrated that muscles that were 
repetitively stimulated had a similar time for tension to fall 50% as wild type mice, indicating that 
the impaired muscle function solely has a muscular basis (Grady et al. 1997b;Deconinck et al. 
1997b). 
In mdx/utrn -/- mice, the synaptic DGC complex is partly maintained despite the lack of 
both utrophin and dystrophin. This strengthened the observation that dystrophin expression is 
not upregulated in utrophin negative synapses. In mdx/utrn -/- mice levels of β-dystroglycan and 
α-sarcoglycans are comparable to those of mdx mice, while β2-syntrophin and dystrobrevin are 
nearly undetectable. Even though expression of utrophin, dystrophin and a majority of the 
synaptic DGC proteins is altered in mdx/utrn -/- mice, expression of laminin-β2, agrin and rapsyn 
is unaffected. This indicates that synaptic development does not depend on these proteins, but 
that structural stabilization and maintenance do (Deconinck et al. 1997b;Grady et al. 1997b).   
  Muscle force is also more severely impaired in mdx/utrn -/- mice compared to mdx mice. 
In vitro electrophysiology showed that twitch tension is significantly reduced in steromastoid 
muscle, EDL, soleus and diaphragm. Relaxation time was also found to be greatly prolonged 
especially in the diaphragm. Time to peak tension, on the other hand, does not differ between 
mdx/utrn -/- and mdx mice in the steromastoid muscle, EDL, soleus and diaphragm. Interestingly, 
although force is greatly reduced in mdx/utrn -/- mice, repeated stimulation of the soleus did result 
in the same level of fatigue compared to mdx and wild type muscle, as force remained relatively 
stable. Apparently, where 40-50% of the soleus consists of fatigable type II fibers in mdx and wild 
type mice, in mdx/utrn -/- mice the soleus mainly consists of type I fibers (Deconinck et al. 
1998;Grady et al. 1997b). The drop in force described can be partly addressed by administration of 
several compounds (Call et al. 2011;Yue et al. 2006).  
Heart function of mdx/utrn -/- mice has been studied both by ECG and cine-MRI 




From the age of seven weeks onwards, Evans blue dye uptake is significantly elevated and large 
patches of degenerating cardiomyocytes, inflammation and fibrosis has been reported in some 
studies (Chun et al. 2012;Hainsey et al. 2003;Verhaart et al. 2011;Grady et al. 1997b). Other 
studies did not find histopathology in 10 week old mice (Deconinck et al. 1997b). The onset of 
cardiomyopathy in mdx/utrn -/- is significantly earlier than that in mdx mice as first abnormalities 
are already observed at the age of five weeks consisting of a significantly decreased heart rate. 
Discrepancy in literature exists about the heart rate in eight week old mice as both a decrease and 
increase in heart rate has been described. Abnormal ECG patterns have been found with 
significantly decreased S- to R-wave ratios and depressed contractile function of the right 
ventricular muscles (Bia et al. 1999;Chun et al. 2012;Janssen et al. 2005). In depth cine-MRI 
revealed a diminished left ventricular function with a significantly decreased cardiac output, 
stroke volume, end diastolic volume and cardiac mass while ejection fraction remained 
comparable to age-matched wild type mice. These findings correspond to cardiomyopathy seen in 
DMD patients which also display a decreased stroke volume, resulting from hypertrophy of the 
left ventricle (Maciver and Townsend 2008). With declining heart function one would expect an 
increase in end diastolic volume, however, in mdx/utrn -/- mice the end diastolic volume is 
decreased probably due to the decreased cardiac mass. The right ventricular function of mdx/utrn 
-/- mice is less severely affected, with only a decreased ejection fraction. This probably results 
from their severe respiratory impairment which decreases the work load for the right ventricle, 
but to compensate for the low oxygen supply increases the work load for the left ventricle (Chun 
et al. 2012;Verhaart et al. 2011). With ECG, decreased thickness of the left ventricular posterior 
wall and intraventricular septum was found in 10 week old mdx/utrn -/- mice. The decreased 
ejection fraction and end diastolic volume seen already in eight week old mice with cine-MRI 
was observed by ECG in 15 weeks old mice, accompanied by end systolic volume and fractional 
shortening. This difference probably reflects the difference in sensitivity between the two 
techniques used.  
 
1.2.5. The mdx/utrn +/- mouse 
 
Only recently, more attention has been drawn to the mdx/utrn +/- mouse (Huang et al. 2011;Zhou 
et al. 2008;Rafael-Fortney et al. 2011;Verhaart et al. 2011;van Putten et al. 2012). Previously, this 
mouse model was only used for breeding purposes to obtain mdx/utrn -/- mice. A limitation of the 
latter model is the short life span making long-term experiments impossible. The mdx/utrn +/- 
mouse expresses utrophin from only one allele and has a life span comparable to that of mdx 
mice. It was postulated that the phenotype of mdx/utrn +/- mice would be more severe than that of 
mdx mice and therefore would mimic the human phenotype better, without premature death.   
 Zhou et al. described that the quadriceps and diaphragm of three and six months old 
mdx/utrn +/- mice had more pronounced inflammation and fibrosis respectively, compared to age-
matched mdx mice (Zhou et al. 2008). The diaphragm was more severely affected than the 
quadriceps for both strains. This results in impairment of respiratory function at the age of three 
and six months in both strains, measured with whole body pleismography (method to measure 
respiratory rate and amplitude in conscious mice) (Huang et al. 2011). Only at the later time 
point, mdx/utrn +/- mice performed significantly worse than mdx mice. Our own study addressed 
functional performance of these mice and directly compared it to that of mdx/utrn +/+ and -/- mice, 
revealing severely affected motor function (Chapter 3). Heart function of both 2, 5, 6 and 10 
months old mdx/utrn +/- mice is however not more severely impaired than that of age-matched 
mdx mice, as both strains show a mild decrease in left ventricle function and a large decrease in 
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right ventricle function at the latter time point (Verhaart et al. 2011;Rafael-Fortney et al. 2011). 
Further research is needed to elucidate why the heart is spared in these mice. It might be that this 
is caused due to differences in physical abilities, causing less strain on the heart of mdx/utrn +/- 
mice, or due to differences in genetic background.  
 The first article in which the phenotype of mdx/utrn +/- mice was partly corrected by 
compound administration was published by Rafael-Fortney et al. They showed that ex vivo 
function of cardiac, limb and diaphragm was partly corrected by lisinopril and spironolactone 
administration starting at four or eight weeks of age (Rafael-Fortney et al. 2011). Also tetanic 
force of the EDL and diaphragm was significantly impaired in 20 week old mdx/utrn +/- mice 
compared to wild type mice. Direct comparison with mdx mice is impossible as these were not 
included. 
 As functional compensation for dystrophin by monoallelic expression of utrophin seems 
to be insufficient in mdx/utrn +/- mice, AON treatment was assumed to have a more pronounced 
effect in these mice compared to mdx mice. Upon subcutaneous administration of 2OMePS for six 
months, we observed that AON uptake, exon skip levels and functional improvement was 
significantly higher in mdx/utrn +/- than in mdx mice (Tanganika-de Winter et al. manuscript 
submitted).  
Based on these studies, it can be concluded that the mdx/utrn +/- mouse is a more 
severely affected model. This suggests that the functional compensation of dystrophin by 
heterozygous expression of utrophin is incomplete. Taken together, this underlines that the 





1.3. Low dystrophin levels in human and mice  
 
1.3.1.  DMD and BMD carriers 
 
Although no therapy is available for DMD yet, different potential therapeutic approaches aiming 
to restore dystrophin synthesis are currently tested in clinical trials. These trials result in the 
expression of low dystrophin levels. However, it is not yet known how these levels affect disease 
pathology and which levels are needed to maintain or improve muscle integrity, to prevent 
against exercise-induced damage or to improve muscle function. In addition, it is unknown 
whether the percentage of dystrophin that is needed for these outcome measures will be similar 
for skeletal muscle and heart, or whether different muscles need different levels.  
The first hints to answer these questions were obtained from DMD and BMD carriers. 
Symptoms in these females vary from mild muscle pain and cramps, to severe muscle weakness 
leading to wheelchair dependency. Muscle weakness is proximally distributed first affecting the 
legs and later the shoulder girdle. The age at onset ranges from the first to the fourth decade. 
Generally, onset before the age of 15 results in a severe phenotype (Hoogerwaard et al. 1999). The 
majority of DMD and BMD carriers (76% and 81% respectively) express ~50% of dystrophin early 
in life, based on random X-inactivation levels and these females are not affected. This indicates 
that these levels are sufficient to maintain skeletal muscle function and prevent pathology 
(Pegoraro et al. 1995;Schmidt-Achert et al. 1993). Non-random X-inactivation results in a mild 
dystrophic phenotype in rare cases. Despite muscle weakness being absent or only very mild, a 
small percentage (~8%) of the carriers develops DMD-associated dilated cardiomyopathy (Ogata et 
al. 2000;Hoogerwaard et al. 1999).  
Manifesting carriers have also been described which express <50% of dystrophin. The 
prevalence of clinically manifesting DMD and BMD carriers in the female population is 1:45,000 
and 1:100,000 respectively. Several mechanisms are known to cause symptoms in these carriers. 
The majority of manifesting carriers are the consequence of unfortunate, skewed X-inactivation 
(section 1.3.4.1.). In this case, the intact X-chromosome is predominantly inactivated, so that the 
X-chromosome with the DMD mutation is active in the majority of the cells. Disease severity in 
these carriers depends on the degree of inactivation of the intact X-chromosome. Examinations of 
biopsies from carriers reveal a mosaic pattern of fibers that do express dystrophin at normal 
intensities and fibers that lack dystrophin expression (Azofeifa et al. 1995;Pegoraro et al. 
1995;Soltanzadeh et al. 2010). Some manifesting carriers however, have gross chromosomal 
rearrangements involving translocations between the X-chromosome and an autosome. These 
translocations lead to almost complete inactivation of the normal X-chromosome with the intact 
DMD gene, resulting in much decreased dystrophin levels (Lindenbaum et al. 1979;Boyd et al. 
1986). Alternatively, a few rare cases have been described of females who suffered from Turner’s 
syndrome (patients with this syndrome lack one X-chromosome) and also carried mutations in 
their DMD gene. In these patients, lack of dystrophin resulted in the typical DMD phenotype 
(Ferrier et al. 1965;Bjerglund and Nielsen 1984;Chelly et al. 1986). Also a number of monozygotic 
twins have been described with heterozygous mutations in their DMD gene. In all these cases one 
of the twins was phenotypically normal while the other had severe DMD-like symptoms. The 
affected twin showed unfortunate skewed X-inactivation resulting in low dystrophin levels. It is 
hypothesized that the twinning process directly relates to the observed low dystrophin levels, as 
no reports exists on cases in which both twins are manifesting. In rare occasions, during random 
X-inactivation, the maternal derived X-chromosome (Xm) is inactivated in particular clumps of 
cells while the paternal derived X-chromosome (Xp) is inactivated in other clumps. These clumps 
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might define each other as ‘foreign’ which initiates them to separate 3-8 days post fertilization 
(Richards et al. 1990). One article also reported a twin in which the unaffected girl had random 
X-inactivation while the affected girl had unfortunate skewed X-inactivation. This resulted from 
asymmetric splitting of the inner cell mass (ICM) (Lupski et al. 1991).  
 
1.3.2. BMD patients 
 
As mentioned in section 1.1.4., BMD patients express low levels of truncated but partly functional 
dystrophin. In these patients, disease severity varies from very mild, in which patients remain 
asymptomatic until later in life, till quite severe where patients are diagnosed in childhood and 
lose ambulation in the early to late teens. The clinical outcome depends primarily on the amount 
of dystrophin expressed. Patients expressing <3% of normal on average become wheelchair 
dependent before the age of 11 years. Levels between 3 and 10% lead to wheelchair dependence 
between the age of 13 and 20 years whereas levels >20% delay wheelchair dependence till the 
second decade (Hoffman et al. 1988;Hoffman et al. 1989). Most patients lose ambulation between 
20-30 years after diagnosis. Life span of mildly affected patients is near normal, whereas severely 
affected patients die between the age of 40 and 50 years. Some BMD patients also suffer from 
dilated cardiomyopathy, which can be the main symptom in the less severely affected patients. 
Other patients only have very mild symptoms of either skeletal muscles and/or heart 
(Helderman-van den Enden et al. 2010). A case report of one BMD patient expressing 29% of 
dystrophin in a uniform manner revealed that this already completely prevented muscle 
pathology (Neri et al. 2007). Another study described patients expressing <10% dystrophin that 
were more severely affected than the patient that expressed ~20% of dystrophin (Beggs et al. 
1991). Taken together, expression of dystrophin correlates with disease severity and even levels of 
~30% can largely prevent pathogenesis.  
 
1.3.3. Mouse models expressing low dystrophin levels from birth  
 
With only limited access to tissues from DMD and BMD carriers and BMD patients, in-depth 
research was warranted in animal models expressing low dystrophin levels. Experiments in 
heterozygous mdx mice revealed that also in mice ~50% of dystrophin completely prevents 
skeletal muscle pathology. Additionally, they revealed that the number of dystrophin positive 
fibers increases over time due to their survival advantage over dystrophin negative ones. 
Surprisingly, these mice do not develop any heart pathology, while this is observed in ~8% of the 
DMD and BMD carriers. The cause for this difference is poorly understood (Bostick et al. 
2008;Tanaka et al. 1990).  
From the early nineties onwards, transgenic mice expressing full-length or truncated 
dystrophin of murine or human origin were generated to study the applicability of gene therapy 
for DMD (Dunant et al. 2003;Lee et al. 1993;Phelps et al. 1995;Rafael et al. 1994;Wells et al. 
1995). The majority of these lines expressed dystrophin at intensities exceeding wild type levels 
or at both moderate and high intensities. Interestingly, some of these mice expressed <50% 
dystrophin as assessed by Western blot in a uniform or mosaic manner (Table 4). The way in 
which dystrophin was expressed and at which intensities differed per line. Within an individual 
mouse differences in expression between muscles and/or fiber types were observed, with fast 
fibers predominantly expressing dystrophin (Lee et al. 1993). These differences resulted most 




Studies in these transgenic mice indicate that the beneficial effect of different types of 
dystrophins (full-length versus truncated) and the manner in which it is expressed (uniform 
versus mosaic) varies. Complete restoration of disease pathology was observed in mice uniformly 
expressing full-length dystrophin (mouse line 852 diaphragm) at intensities of ~20% of wild type 
levels. Expression of 40% of truncated dystrophin (mouse line 12157 quadriceps) did not 
completely restore pathology, although it dramatically reduced symptoms. This was confirmed by 
others: an incomplete restoration of pathology was observed upon uniform expression of 20-30% 
of truncated dystrophin (lacking exon 17-48), while no pathology was seen in mice expressing 
similar amounts of full-length dystrophin (Wells et al. 1995). This suggests that fibers expressing 
truncated dystrophin are more vulnerable to damage than those expressing full-length dystrophin 
(Chamberlain 1997;Phelps et al. 1995;Wells et al. 1995).  
 
Author Transgenic model Dystrophin pattern Histopathology 
Lee 1993 Full-length 
murine 
Mosaic (only dys positive in fast fibers)  
Western blot 20% in 1 month while 
60% in 4 month old mice  
Improved 
Rafael 1994 Truncated murine 
lack 71-74 
Mosaic 
50% dys positive fibers in Qua  
(intensities from 1 to >100%) 
10-20% dys positive fibers in Dia 
Qua: improved fibrosis 
Dia: no improvement 
Phelps 1995 Full-length 
murine Line 8487 
Mosaic 
Western blot 15% dys in Qua 
Western blot <5% dys in Dia 
Qua: partial reduction CN 
Dia: reduction fibrosis and 
inflammation 
Phelps 1995 Full-length 
murine Line 852 
Uniform (U)/Slightly variable (Sv) 
Western blot >70% dys in Qua (U) 
Western blot 20% dys in Dia (Sv) 
Qua: prevented all 
pathology 
Dia: prevented all pathology 
Phelps 1995 Truncated murine 
lack 17-48  
Line 12157 
Uniform (U)/Mosaic (M) 
Western blot 40% dys in Qua (U) 
Western blot 20% dys in Dia (M) 
Qua: dramatic reduction of 
pathology 
Dia: no improvement 
Wells 1995 Human full-length Uniform 
Western blot 20-30% dys in Dia 
Prevented all pathology 
Wells 1995 Human mini-dys 
lack 17-48 
Uniform 
Western blot 20-30% dys in Dia 
Nearly prevented all 
pathology still some CNs 
Hauser 1997 MCK promoter 
driven expression 
Uniform 
Western blot 20% of wild-type in Dia 
Nearly prevented all 
pathology 
Hauser 1997 MCK promoter 
driven expression 
Mosaic 
Levels not mentioned in article 
Improvement depended on 
% dys positive fibers 
Dunant 2003 MCK promoter 
driven expression 
Mosaic (only dys positive in fast fibers) 
In ~50% of the fibers 
Improved 
Stillwell 2009 Wild-type ES-cell 
incorporation 
Mosaic 
Western blot 60-100% or  
<5% of wild-type 
Dose dependent 
improvement 
Li 2008 Mdx3cv  mouse Uniform 
Western blot ~5% of wild-type 
Some improvement in 
young not old mice 
 
Table 4. Overview of mdx mice generated that express <50% dystrophin. 
This table summarizes some of the transgenic mdx mice that express low levels of full-length or truncated dystrophin 
from murine or human origin. Dystrophin expression is either in a mosaic or uniform manner. The amount of 
dystrophin expressed correlates with histopathology. CN= centralized nuclei, Dia= diaphragm, Qua= quadriceps. 
 
Mosaic expression of dystrophin clearly protects fibers to damage to a smaller extent than 
homogenous expression, as higher total protein levels are needed to prevent pathology. While 
full-length dystrophin expressed at 20% of wild type uniformly, completely prevented pathology 
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(as stated above), mosaic expression only partly decreased the percentage of centralized nuclei 
(line 8487). However, mosaic expression of 20% of truncated dystrophin (line 12157), did not 
improve histopathology at all (Phelps et al. 1995). This indicates that the uniformity of dystrophin 
expression might be more relevant than the level of expression in protecting muscle fibers against 
pathogenesis. This observation was confirmed in an independent study generating different 
transgenic mouse lines (Hauser et al. 1997).  
Although decreases in numbers of centralized nuclei were found in the majority of 
these lines, no clear correlation was observed between dystrophin expression in a particular fiber 
and the presence of nuclei located at the periphery or the center of that fiber (Rafael et al. 1994). 
However, others observed that dystrophin negative fibers neighbouring dystrophin positive ones 
were more likely to have nuclei at the periphery, than those surrounded by dystrophin negative 
fibers (Dunant et al. 2003). An increment in dystrophin positive fibers over time, which was 
observed in heterozygous mdx mice, was found in some (Lee et al. 1993), but not all transgenic 
models (Dunant et al. 2003;Rafael et al. 1994). This might be caused by the different ways in 
which these models were generated, or due to the young age of the mice at time of assessment.  
Besides transgenic mice, alternative approaches have also been undertaken to generate 
mice expressing low dystrophin levels. Stillwell et al. injected wild type ES cells into mdx 
blastocytes (Stillwell et al. 2009). Depending on the incorporation of the ES cells, mice expressed 
dystrophin in either a very high (60-100%) or low (<5%) percentage of the muscle fibers at wild 
type intensities. The percentage of dystrophin positive fibers in these mice also differed per 
muscle. A dose-dependent restoration of muscle pathology was observed. This approach of 
generating animals for further investigations is less favourable as it is labour intensive and results 
in mice with dystrophin levels on both extremes of the scale only.  
The final model expressing very low dystrophin levels is the mdx3cv mouse. As described 
earlier, these mice express dystrophin in all fibers but at ~5% of the intensity of wild type mice. Li 
et al. observed that these levels resulted in some improvements in young but not in older mice. 
The EDL of young mice was partially protected from eccentric contraction-induced injury and 
had a significant higher tetanic force compared to mdx4cv mice (Li et al. 2008). Also the forelimb 
grip strength of the mdx3cv mice was slightly increased. No difference in CK was detected, nor did 
histopathology differ between mdx3cv and 4cv mice.  
 
1.3.4. Treated mdx mice expressing low dystrophin levels  
 
Despite the lack of a good mouse model to assess the effect of low dystrophin levels on disease 
pathology, knowledge could still be obtained from mice that expressed low dystrophin levels 
upon treatment with AONs, AAV-U1 and gentamycin. These studies primarily focussed on the 
effect of low dystrophin levels on functional and biomarker outcome measures. Intramuscular 
PMO administration revealed that dystrophin expression in ~20% of the fibers (resembling ~10% 
assessed by Western blot) largely protects muscles against eccentric contraction induced injury. 
The functional improvement correlated more strongly to the number of dystrophin positive fibers 
than to levels assessed by Western blot, which again indicates that the total number of fibers 
expressing dystrophin is most relevant (Sharp et al. 2011). The same compound was also 
systemically injected in mdx mice at a low (5mg/kg) and high (50mg/kg) dose for 20 or 50 weeks. 
Short term treatment resulted in 23% (5mg/kg, resembling 20% on Western blot) and 27% 
(50mg/kg, 40% on Western blot) of dystrophin positive fibers in the tibialis anterior, expressing 
dystrophin at intensities slightly lower and higher than wild type for the low and high dose 




Treatment for 50 weeks with the same doses resulting in ~60% of dystrophin in the tibialis 
anterior improved voluntary activities and grip strength, but not resistance to eccentric 
contractions. Histopathology in all mice was only slightly improved (Malerba et al. 2011b). 
Uniform dystrophin at intensities of 20% of wild type, induced by gentamycin treatment has 
been found to partly protect muscles even while chronically challenged with horizontal treadmill 
exercise twice weekly. In these mice, histopathology and CK levels were reduced, however 
higher levels were needed to restore altered calcium homeostasis (De Luca et al. 2008). Very low 
dystrophin levels (<10%) resulting from exon skipping either induced with 2OMePS or AAV-U1 
have been shown to reduce the expression of some mRNA and miRNAs involved in various 
aspects of disease pathology (Verhaart et al. 2012;Cacchiarelli et al. 2010).  
 
1.3.5. The mdx-Xist∆hs mouse 
 
Despite the fact that transgenic mice and mice treated with potential therapeutic compounds 
provided us with important information regarding the effects of low dystrophin expression on 
muscle pathology, these approaches are not ideal for more in-depth research. The disadvantages 
of the transgenic lines are the big differences in dystrophin intensities between individual fibers 
as well as fiber type specific dystrophin expression which are not favoured. An obvious 
disadvantage of treating mice is that treatment is quite expensive, stressful to the mice and labour 
intensive.  With this in mind, we generated the mdx-Xist∆hs mouse model, which expresses low 
levels of dystrophin from birth onwards based on intentionally skewed X-inactivation.  
 
1.3.5.1. X-inactivation 
In all animals in which there is an imbalance in the amount of sex-chromosomes (e.g. female 
humans and mice carry two X-chromosomes, while males only carry one X-chromosome), 
compensation is ensured by sex chromosome inactivation (generally X-inactivation in mammals) 
resulting in equal transcript levels between females and males (Lyon 1961). This is a critical event 
as failure results in significant copy number variation of around 1000 genes resulting in 
embryonic lethality or malformations. Although X-inactivation was discovered 50 years ago, the 
exact mechanism, which differs between species, is still poorly understood. Two distinct cycles of 
X-inactivation (imprinting and random X-inactivation) have been described in mice, whereas 
only the latter occurs in humans. In mice, at the 2-4 cell stage, equal levels of both the Xp and the 
Xm are active (Figure 14). From this stage onwards, Xp is inactivated via imprinting, ensuring Xm 
being active in all extra-embryonic tissues. Maternal germ line cells are protected against 
inactivation by an imprint which represses Xist expression (see below). The inactive state of Xp is 
reversed again in the ICM of the blastocytes. Thereafter, either Xp or Xm is inactivated in each 
cell during random X-inactivation. All descendants of these cells inherit the same inactivation 
pattern which is maintained throughout life. Only in the female germ line, the inactivation 
pattern is reversed ensuring that all oocytes have an active X-chromosome (Xa) (Ng et al. 2007).  
Both imprinted and random X-inactivation rely on one single locus; the X-inactivation 
center (Xic). The Xic expresses many regulatory elements which mediate in the inactivation 
process. At the onset of random X-inactivation, the X-pairing region ensures pairing of the X-
chromosomes. Subsequently, the number of X-chromosomes rerlative to the number of autosome 
is counted. This is done based on levels of Rnf12, which is expressed from the Xic. 




Figure 14. The mechanism of random X-inactivation in mice.  
In mice the paternally derived X-chromosome (Xp) is inactivated in all extra-embryonic tissue from the 2-4 cell stage 
onwards. The maternally derived X-chromosome (Xm) is protected from X-inactivation by an imprint. In the 
blastocytes, upon reversion of the inactive state of the Xp, either the Xp or Xm are inactivated in a random manner. 
At initiation of random X-inactivation both Xp and Xm express high levels of Rnf12, Tsix and pluripotency factors. In 
one of the two chromosomes, Rnf12 and Tsix expression decrease initiating overexpression of Xist on the other X-
chromosome. The Xist expression leads to coating of that X-chromosome which makes it transcriptional inactive. The 
active or inactive state of the X-chromosomes is maintained throughout life. Only the X-chromosomes in the germ 
line remain active and become imprinted (Picture based on by Augui et al 2011 Nat. Rev. Genet.).  
  
Females express twice as much Rnf12 compared to males. Regardless of the number of X-
chromosomes present, only one of them remains active. This decision is made during an interplay 
between the main players Rnf12, Tsix, Jpx and Xist, but the pluripotency factors NANOG, OCT4 
and SOX2 are thought to play a role as well (Augui et al. 2011). Xist and Tsix are two long non-
coding RNAs which are expressed from partly the same location of the Xic in sense and antisense 
direction respectively. At initiation of X-inactivation, both X-chromosomes express Rnf12 and 
Tsix and thereby trigger the expression of Xist. Later on, downregulation of Rnf12 and Tsix, and 
upregulation of Jpx on the future inactive X-chromosome (Xi) lead to a monoallelic upregulation 
of Xist (Tian et al. 2010;Lee et al. 1999). This results in coating of this X-chromosome, initiating 
its inactivation. Consequently, Polycomb protein complexes are recruited which ensure 
packaging of the DNA by histone modifications into heterochromatin thereby making it 
transcriptionally inert. In this way, a discrete body in the nucleus called the Barr body is formed. 
As previously mentioned the inactive state of Xi is inherited by daughter cells and maintained 




These regions are called pseudoautosomal regions and contain genes that are also present on the 
Y-chromosome, obviating the need for dosage compensation (Carrel and Willard 2005).  
To study the mechanism of X-inactivation, many mouse models have been generated 
each lacking an important modulator of X-inactivation on one or both alleles (Barakat et al. 
2011;Shin et al. 2010;Tian et al. 2010;Penny et al. 1996). We used one of these models (Xist∆hs 
mouse) for the generation of two new innovative mouse models for DMD, which are described in 
Chapters 5, 6 and 7 of this thesis. As previously mentioned, in these models the phenomenon of 
skewed X-inactivation, as seen in some female symptomatic DMD and BMD carriers, was used as 
a concept. The mouse model used had a PGKneo cassette inserted immediately upstream of the 
Xist promoter P1 (Newall et al. 2001). The authors observed that in heterozygous Xist∆hs females, 
targeting this locus resulted in preferential inactivation in ~80-90% of X-chromosomes carrying 
the mutation in Xist. We crossed Xist∆hs females with mdx males in our lab. In the female pups, 
the mutated Xist gene was heterozygously expressed, resulting in preferential inactivation of the 
X-chromosome with the mutation in the Xist gene. As these X-chromosomes do not carry a 
mutated Dmd gene, their preferential inactivation causes a preponderance of active X-
chromosomes from the mdx-background on overall deficit of dystrophin positive cells in female 
progeny. Therefore, female mdx-Xist∆hs offspring typically express dystrophin levels between 3-
47% depending on their X-inactivation ratio. Detailed information regarding their phenotype can 
be found in Chapters 5 and 6 of this thesis.  
 
1.3.6. The mdx/utrn -/- /Xist∆hs mouse 
 
In mdx mice utrophin very effectively compensates for the lack of dystrophin resulting in a very 
mild phenotype. It is therefore of interest to study the effects of low dystrophin levels in a 
utrophin negative background. Due to the severe phenotype of mdx/utrn -/- mice, this model is 
more suitable to assess the dystrophin levels needed for improved life expectancy as well as 
pathology and muscle function.  
Several labs have put effort in generating such a mouse over time, unfortunately 
without any success as none of the models expressed a variety of low dystrophin levels. The first 
attempt was made in 1999, in a paper focussing on the role of dystrophin and utrophin in non-
muscle tissues but no protective effects were observed for the low dystrophin levels expressed 
(Rafael et al. 1999). Several years later, Li et al. generated utrophin negative mdx3cv mice (Li et al. 
2010). For these mice, a significantly improved life span has been reported (in contrast to the 
findings of Rafael et al). The difference might result from differences in backgrounds of the 
strains among others.  
 Exploiting the principle of skewed X-inactivation patterns like we did for the mdx-
Xist∆hs mice, we generated mdx/utrn -/- mice expressing low dystrophin levels. To utilize these 
mice, utrn -/- Xist∆hs males were needed. These mice were generated by crossing Xist∆hs females 
with utrn -/- hDMD +/- males. The hDMD mouse has an intact and functional copy of the human 
dystrophin gene on a C57BL/6 background. This mouse model was generated earlier in our group 
('t Hoen et al. 2008). The hDMD gene functionally compensates for the absence of mouse 
dystrophin. In the pups we selected against the hDMD gene so that we obtained utrn -/- Xist∆hs 
mice. These mice were further crossed with mdx/utrn +/- females to generate mdx/utrn -/- /Xist∆hs 
female pups. This model is the first in its kind expressing dystrophin levels that are between 1 and 
38% and extensive research is described in Chapter 7 of this thesis.   
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1.4. Outcome measures 
 
1.4.1.  Functional tests 
 
Preventing or delaying the onset of progressive loss of muscle function is the ultimate goal of 
clinical trials currently ongoing for DMD. Therefore, muscle function is the most important 
outcome measure in pre-clinical screening of potential therapeutic approaches and compounds. 
To determine motor function pre-clinically in mouse models of DMD, several different functional 
tests have been designed. As they do not interfere with disease progression, they can be used to 
either assess the course of natural history of the disease, or the effects of compounds on disease 
progression (Chapter 2) (van Putten et al. 2010). Examples of non-invasive functional tests are the 
grip strength, the rotarod and hang tests (Figure 15A-E). Using the grip strength test, strength of 
either the forelimbs or hindlimbs can be tested based on the instinct of a mouse to grasp an object 
(Connolly et al. 2001). The rotarod is used to test muscle function and coordination and involves 
walking on a rotating tube that increases in speed in the first minute (Chapillon et al. 1998). 
Balance, coordination and muscle condition can be tested with hanging tests. A distinction can be 
made between two types of hanging tests in which either only the forelimbs of all four limbs are 
used at start of the test. The start position with two limbs allows direct distinction in the 
functional abilities of a mouse to also start using its hindlimbs and tail thereby reducing the 
maximum load per leg. Contrastingly, in the hang test in which all limbs are used from the start 
onwards equal chances are given to all mice (Raymackers et al. 2003;van Putten et al. 2010). With 
dystrophin negative fibers being vulnerable to damage caused by exercise, the type, load and 
duration must be correctly chosen in these cases.  
On the other hand, forced treadmill exercise can be chronically used to intentionally 
exacerbate disease progression and to determine the protective effect of compounds more 
thoroughly in mdx mice (Figure 15F). Horizontal treadmill running increases muscle necrosis of 
the quadriceps, gastrocnemius and triceps, whereas the diaphragm and tibialis anterior are 
affected to a lesser extent. Also an increase in the number of centrally nucleated fibers, the 
proportion of fast fibers and serum CK levels is found, whereas muscle strength decreases (De 
Luca et al. 2005;Payne et al. 2006;Radley et al. 2008;Pierno et al. 2007). Besides horizontal 
treadmill running, also downhill running can be applied. As mdx fibers are especially vulnerable 
to eccentric contractions, this type of exercise induces major pathology. Muscles mostly affected 
by this exercise are the diaphragm and triceps, while the tibialis anterior and EDL only show 
minor damage (Brussee et al. 1997). Alternatively, the treadmill can also be used to measure the 
ability of mdx mice to run on a horizontal treadmill and encouraged to run till exhaustion. Six 
months old mdx mice exhaust earlier (after ~12 min) than age-matched wild type mice (~after 60 






Figure 15. Overview of the most often used functional tests.  
A. Grip strength device used to monitor strength of the extremities. B. Rotarod running device, used to measure the 
ability of a mouse to run on a rotating rod. C-D. Two limb hanging wire test. In this test, the begin position is with 
the two forelimbs. Mice that perform well can be distinguished by their ability to use their hindlimbs and tail 
additionally. E. Hanging wire test in which the start position is with four limbs. F. Treadmill device used in 
experiments to either exacerbate disease progression or to assess running abilities.  
 
Interestingly, voluntary running exercise results in improved muscle function. 
Voluntary wheel running is assessed in mice that are individually housed in a cage enriched with 
a metal wheel and is used to determine neuromuscular impairment. Studies assessing the direct 
consequences of this exercise on muscle pathology in mdx mice showed that within 24-48 hours 
post exercise necrosis is doubled in the quadriceps, while the tibialis anterior remained spared. 
Also the EDL is more affected than the plantaris and soleus muscles (Archer et al. 2006;Radley 
and Grounds 2006). Long term voluntary running exercise has beneficial effects on muscle quality 
of mdx mice (Dupont-Versteegden et al. 1994;Carter et al. 1995;Landisch et al. 2008;Hara et al. 
2002;Hayes and Williams 1996). Accumulation of dirt increases the resistance of the wheel 
rotation which is likely to influence outcomes, as even mild resistance already influences skeletal 
and heart muscle physiology in wild type mice (Konhilas et al. 2005). Interestingly, increased 
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workload does not negatively impact pathology in mdx mice. It does however force mdx mice to 
run less when the load is 13% of their body weight. This is only observed in wild type mice when 
the load is 25% of their body weight (Call et al. 2010). Alternatively voluntary activity can also be 
assessed in cages equipped with multiple photocell receptors and emitters that monitor horizontal 
and vertical movements (Spurney et al. 2009).   
To summarize; major differences in the impact of different exercise types on disease 
pathology have been described ranging from extremely detrimental to beneficial. Generally, 
treadmill running is detrimental to mdx mice, voluntary exercise is beneficial and other 
functional tests do not have a distinct impact on muscle pathology. Exercise-induced 
histopathology does differ between muscles, as type II fibers are more prone to damage than type 
I fibers. Additionally, the likelihood that specific muscles get damaged depends on the 
recruitment of these muscles during the specific exercise. Also age influences the impact with 
young mdx mice being more vulnerable to exercise than old mice (Faist et al. 2001). When 
exercise is applied, physiological, metabolic and vascular adaptations can be observed (Kobayashi 
et al. 2008). It has been reported that these response can differ between dystrophic and wild type 
strains, which in turn might affect drug absorption and metabolism. A high degree of 
standardization in the methodology is essential to enable comparisons between experiments and 
labs. In a collaborative effort of the TREAT-NMD network of excellence and the Wellstone 
Center, numerous standard operating procedures for functional tests to be used in mdx mice are 
now available (http://www.treat-nmd.eu/resources/research-resources/dmd-sops/). Eventually 
extended knowledge on the influence of exercise on disease pathology is important to better 
advise DMD patients. 
 
1.4.2. Heart function  
 
In mice, heart function can be measured by ECG or MRI. During an ECG-scan, the heart’s 
electric activities are recorded, which is visualised by waves and peaks (Figure 16). To do so, the 
mouse is anesthetized, after which two fine needle electrodes are subcutaneously inserted at the 
ventral junction between the chest and the right and left forelimbs. Additionally, one needle is 
inserted at the junction between the lower abdomen and left hindlimb (Bia et al. 1999). 
Recordings provide information regarding the heart rate, the rhythm of the heart beat and the 
strength and timing of the electrical signals. The cycle starts with spontaneous depolarization in 
the sinoatrial node located at the top of the right atrium, transmitting an electric signal that 
spreads from the right to the left atrium and results in contraction of the atria. The signal ends up 
in the atrioventricular node while the blood is pumped to the ventricles. This atrial 
depolarization is characterized in the ECG by the P-wave. The duration of this (PR interval) is an 
estimation for atrioventricular node function. The signal is further directed to the His bundle and 
the Purkinje cells. Both ventricles are depolarized when the signal is redirected back to the atria. 
This results in contraction (systole) of the ventricles pumping blood through the aorta and is 
reflected by the QRS complex. Relaxation of the atria and ventricles is ensured upon 
repolarisation of the ventricles (T-wave) which enables the heart to fill with blood (diastole). The 
QT interval reflects the de and repolarisation of the ventricles e.g. the time it takes for the 
ventricles to fully contract and relax. The ST segment is the period of depolarization of the 







Figure 16. Electrocardiogram of the heart. 
The ECG consists of a P-wave indicating atrial depolarisation, the QRS peak which resembles ventricular 
depolarisation whereas repolarisation of the ventricles is resembled by the T-wave. The PR interval reflects the time 
of the signal leaving the sinoatrial node to it ending up in the AV node. The QT interval is a reflection of the de and 
repolarization of the ventricles, so the total time for the ventricles to fully contract and relax. The ST segment is the 
period of depolarization of the ventricles. Heart failure is characterized by alterations in amplitude and timing of the 
waves and peaks.  
 
The major disadvantage of the ECG is that it only provides indirect information regarding the 
ventricular contractions. Additionally, ECG measurements are significantly hampered in severely 
affected mouse models like the mdx/utrn -/- mice in which the position of the heart varies per 
individual due to severe kyphosis. Here, reliable data can still be obtained with MRI as this 
technique enables more in-depth and accurate assessments of the heart function (Verhaart et al. 
2011). An MRI machine has an extremely powerful magnetic field, which forces all the hydrogen 
atoms in the body to align to the direction of this field. Upon generation of extremely strong 
radiofrequency waves, the nucleus of the hydrogen atoms in the body move slightly. When this is 
turned off, these atoms regain their position, sending out radiofrequency waves themselves which 
are detected and used to generate a picture. Hydrogen atom rich areas (i.e. blood) appear much 
brighter in these images then areas containing less hydrogen atoms (muscle) (Bothwell and 
Griffin 2011). Although mice are scanned in a vertical position in the coil of the MRI this does 
not affect heart function (Schneider et al. 2003). Pictures obtained cover the entire heart beat 
cycle and can be used to precisely determine contractions. The most often used outcomes 
measures are: the end diastolic volume and end systolic volume which represent the volume in 
the ventricle prior contraction and after ejection respectively. The stroke volume is the difference 
between those two parameters and represents the volume of blood which is pumped from a 
particular ventricle within a heart beat. The ejection fraction is the amount of blood which leaves 
the heart at every heart beat. The cardiac output is the volume of blood pumped by a particular 
ventricle within one minute (Crisp et al. 2011;Verhaart et al. 2011;Zhang et al. 2008). 
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1.4.3.  Serum and gene biomarkers 
 
Although functional tests are extremely valuable outcome measures, subtle changes cannot easily 
be detected. For potential upcoming therapies like AON-induced exon skipping, chronic 
administration will be necessary. Timing of these administrations will probably be patient 
dependent and monitoring disease progression with the use of serum biomarkers will be critical. 
Biomarkers are biological measurable parameters that offer a way to monitor normal and 
abnormal processes in e.g. body fluids that replace invasive biopsies (Nadarajah et al. 2011). One 
would aim for the use of robust biomarkers that are stable (not influenced by life style and dietary 
changes), specific (to a disease, pathway or genotype) and can repeatedly be quantified in which 
different analysis and laboratories obtain similar results. To date, serum CK has been used as a 
biomarker for diagnostic screenings of DMD patients. As CK leaks out of damaged muscle fibers, 
levels are low in more advanced stages of the disease when fibers are largely replaced by fibrotic 
and fat tissue. Additionally, CK levels increase upon activity, even in healthy controls. This 
reduces the utility of this biomarker, requiring the discovery of more robust biomarkers that can 
be used to monitor disease progression throughout the patient’s life. In this thesis, several serum 
and gene expression biomarkers were assessed. To identify potential biomarkers, targeted (based 
on literature) and non-targeted (screening serum from DMD, BMD and controls to identify 
which proteins are differentially expressed) approaches were used for the gene and serum 
biomarkers respectively. The biomarkers used in this thesis were identified by the targeted 
approach and are important players in either maintenance of the ECM, inflammation, fibrosis, 












A 3 months mild functional test regime  
does not affect disease parameters  
in young mdx mice  
 
M. van Putten, C.L. de Winter, W.M. van Roon-Mom,  
G.J.B. van Ommen, P.A.C. ’t Hoen, A.M. Aartsma-Rus 
 




                                   Functional test regime does not affect disease in mdx mice           
 59 
Abstract 
To assess the effect of potential therapeutic agents in dystrophic mice it is useful to have a 
functional test regime that does not affect the natural disease progression of mdx mice with 
dystrophinopathy. We determined the effect of a 12 week test regime consisting of fore limb grip 
strength, rotarod analysis and two and four limb hanging wire tests on the disease progression of 
4-week-old mdx mice. Mice performed the different functional tests on consecutive days on a 
weekly basis. No difference was found in serum creatine kinase levels between functionally active 
and sedentary mice. The percentage of fibrotic/necrotic areas assessed in a semi-automated way 
with colour deconvolution of skeletal muscles, heart and diaphragm did not vary within muscles 
or between groups, nor did the gene expression levels of disease-related genes. We conclude that 
this test regime may be suitable for short-term functional evaluation of therapeutic approaches in 
the mdx mouse. 
 
Introduction 
Duchenne Muscular Dystrophy (DMD) is an X-linked, severely progressive, muscle wasting 
neuromuscular disorder, which is caused by frame-shifting or nonsense mutations in the DMD 
gene. Translation of the disrupted reading frame results in the synthesis of truncated, non 
functional dystrophin protein (Hoffman et al. 1987). Intact dystrophin anchors the intracellular 
cytoskeleton of muscle fibers to the extracellular matrix and thereby protects the fibers from 
disruption during contraction. It also controls the calcium (Ca2+) homeostasis, which is essential 
for normal fiber function (Blake et al. 2002). In dystrophin-negative muscles the Ca2+ homeostasis 
is disturbed due to an excessive influx through stress-activated channels and membrane tears. 
This leads to altered mitochondrial metabolism and down regulation of several mitochondrial 
genes, the activation of proteases, such as calpain, and the production of reactive oxygen species, 
resulting in more fiber damage and more Ca2+ uptake (Chen et al. 2000;Whitehead et al. 2006). 
This Ca2+ induced cascade leads to fiber necrosis, which attracts inflammatory cells that trigger 
fibrosis. Regeneration of fibers compensates for the lost muscle fibers, but eventually the 
regenerative capacity of the fibers becomes exhausted resulting in the replacement of healthy 
fibers by connective and adipose tissue (Deconinck and Dan 2007). In most patients, this causes 
profound muscle weakness leading to wheelchair dependency in the early teens and death due to 
respiratory and heart failure in their mid twenties.  
The mdx mouse carries a nonsense mutation in exon 23 of the mouse Dmd gene 
(Sicinski et al. 1989). It is the most commonly used mouse to study the pathogenesis of DMD and 
to test putative therapeutic approaches (Grounds et al. 2008). Despite the similarity in gene 
defects, mdx mice are functionally less severely affected than DMD patients and their life 
expectancy is only slightly reduced compared to healthy mice. Muscle degeneration appears in 
cycles, the most pronounced acute phase lasts from 3 to 8 weeks of age, followed by relatively 
successful regeneration. In contrast to skeletal muscles, the diaphragm and tongue reflect the 
severe pathology found in DMD patients (Chamberlain et al. 2007). The less severe phenotype of 
mdx mice is thought to result from a combination of improved regeneration and, to some extent, 
functional compensation by the dystrophin homologue utrophin, although other yet unidentified 
factors may play a role as well (Blake et al. 2002;Perkins and Davies 2002).  
Nonetheless, as a consequence of the genetic defect, mdx mouse muscle fibers cannot 
produce functional dystrophin resulting in fibers that are, like human DMD fibers, more 
vulnerable to contraction-induced injury and degeneration. Serum creatine kinase (CK) levels are 




skeletal muscles including the heart in aging mdx mice (De Luca et al. 2008;Perkins and Davies 
2002;Spurney et al. 2008).  
Due to the pathology, transcription levels are altered for genes involved in 
immunological and tissue remodelling pathways. Microarray analyses of a series of dystrophic 
mice has resulted in several biomarkers that correlate with disease severity and progression, and 
that normalize upon therapeutic intervention ('t Hoen et al. 2006). These biomarkers are thus a 
useful tool to follow the natural course of the disease and monitor therapeutic effects over time.  
Phenotypic severity in mdx mice can be exacerbated by exercise and eccentric 
contraction regimes (De Luca et al. 2008). The effect of a mild exercise regime on disease 
progression is less well understood.  Several studies revealed beneficial effects, while other studies 
point towards harmful effects on disease progression (Dupont-Versteegden et al. 1994;Radley et 
al. 2008).  
To determine whether genetic or pharmacologic treatment strategies are effective, more 
insight in the functional, histological and biomarker levels during the natural history of the 
disease in mdx mice is needed. To achieve this, a functional test regime that is not detrimental to 
the phenotype is needed. Therefore, we here assessed the effect of a 12 week functional test 
regime, consisting of four functional tests, on young mdx males. We monitored functional 
performance over time, and compared levels of previously identified fibrotic and immunologic 
RNA biomarkers between functionally challenged and unchallenged mice. In addition, we 
assessed the percentage of necrotic, fibrotic and regenerating cells using histological staining 
followed by a new semi-automatic analysis method based on the principle of colour 
deconvolution (Ruifrok et al. 2003). This analysis provides a more accurate, unbiased and faster 
method to analyze histopathology in whole muscle sections.  
 
Materials and methods 
Animal care 
Mdx mice (C57BL/10ScSn-mdx/J) were bred at the animal facility of the LUMC. Mice were 
housed in individually ventilated cages with 12-h light–dark cycles. Standard mouse chow and 
water was given ad libitum. All experiments were approved by the Animal Experimental 
Commission (DEC) of the LUMC. 
 
Functional tests 
Four week old male mdx mice were randomly assigned to a functionally challenged or 
unchallenged group, each consisting of five mice. Functionally challenged mice underwent a 12 
week test regime, consisting of four different functional tests, each addressing different muscle 
groups and/or coordination. Mice performed the four tests in the afternoon on consecutive days 
on a weekly basis (Supplementary Table 1). When possible, standardized operating procedures 
from the TREAT-NMD network were implemented (http://www.treat-
nmd.edu/activities/treatment/html). Both groups were weighed at the beginning and end of each 
week.  
 
Creatine kinase level analysis 
Blood was collected weekly on Monday mornings from all mice in a Minicollect tube (0.8 ml 
Lithium Heparin Sep, Greiner bio-one, Austria) through a small cut at the end of the tail. CK 
levels were determined in sera with Reflotron CK test strips in the Reflotron plus machine 
(Roche diagnostics Ltd., UK).  
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Forelimb grip strength test 
The forelimb grip strength test was performed with a home-made grid attached to an isometric 
force transducer that measures peak force of the forelimbs (Ugo Basile, Italy). Mice were 
suspended above the grid, which they instinctively grasped, and then pulled backwards. Mice 
were tested five times, with three consecutive measurements per trial (15 in total), and a two 
minute interval between trials. The three highest measured values were averaged to calculate 
absolute strength, which was divided by the body weight in grams. The degree of fatigue was 
measured by comparing the average of the first two and the last two trails as described previously 
(Connolly et al. 2001). 
 
Rotarod 
With the Rotarod (Ugo Basile, Italy) coordination, balance, muscle strength and condition was 
tested. Mice were placed on the rod that accelerated from 5 to 45 rotations per minute within 15 
s. When a mouse ran for 500 s without falling from the rod, the test session was ended. Mice that 
fell off within 500 s were given a maximum of two more tries. The longest running time was used 
for analysis. 
 
Two limb hanging wire test 
Overall body coordination and strength was tested by a two limb hanging wire test. Mice were 
suspended above a metal cloth hanger secured 30 cm above a cage. The mouse was released a few 
seconds after instinctively grasping the wire with its forelimbs. Depending on the functional 
ability of the mouse, all limbs and the tail were used during a 10 min hanging session. Mice that 
fell down before the 10 min time limit were given two more tries. The longest hanging time was 
used for further analysis. 
 
Four limb hanging wire test 
Mice were placed on a grid where it stood using all four limbs. Subsequently, the grid was turned 
upside down 15 cm above a cage. Mice that fell down before the 10 min time limit were given 
two more tries. The longest hanging time was used for further analysis. 
 
Histological examination 
Mice were euthanized by cervical dislocation at an age of 16 weeks. Quadriceps, gastrocnemius, 
tibialis anterior, triceps, heart and diaphragm muscles were dissected and snap frozen in 2-
methylbutane (Sigma–Aldrich, The Netherlands) cooled in liquid nitrogen. Sections of 8 μm were 
cut with a Shandon cryotome (Thermo Fisher Scientific Co., Pittsburgh, PA, USA) on Superfrost 
Plus slides (Thermo Fisher Scientific, Menzel-Gläser, Germany) along the entire length of the 
muscle with an interval of 240 μm between the sections. The excess tissue belonging to the 240 
μm intervals was collected in MagNa Lyser Green Beads tubes (Roche diagnostics Ltd., UK) for 
total RNA isolation. Sections were fixed for five minutes with ice-cold acetone and stained with 
Harris haematoxylin and eosin (H&E) (Sigma–Aldrich, The Netherlands) according to 
conventional histological procedures. The diaphragm was stained with the Masson’s trichrome 
staining (Sigma–Aldrich, The Netherlands). Sections were examined with a light microscope 
(LeicaDMLB, Leica Microsystems, The Netherlands) at a 2.5 times magnification at five locations 
in the muscle. Images were captured with a Leica DC500 camera and Leica IM50 software (Leica 
Microsystems, The Netherlands). Blending and background correction was performed with 




haematoxylin/eosin (H&E) colour deconvolution plugin (Rasband, W.S., ImageJ, US National 
Institutes of Health, Bethesda, Maryland, USA, http://rsb.info.nih.gov/ij/, 1997–2008) was used to 
determine the fibrotic/necrotic percentage of the entire cross section. This plugin provides a 
number of ‘‘built in” stain vectors to provide an accurate stain separation of the green, blue and 
red component, which is based on the primary and secondary three-dimensional colour space 
(RGB and CYM) (http://www.dentistry.bham.ac.uk/landinig/software/cdeconv/cdeconv.html). 
Based on this linear description, ImageJ plugins have been created for different histological 
stainings (Ruifrok et al. 2003). The total tissue area was determined on the original picture while 
the area of healthy cells was determined using ImageJ’s automatic threshold on the eosin 
component, obtained after H&E colour deconvolution. For the diaphragm, (Masson’s trichrome 
staining) the haematox component of this plugin was used. This allowed calculation of the 
percentage of fibrosis/necrosis ((whole area minus healthy area) divided by whole area). 
 
Biomarker analysis 
Total RNA was isolated using RNA-Bee (Tel-Test, Bio-Connect, Huissen, The Netherlands) and 
purified with the NucleoSpin RNA II kit according to the manufacturer’s instructions including a 
DNAse digestion (Bioke, The Netherlands). The RNA concentration was measured on a Nanodrop 
(Nanodrop Technologies, DE, USA) and integrity was checked with a total RNA nano assay on a 
labchip assay (Agilent, The Netherlands). cDNA was synthesised with random hexamer primers 
and gene expression levels were determined for CD68, Lgals3 (influx of macrophages and immune 
cells), Tnnt2, MyoG (regeneration), Bgn (extra cellular matrix) Nox2, Nox4, Lox (fibrotic), GLUT 
4 and PGC-1α (exercise induced genes) by Syber Green based Real Time qPCR (95 °C 10 s, 60 °C 
30 s, 72 °C 20 s 45 cycli and melting) on the Roche Lightcycler 480 (Roche diagnostics Ltd., UK). 
GAPDH was used as a reference gene, since the expression of this gene did not differ between 
different muscles or over time. The Cp values were obtained with the second derivative maximum 
method and analyzed with genex (http://www.gene-quantification.com/download.html). 
 
Statistics 
Statistical analyses were performed with statistical software in the R package 2.5.1 
(http://www.Rpackage.org). The two-tailed homoscedastic student’s t-test was conducted for 
comparison between the groups on the weight, CK levels, histological and gene expression data. 
P<0.05 was considered significant for all tests, however to the gene expression data a Bonferroni 
correction was applied to correct for multiple testing, therefore a P<0.01 was considered 
significant. The Spearman correlation test, which is not affected by differences in the distribution 
of values for the different measured parameters, was used for comparisons of all data from both 
the functionally challenged and unchallenged mice. The data obtained in the last week of 
functional testing were used to determine a possible correlation between the functional 
performance and histology, gene expression and creatine kinase levels. For the correlation 




A group of 5 four week old male mdx mice was subjected to a 12 week functional test regime that 
consisted of four different functional tests performed on consecutive days on a weekly basis. The 
functional tests consisted of grip strength analysis, Rotarod running and two and four limb 
hanging wire tests. Each functional test was performed only once a week at the same time in the 
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afternoon and addressed different muscle groups and/or coordination. A group of five 
unchallenged mdx males was used as a control group.  
Body weight was assessed at the beginning and the end of every week. No significant 
differences were found for average body weight at any time point or over time between 
functionally challenged and unchallenged mice. Notably, in the functionally challenged mice, a 
clear trend of a fluctuating body weight was seen that can be related to their functional test 
regime. After each weekend, when no functional tests were performed, there was an increase in 
body weight while a decrease in body weight occurred during the week, when the functional 
tests were performed (Fig. 1A).   
Serum CK levels were elevated compared to C57BL/10ScSnJ mice (<500 U/L, De Luca et al. 2008), 
but did not differ significantly between the functionally challenged and unchallenged mice at any 
time point or over time (Fig. 1B). For each functional test, mice performed badly in the first week 
of testing. This is partly a learning effect, but may also be due to the decreased strength that 
correlates to the re-, and degenerating cycles which are present at the age of 4 weeks. Forelimb 
grip strength corrected for body weight decreased gradually over time from 5 to 15 weeks of age. 
This result is in consensus with a decreased forelimb strength found in mdx mice (5–12 weeks of 
age) that did not perform other functional tests beside the grip strength test De Luca et al. 2008).  
 
Fig. 1. Effect of the functional test regime on body weight and serum CK levels over time. (A) Body weight values of 
functionally challenged and unchallenged mice. Notably, a drop in weight can be observed during the week when 
tests were performed, while weight increases occurred during the weekends when no tests were performed.  
(B) Serum CK levels of both groups over time. For both the body weight and serum creatine kinase levels, no 
significant difference was found between the two groups at any time point or over time. The error bars reflect the 
standard deviation of the average. 
 
This decrease is mainly due to the increase in weight, as uncorrected strength remained virtually 
unchanged (Fig. 2A and B). No indications of fatigue were found at any time point (data not 
shown). On the Rotarod, the mice showed an average peak in their running time of 368 s at an 
age of seven weeks (i.e. after three weeks of testing). From then on, their performance declined to 
an average running time of around 200 s, which remained constant until the end of the test 
regime (Fig. 2C). This again is in agreement with previously reported data (Turgeman et al. 2008). 
Similar to the Rotarod peak performance, a peak at seven weeks was also observed with the two 
different hanging tests. However, the longest hanging time of both tests remained constant till an 
age of 12 weeks after which it dropped by 50% for both hanging tests (Fig. 2D and E), while the 
Rotarod performances dropped after the peak observed at an age of 7 weeks. For the Rotarod and 








Fig. 2. Functional test performances. (A and B) 
Normalized and absolute grip strength values, 
respectively. Normalized forelimb grip strength 
decrease gradually over time, which is mainly due to an 
increase in body weight, since absolute strength values 
remained unchanged over time. Rotarod running time 
(C) peak at an age of seven weeks (383 s) but decrease 
to an average of 200 s for the rest of the testing period. 
Both two and four limb hanging wire tests (D and E) 
show an increase in performance at an age of seven 




The quadriceps, gastrocnemius, tibialis anterior, triceps, heart and diaphragm were isolated from 
the functionally challenged and unchallenged mice at the age of 16 weeks. To determine levels of 
fibrosis, necrosis, connective tissue and recently regenerated tissue, a colour deconvolution based, 
semi-automatic analysis was set up on compiled pictures covering the entire cross sections. The 
haematoxylin/eosin plugin divides the picture in an eosin, haemotoxylin and background 
component. The eosin component represented the healthy area of the muscle examined. This area 
excluded fibrotic, necrotic, connective and recently regenerating tissue (Fig. 3).  
In order to determine whether fibrotic/necrotic cells were equally distributed 
throughout the muscle (from tendon to tendon) the percentage of fibrotic/necrotic cells was 
determined at five levels along each muscle. For both the hind-, and forelimb muscle the 
proximal part was referred to as the beginning of the muscle (A) and the distal part as the end (E). 
The areas in between were referred to as B, C and D respectively. For the diaphragm, the dorsal 
part was designated the beginning (A) and the ventral part the end (E), while for the heart the 
cranial and caudal parts were beginning (A) and end (E), respectively. No significant differences 
in fibrotic/necrotic cell percentages were found between the five locations for any of the analyzed 
muscles (Fig. 4A).  
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Fig. 3. Example of the semi-automatic histopathological determination using the colour deconvolution ImageJ plugin. 
The eosin component obtained with ImageJ after the haematoxylin/eosin colour deconvolution plugin represents the 
healthy area of the total cross section. Using this method, the percentage of necrotic, fibrotic, connective and 
recently regenerated tissue can be calculated from the total and the healthy fiber area. 
 
 
Fig. 4. Histopathology between different areas within a muscle (A) and comparison of histopathology between 
functionally challenged and unchallenged mdx mice for different muscles (B). (A) In four different skeletal muscles, 
the heart and diaphragm, the percentage of damage was determined at five locations from tendon to tendon. No 
significant difference was found between different areas within one muscle, or between functionally challenged and 
unchallenged mice. (B) A clear, significant difference in histopathological severity was found between different 
muscles; the tibialis anterior and the diaphragm were the least and most severely affected muscles respectively. 
 
Therefore, for further comparisons only the middle section (C) of the muscle was analyzed. This 
revealed that the level of fibrosis and/or necrosis did not differ significantly between the 
functionally challenged and unchallenged mice in any of the muscles (Fig. 4B). This indicates that 
the functional test regime had no effect on tissue composition in mdx males. A clear difference in 
muscle damage severity was found between the different muscles. The tibialis anterior was 
significantly less affected (3.5%) than the gastrocnemius (8.5%), the quadriceps and the triceps 
(10% and 10.6%). The diaphragm was significantly more affected (30.3%) than all other muscles 
examined. The triceps was significantly more affected than the heart (5.9%). This is in accordance 
to previous studies based on several arbitrary fields (Turgeman et al. 2008) and an indication that 






The expression levels of several previously identified biomarkers that correlate with disease 
severity were assessed in the different muscles of the functionally challenged and unchallenged 
mice (Fig. 5) ('t Hoen et al. 2006;Baar et al. 2002;Spurney et al. 2009). The genes tested were 
CD68, Lgals3 (influx of macrophages and immune cells), Tnnt2, MyoG (regeneration), Bgn (extra 
cellular matrix) Nox2, Nox4, Lox (fibrotic), GLUT 4 and PGC-1α (exercise induced genes). When 
P<0.05 was considered significant, the expression of Lox differed between the groups in the 
diaphragm (P = 0.027), Nox2 (P = 0.038) and PGC-1α (P = 0.022) in the tibialis anterior and MyoG 
(P = 0.039) and GLUT 4 (P = 0.010) in the Triceps. However, after we conducted a Bonferroni 
correction, none of the tested genes were significantly differentially expressed between 




Fig. 5. Expression of genes involved in influx of macrophages and immune cells, regeneration, extracellular matrix 
stability, fibrosis and exercise. (A) Quadriceps, (B) gastrocnemius, (C) tibialis anterior, (B) triceps, (E) heart, (F) 
diaphragm. No significant difference was found between the functionally challenged and unchallenged mice for all 
the muscles examined. 
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Correlation between muscle function, histology and biomarker levels 
Spearman correlation analysis was conducted to test for correlations between the functional 
performance, histological results and relative RNA levels of the genes examined in the current 
study. In addition we determined the correlation between genes (Table 1). No significant 
correlation was found between performance and histology, or between performance and serum 
CK levels. A positive correlation was observed between forelimb grip strength and the four limb 
hanging wire test (P = 0.016). Elevated serum CK levels correlated positively to the severity of 
fiber damage in the diaphragm (P = 0.026). A significant positive correlation was found between 
the percentage of fibrosis and both immunological genes (CD68 P = 0.011 and Lgals3 P = 0.006) in 
the tibialis anterior, indicating that the expression of these genes was increased in mice that had 
more fibrosis. In the gastrocnemius a significant positive correlation was found between histology 
and gene expression of CD68 (P = 0.013), MyoG (P = 0.006), Nox2 (P = 0.033) and Lox (P = 0.003). 
GLUT 4 was positively correlated with histopathology in the quadriceps (P = 0.042) and Bgn was 
positively correlated with histopathology in the diaphragm (positive, P = 0.017) and PGC-1α 
(negative, P = 0.021). Almost all examined muscles showed a correlation between the 
immunological and fibrotic genes. In addition, correlations between genes involved in 
macrophage and immune cells influx, fibrosis and regenerative genes were found in some 
muscles. Bgn was correlated to immunologic and fibrotic genes in the quadriceps and triceps. 
Most correlations between genes were found in the quadriceps (21) and the fewest in the heart 
(6).  
 
Table 1 Significant correlations between histology, biomarkers and muscle function. Both tissue dependent positive 
and negative correlations were found between genes. Functional performance did not correlate to gene expression or 
histopathology, but some tests results did correlate to other tests. Fiber pathology did correlate to serum CK levels in 
the diaphragm. TA, tibialis anterior; G, gastrocnemius; Q, quadriceps; T, triceps; H, heart; D, diaphragm; LHW, limb 
hanging wire. Normal and bold abbreviations resemble positive and negative correlations, respectively. All 
correlations have P values <0.05. 
 
Discussion 
There is an increasing interest to gain more insight into the natural progression of the phenotype 
of the mdx mice on a functional, histological and biomarker level, since multiple studies aim to 
assess the efficacy of genetic or pharmacologic treatment strategies. Recently, effort was put into 
the standardization of pre-clinical testing in mdx mice with an emphasis on functional testing 
(Grounds et al. 2008;Spurney et al. 2009;Willmann et al. 2009). Due to inconsistencies in the 
experimental methods used, such as differences in outcomes measures, initiation age of the 
animals and exercise intensity and duration, discrepancies in the effects of exercise on disease 
progression are often seen in literature. Whether beneficial or detrimental effects will be found is 
largely influenced by the type of exercise. A delay in pathology progression can be found after 
voluntary exercise, such as swimming or wheel running (Carter et al. 1995;Dupont-Versteegden 
et al. 1994;Hayes and Williams 1998), while forced horizontal treadmill exercise results in muscle 




2003;De Luca et al. 2008;Granchelli et al. 2000). In addition, age dependent effects have been 
found within an experimental protocol, where detrimental and beneficial effects were found in 
young (4 weeks) and old (16 weeks) animals, respectively (Faist et al. 2001). In pharmacological 
studies, treadmill exercise is often used to aggravate the pathogenic phenotype, after which grip 
strength analysis is used to monitor functional improvement (De Luca et al. 2008). Until now, the 
effect of a combination of several functional tests addressing different muscle groups and/or 
coordination on disease progression of mdx mice has not been studied.  
We here assessed the effects of a 12 week functional test regime consisting of four 
functional tests, not including the treadmill, on disease progression. Our objective was to have a 
functional testing regime of which the outcome parameters would not interfere with the normal 
disease progression. We determined differences in histopathology and expression levels of 
previously identified fibrotic and immunologic RNA biomarkers between functionally challenged 
and unchallenged mice. The functional test regime used is intense and requires prolonged daily 
mouse handling. As this is an unavoidable part of functional testing, we actually compared the 
combination of functional testing and handling-induced stress to unchallenged mice that were 
handled only twice weekly for a short period to assess weight and CK. The fluctuations in body 
weight found in the present study might be caused by the functional test regime, however it 
cannot be ruled out that differences in handling time play a role as well. 
Our functional test regime was chosen to assess which of the tests showed the lowest 
variation between mice over time, without interfering with disease pathology, thereby providing 
the most reliable outcome parameter(s). The current study included five male mdx mice per 
group, which is small. However, in a similar set up using dystrophic mice of different severities, 
we were able to pick up significant differences (unpublished data). To optimally use the mdx 
mouse for the efficient development of novel therapies to be used in humans, it is crucial to 
perform long-term blinded controlled studies in young and old mice, which thoroughly assess 
and compare the clinical phenotype of active versus placebo-treated animal cohorts. For these 
studies even longer term functional test regimes are needed.  
The obtained grip strength and Rotarod data showed an age dependent performance 
decrease that is in accordance with previous data in sedentary mdx mice (mice that did not 
perform treadmill running prior to the functional test). The grip strength data obtained with the 
Ugo Basile meter are not comparable to those obtained by a Columbus meter by others. 
Preliminary data obtained with the Columbus meter in our mdx mice indicate that approximately 
two fold lower values are obtained with the Ugo Basile meter. Exercise, especially eccentric 
contraction, is known to directly cause an intensity dependent increase in serum CK level 
(Vilquin et al. 1998). Our functional test regime had no influence on the serum CK levels of the 
mice, which indicates that the functional test regime was mild. Carter et al. also found no effect 
on serum CK in mice that were exposed to voluntarily wheel running, while treadmill running is 
known to increase CK levels in mdx mice (Carter et al. 1995;De Luca et al. 2008). Both hanging 
wire test designs have not been reported before and the performances could therefore not directly 
be compared with results obtained by others. However, an age dependent de cline in hanging 
performance was earlier obtained with a different hanging wire test design (Golumbek et al. 
2007).  
Histological examination found no difference in pathology along the muscles. This 
indicates that the pathological features were equally distributed throughout the muscle. No 
difference in severity of muscle damage was found between the functionally challenged and 
unchallenged mice, which is in consensus with earlier data obtained after mild exercise (Carter et 
al. 1995). The percentage of damaged muscle differed between muscles, with the highest 
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percentage found in the diaphragm, which is known to be the most severely affected muscle in 
these mice (Ishizaki et al. 2008).  
The here described semi-automatic procedure to determine histopathology provides an 
unbiased, accurate and fast method to determine the severity of histopathology in entire muscle 
cross sections. The main advantage of this methodology is that it provides an objective measure of 
fibrotic tissue but also of necrotic tissue, in contrast to other analysis in which only a collagen 
specific staining is used to determine the fibrosis percentage (Ishizaki et al. 2008). Furthermore, 
for this analysis the entire cross section of the muscle is used and not only a subsection, as was 
done in previous studies (Turgeman et al. 2008). Finally, the analysis software is freely available. 
This all together makes it an attractive method to determine histopathology in mdx mice.  
In addition to comparing the functionally challenged and unchallenged mice on a 
histological level, we also looked at expression levels of several RNA biomarkers, but found no 
difference. Lox is known to be significantly increased in mdx mice compared to wild type mice 
(Spurney et al. 2009). A decreased Lox expression was expected in the heart upon a beneficial 
effect of exercise. However, no difference was found for this gene. This may be because the 
functional test regime was too mild to have an effect on the heart. Upon exercise the expression 
of genes like PGC-1α and GLUT 4 were expected to increase, which is in contrast to our findings. 
However, the time gap between the last exercise and dissection was four days while in the study 
of Baar et al. this period was limited to 6 h (Baar et al. 2002). Therefore, by the time we analyzed 
the muscles, expression levels probably had already normalized. Comparison of gene expression 
levels between the different muscles was impossible due to the experimental design, which was 
aimed at comparing functionally challenged and unchallenged mice.  
With the Spearman analysis, muscle dependent correlations between immunologic, 
fibrotic and regenerative genes were found. These correlations were in accordance to the 
pathogenic cellular events, in which necrotic fibers initiate immune responses and will be 
replaced by newly generated fibers (Deconinck and Dan 2007). Elevated serum CK levels 
correlated positively to the severity of fiber damage in the diaphragm. Due to a relative small 
sample size and high variation in biomarkers and other variables possible existing correlations 
might have been missed. A correlation between functional performance, histopathology and gene 
expression was not found. Possible correlations are likely to become undetectable due to high 
individual variations, but might be detected after a forced treadmill running protocol, which 
enhances the pathological phenotype.  
Our findings indicate that our functional test regime is a useful tool to monitor muscle 
function and/or coordination in young mdx mice over time without accelerating the disease 
progression. Combined with our histological assay, this provides a convenient and accurate tool to 
functionally monitor the natural course of the disease in mdx mice.  
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The genetic defect of mdx mice resembles that of Duchenne muscular dystrophy, although their 
functional performance and life expectancy is nearly normal. By contrast, mice lacking utrophin 
and dystrophin (mdx/utrn -/-) are severely affected and die prematurely. Mice with one utrophin 
allele (mdx/utrn +/-) are more severely affected than mdx mice, but outlive mdx/utrn -/- mice. We 
subjected mdx/utrn +/+, +/-, -/- and wild type males to a 12 week functional test regime of four 
different functional tests. Mdx/utrn +/+ and +/- mice completed the regime, while mdx/utrn -/- mice 
died prematurely. Mdx/utrn +/- mice performed significantly worse compared to mdx/utrn +/+ mice 
in functional tests. Creatine kinase levels, percentage of fibrotic/necrotic tissue, morphology of 
neuromuscular synapses and expression of biomarker genes were comparable, whereas mdx/utrn 
+/- and -/- mice had increased levels of regenerating fibers. This makes mdx/utrn +/- mice valuable 
for testing the benefit of potential therapies on muscle function parameters. 
 
Introduction 
Duchenne muscular dystrophy (DMD) is an X-linked, severe, muscle wasting neuromuscular 
disorder leading to death in the early thirties in the Western world. Due to frame shifting or 
nonsense mutations in the DMD gene, truncated, non functional dystrophin proteins are 
synthesised. Intact dystrophin is part of the dystrophin–associated protein complex that connects 
the extracellular matrix to the cytoskeleton thereby providing muscle fibers with stability during 
contraction. In the absence of dystrophin, fibers are more injury-susceptible and eventually the 
regenerative capacity of the fibers becomes exhausted resulting in the replacement by connective 
and adipose tissue (Hoffman et al. 1987).  
The mdx mouse, which carries a nonsense mutation in exon 23 of the mouse Dmd gene, 
is the most commonly used mouse strain for DMD research. Despite the resembling genetic 
defects, their functional performance and life expectancy is nearly normal, which is thought to 
result from a combination of improved regeneration, upregulation of muscle transcription factors 
like myoD and functional compensation by upregulation of the dystrophin homologue utrophin 
(Deconinck et al. 1997c;Sicinski et al. 1989).  
During development, utrophin is predominantly found at the sarcolemma of developing 
and regenerating fibers before dystrophin is expressed (Perronnet and Vaillend 2010). In mature 
muscle fibers, dystrophin replaces utrophin, which is in this phase only present at the 
neuromuscular junction (NMJ) where it colocalizes with acetylcholine receptors and is involved 
in post-synaptic membrane maintenance and acetylcholine receptor clustering (Ohlendieck et al. 
1991;Pons et al. 1993). In DMD patients, female DMD carriers and the mdx mouse, the expression 
of utrophin at the extra-synaptic sarcolemma is dramatically increased in dystrophin negative 
fibers (Kleopa et al. 2006;Mizuno et al. 1993). In mdx mice, muscles with the greatest 
upregulation of utrophin exhibit the least pathological changes and are most resistant to injury 
(Tinsley et al. 1996). Also in DMD patients, a negative correlation between utrophin upregulation 
and disease severity has been described (Kleopa et al. 2006). Moreover, overexpression of a 
truncated or full length utrophin in mdx mice improves dystrophic pathology in a utrophin 
concentration dependent manner (Baban and Davies 2008;Deconinck et al. 1997c;Squire et al. 
2002;Tinsley et al. 1998;Tinsley et al. 1996). Mice lacking only one or both utrophin alleles are 
viable and fertile and display only a mild (subclinical) congenital myasthenia, which was 
concluded to result from effective replacement of utrophin by dystrophin at the NMJ (Deconinck 
et al. 1997b;Grady et al. 1997b).  
By contrast, mice deficient for both dystrophin and utrophin (mdx/utrn -/-) are severely affected, 




reduced life expectancy of around 3 months, thus more closely resembling the DMD patient 
phenotype (Deconinck et al. 1997b;Grady et al. 1997b). Unfortunately, since mdx/utrn -/- mice are 
short lived and difficult to breed and maintain, they are not an ideal animal model for the study 
of long term effects of potential therapeutic compounds. In addition, on a histological level, 
mdx/utrn -/- mice are comparable to mdx mice, possibly because they do not live long enough to 
develop a more severe dystrophic and/or fibrotic phenotype (Deconinck et al. 1997b). Mdx mice 
with haploinsufficiency of the utrn gene (mdx/utrn +/-) have an almost normal life span, but show 
more pronounced skeletal inflammation and fibrosis at an age of 3 and 6 months, respectively 
(Zhou et al. 2008). At 6 months of age, they also show a more severe impaired respiratory 
function and fibrosis of the diaphragm than mdx mice (Huang et al. 2011). This suggests that the 
functional compensation of dystrophin by utrophin is incomplete when expressed in a 
heterozygous manner in mdx mice.  
To assess how heterozygous expression of utrophin in mdx mice affects disease 
progression, muscle function and histology, mdx/utrn -/-, mdx/utrn +/-, mdx/utrn +/+ and 
C57BL/10ScSnJ (wild type) mice were subjected to a previously developed 12 week functional test 
regime addressing strength and coordination of different muscle groups (van Putten et al. 2010). 
We show here that mdx/utrn +/- mice perform significantly worse than mdx/utrn +/+ mice, while 
levels of fibrosis and mRNA biomarkers are comparable at 4 months of age. We propose that the 
mdx/utrn +/- model is a more suitable mouse model for testing potential therapies for DMD. 
 
Materials and methods  
Animal care 
All studied mouse strains were bred at the animal facility of the LUMC where they were housed 
in individually ventilated cages with 12-h light–dark cycles. Mice were given standard chow and 
water ad libitum. Breeding pairs of mdx mice heterozygous for a utrophin knockout mutation 
(mdx/utrn +/-) gave birth to mdx mice with two (mdx/utrn +/+), one (mdx/utrn +/-) and zero 
(mdx/utrn -/-) utrophin alleles. Genotyping was performed on DNA obtained from tail tips by PCR 
analysis (primers and PCR condition on request). All experiments were approved by the Animal 
Experimental Committee (DEC) of the LUMC. 
 
Functional tests 
Four week old male mdx/utrn +/+, +/-, -/- and C57BL/10ScSnJ mice (n = 6 per group) were subjected 
to a 12 week functional test regime consisting of four different functional tests, each addressing 
different muscle groups and/or coordination (van Putten et al. 2010). Mice performed the tests in 
the afternoon on consecutive days on a weekly basis. Body weight was assessed at the beginning 
and end of each week. Where possible, standard operating procedures from the TREAT-NMD 
network were implemented (http://www.treat-nmd.eu/resources/research-resources/dmd-sops/). 
 
Fore limb grip strength test  
Fore limb grip strength was assessed by means of a grip strength meter (Columbus Instruments, 
USA). Mice were suspended above a grid which they instinctively grasped. Mice were then pulled 
backwards so that they released the grid. This was repeated five times in a row. The average of 
the three highest measured values was used to calculate the absolute strength, which was divided 
by the body weight in grams to obtain the normalized strength. 
 
 




Mice were placed on the Rotarod (Ugo Basile, Italy) that accelerated from 5 to 45 rotations per 
minute within 15 s. The test session ended when a mouse ran for 500 s without falling. Two more 
tries were given to mice that fell off within 500 s. The longest running time was used in all 
analyses. 
 
Two limb hanging wire test 
Mice were suspended above a metal cloth hanger which was secured above a cage with bedding 
and released a few seconds after instinctively grasping the wire with the fore limbs. Depending 
on the functional ability of the mouse, all limbs and the tail were used during a 10 min hanging 
session. Mice that fell down before the 10 min time limit were given two more tries. The longest 
hanging time was used for further analysis. 
 
Four limb hanging wire test 
The start position of this test was with all four limbs. To this end, mice were placed on a grid, 
which was then turned upside down above a cage filled with bedding. The session ended after a 
hanging time of 10 min was achieved or otherwise after three sessions. The maximum hanging 
time was used for further analysis. 
 
Creatine kinase level analysis 
Blood was collected weekly on Monday mornings via a small cut at the end of the tail in a 
Minicollect tube (0.8 ml Lithium Heparin Sep, Greiner bio-one, Austria). Creatine kinase (CK) 
levels were determined in plasma with Reflotron CK test strips in the Reflotron plus machine 
(Roche diagnostics Ltd., UK). 
 
Histological examination 
After performing the functional test regime for 12 weeks, mice (aged 16 weeks) were euthanized 
by cervical dislocation and the tibialis anterior, triceps and quadriceps were dissected and snap 
frozen in 2-methylbutane (Sigma–Aldrich, The Netherlands) cooled in liquid nitrogen. Sections 
of 8 μm were cut on Superfrost Plus slides (Thermo Fishes Scientific, Menzel-Gläser, Germany) 
with a Shandon cryotome (Thermo Fisher Scientific Co., Pittsburgh, PA, USA) along the entire 
length of the muscle with an interval of 240 μm between the sections. The excess tissue belonging 
to the 240 μm intervals was collected in MagNa Lyser Green Beads tubes (Roche diagnostics Ltd., 
UK) for total RNA isolation. Sections were fixed for 5 min with icecold acetone and stained with 
Harris Haematoxylin and Eosin (H&E) (Sigma–Aldrich, The Netherlands) according to 
conventional histological procedures. Sections were examined with a light microscope (Leica DM 
LB, Leica Microsystems, The Netherlands) at a 5 times magnification and images were captured 
with a Leica DC500 camera and Leica IM50 software (Leica Microsystems, The Netherlands) from 
the middle section of the muscles. Blending and background correction was performed with 
Adobe Photoshop CS3 version 10.0.1. Freely available ImageJ software with the H&E color 
deconvolution plugin (Rasband, W.S., ImageJ, U. S. National Institutes of Health, Bethesda, 
Maryland, USA, http://rsb.info.nih.gov/ij/) was used to determine the fibrotic/necrotic percentage 
of the entire cross section by two individuals in a double blinded manner, as described previously 
(van Putten et al. 2010).  
Fiber size and the proportion of centrally nucleated fibers were determined with 




tibialis anterior. Sections were stained with a laminin antibody, (ab11575, dilution 1:50, Abcam, 
USA), goat-anti-rabbit Alexa 594 (dilution 1:1000, Invitrogen, The Netherlands) and DAPI. 
Sections were examined and the middle section of the muscle was captured with a fluorescent 
microscope (Leica DM 5500B) and a Snapshot camera (Photometrics Coolsnap K4) at a 5 times 
magnification. Images were mozaiked with the Mayachitra Imago 1 
(http://www.mayachitra.com/imago/) and preprocessed with ImageJ to obtain an even 
illumination of laminin. Pictures were segmented by the Mayachitra Imago software based on the 
staining intensity difference between the membranes and the cytoplasm. Of these segmented 
fibers, the area (μm2), fiber density and the percentage of central nucleation were determined. 
Fibers were assessed for presence of centralized nuclei based on the maximum intensity (from the 
blue channel) of the cytoplasm. Objects smaller than 200 μm2 were excluded from analysis. Fiber 
density was determined by dividing the total number of fibers by the total area of the cross 
section.  
Utrophin and dystrophin expression was analyzed for the quadriceps stained with 
utrophin (MANCHO7, dilution 1:50, Santa Cruz, Germany), dystrophin (C-20, dilution 1:50, 
Santa Cruz, Germany), donkey-anti-goat Alexa 594 (dilution 1:1000, Invitrogen, The 
Netherlands) and DAPI with use of the mouse on mouse (MOM) kit (Vector Laboratories, UK). 
Sections were examined with a fluorescent microscope (Leica DM RA2) at a 16 times 
magnification and captured with a Leica DC350FX Snapshot camera.  
Morphology of the NMJ was assessed on whole-mount diaphragm muscles of two mice 
per genotype. The snapfrozen diaphragm was thawed in PBS, pinned out on a silicone-rubber 
lined Petri dish and fixated with 1% paraformaldehyde in PBS for 30 min after it was washed 
with PBS (30 min). Incubation with Alexa Fluor 488 α-bungarotoxin (1 μg/ml, Molecular Probes, 
The Netherlands) lasted 2.5 h and was followed by PBS washing (30 min). All incubations were 
performed at room temperature (20–22 °C). Muscle strips were mounted with Citifluor AF-1 
(Citifluor Ltd., UK) and covered with a cover slip which was secured with nail polish. Slides were 
examined with an Axioskop 2FS microscope equipped with fluorescence optics (Zeiss, Jena, 
Germany) at a 400 times magnification and pictures were taken using Zeiss Axiovision (Kaja et al. 
2007). 
 
Western blot analysis 
Muscles were homogenized using treatment buffer (100 mM Tris–HCl pH 6.8 and 25% SDS) 
using MagNa Lyser green beads in the MagNa Lyser (Roche Diagnostics, The Netherlands). 
Protein concentration was determined with the BCA protein assay kit (Thermoscientific, IL, 
USA), according to the manufacturer’s instructions. Subsequently, the homogenate was 
complemented to contain 75 mM Tris–HCl pH 6.8, 15% SDS, 5% β-mercaptoethanol, 20% 
glycerol and 0.001% bromophenol blue. Samples (50 μg) were boiled for 5 min and 75 μl was 
loaded on a 4–7% gradient polyacrylamide gel and run overnight at 4 °C. Gels were blotted to 
nitrocellulose BA83 (Whatman, Schleicher & Schuell, Germany) for 6 h at 4 °C and blocked with 
5% non-fat dried milk (Campina Melkunie, The Netherlands) in TBS. Primary utrophin antibody 
8A4 (dilution 1:100, Santa Cruz, Germany) was incubated over night at 4 °C. The fluorescent 
IRDye 800CW goat-anti-mouse IgG (dilution 1:5000, Li-Cor, NE, USA) was used as a secondary 
antibody. Blots were visualized and quantified with the Odyssey system and software (Li-Cor, 








cDNA was synthesised from 1 μg of total RNA with random hexamer primers and expression 
levels of genes involved in regeneration (Myog, Myh3), inflammation (Lgals3, Cd68) and fibrosis 
(Col1a1, Lox) were determined by Sybr Green based Real Time qPCR (95 °C 10 s, 60 °C 30 s, 72 °C 
20 s, 45 cycles followed by melting curve analysis) on the Roche Lightcycler 480 (Roche 
diagnostics Ltd., UK). Gapdh was used as a reference gene, since the expression of this gene did 
not differ between different strains, different muscles or over time. Primer efficiencies were 
determined and analysis was performed with LinREgPCR version 11.1 (Ramakers et al. 2003). 
The average expression levels of C57BL/10ScSnJ mice were set to one. 
 
Statistics 
Statistical analyses were performed with statistical software in R (version R2.11.1). Figs. 1 and 2 
summarize the data, i.e. showing the mean and standard deviation per genotype and age. To 
overcome applying separate tests for each age between genotypes, which suffers from multiple 
testing and ignores the age trend, we applied an analysis of covariance (ANCOVA) to the data. 
ANCOVA was applied to temporal functional performance, body weight and CK level data with 
age as continuous and genotype as a categorical variable. In choosing the appropriate model we 
applied the principle of parsimony. Given the application of tests for several different variables, 
we considered P<0.01 as significant.  
The two-tailed homoscedastic Student’s t-test was conducted for comparison of the 
single time point histological and gene expression data. P<0.05 was used to determine significance 





Four week old male mdx/utrn +/+, mdx/utrn +/-, mdx/utrn -/- and wild type mice followed a 12 week 
functional test regime consisting of four different functional tests on consecutive days on a 
weekly basis (van Putten et al. 2010). The test regime consisted of fore limb grip strength, rotarod 
running and two and four limb hanging wire tests. Mdx/utrn -/- mice were humanely sacrificed 
when their body weight had dropped >15% within 2 days, which was the case between 6 and 9 
weeks of age for all mice (Fig. 1A). All mdx/utrn -/- developed severe kyphosis and showed 
difficulties moving and breathing. Once a week, body weight and plasma CK levels were assessed. 
When body weight was compared between groups over time, mdx/utrn -/- mice were significantly 
(P<0.01) lighter compared to the other strains (Fig. 1B). By contrast, mdx/utrn +/- mice were 
significantly (P<0.01) heavier than both mdx/utrn +/+ and wild type mice. Plasma CK levels were 
significantly (P<0.01) elevated for all mouse strains compared to wild type (<500 U/L), but no 
differences were found between the dystrophic strains (Fig. 1C).  
Wild type mice outperformed (P<0.01) all the dystrophic mouse strains in the fore limb 
grip strength test with an average normalized fore limb strength of 5.4. No difference was 
observed between the mdx/utrn +/+, +/- and -/- mice ((5.0, 4.9, 4.2, respectively) Fig. 2A). On the 
rotarod, the wild type mice ran, with an average highest running time of 224 s, significantly 





Fig. 1. Survival, body weight and 
plasma CK levels of the different 
mouse strains over time. (A) 
Survival curve of the mdx/utrn -/- 
mice. All mice died before the 
age of 10 weeks. (B) Body weight 
of mdx/utrn -/- mice was 
significantly lower than that of 
all other mouse strains. Mdx/utrn 
+/- mice were significantly heavier 
than mdx/utrn +/+ and wild type 
mice. (C) CK levels of the wild 
type mice were significantly 
lower (<500 U/L) when compared 
to the three dystrophic mouse 
strains, which did not differ 
among themselves. Data 
represent the mean and standard 






















Up to an age of 10 weeks, no difference between the dystrophic mouse strains was observed. 
However, from 11 weeks on, running times for mdx/utrn +/+ increased and mice ran significantly 
(P<0.01) longer (140 s) than age-matched mdx/utrn +/- mice (average 77 s), which performance did 
not increase and remained as poor as the mdx/utrn -/- mice did when they were still alive (Fig. 
2B). For the hanging wire tests the maximum hanging time was used as outcome measure which 
did not differ between wild type and mdx/utrn +/+ mice for both the two and four limb hanging 
wire tests (Fig. 2C and D). Mdx/utrn +/- mice hang for a significantly shorter time period of 141 
and 135 s, for the two and the four limb hanging test, respectively. The two limb hanging test 
performance of the mdx/utrn -/- mice was as bad as that of the mdx/utrn +/- mice, whereas they 
performed better in the four limb hanging test. This is because of the survival of only the good 
performing mice. 
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Fig. 2. Functional test performance of 
the different mouse strains over the 12 
week functional test regime. (A) 
Normalized grip strength was 
significantly higher in wild type mice 
when compared to the dystrophic 
mouse strains, but did not differ 
between them. (B) Rotarod running 
times of wild type mice were 
significantly longer (224 s) than that of 
mdx/utrn +/+ mice. From an age of 10 
weeks, mdx/utrn +/- mice ran 
significantly shorter (77 s) than 
mdx/utrn +/+ mice (140 s), but running 
times did not differ from mdx/utrn -/- 
mice. (C) Two limb hanging wire 
performance was best for wild type and 
mdx/utrn +/+ mice. Mdx/utrn +/- and -/- 
performed significantly worse. (D) In 
the four limb hanging wire test, wild 
type and mdx/utrn +/+ mice had a 
significantly longer hanging time than 
mdx/utrn +/- mice. For all mice except 
for the mdx/utrn -/- mice maximum 
hanging time was longer in the two 
limb hanging tests than the four limb 
hanging test (compare C versus D). 
Data represent the mean and standard 






After the mice completed the 12 week functional test regime, they were sacrificed and skeletal 
muscles were isolated. Cryosections of the quadriceps stained for utrophin and dystrophin 
showed a strong dystrophin staining in the wild type mice, whereas utrophin staining was weak. 
By contrast, fibers were clearly utrophin positive in the mdx/utrn +/+  and +/- mice (Fig. 3A). As 
anticipated, mdx/utrn -/- mice lacked both dystrophin and utrophin. These results were confirmed 
by western Blot analysis, which showed an upregulation of utrophin in mdx/utrn +/+  mice and to 
a lesser extent in the mdx/utrn +/- mice of approximately 2.2- and 1.8-fold, respectively (Fig. 3B).  
 
Fig. 3. Utrophin and dystrophin immunostaining and western blot analysis of the quadriceps. (A) Fibers of wild type 
mice expressed dystrophin whereas utrophin was hardly detectable. Fibers of mdx/utrn +/+ and +/- mice were strongly 
positive for utrophin staining, while dystrophin staining was negative. In mdx/utrn -/- mice, fibers were negative for 
both utrophin and dystrophin. (B) Utrophin western blot of the quadriceps. Utrophin was upregulated in both 
mdx/utrn +/+ and +/- mice, but to a larger extent for mdx/utrn +/+ mice. Each lane represents an individual mouse. 
Mdx/utrn -/- mice did not express utrophin. Scale marker is 64 μm. 
 




Fig. 4. Percentage of fibrotic/necrotic area, central nucleation, fiber size and density. (A–C) For the tibialis anterior 
and triceps no significant difference in the percentage of fibrosis/necrosis was observed between the dystrophic 
mouse strains. In the quadriceps, the level significantly differed between mdx/utrn +/- and -/- mice. The levels in the 
wild type mice were significantly lower (P<0.05) than the other mouse strains as indicated by the #. Single asterisks 
indicate a P<0.05. (D–E) The fiber size and percentage of central nucleation was automatically determined with 
Mayachitra Imago, which segments the fibers into individual objects. Based on the maximum intensity (from the blue 
channel) of the cytoplasm, fibers were assessed for presence of centralized nuclei. The percentage of centralized 
nuclei was significantly increased in the dystrophic mouse strains compared to the wild type. The mdx/utrn -/- mice 
had significantly more central nucleated fibers than the mdx/utrn +/+ mice. (E) Especially the mdx/utrn +/- and -/- mice 
had a large number of small regenerated fibers (<1000 μm2). No hypertrophic fibers were found in the mdx/utrn -/- 
mice. (F) Fiber density was comparable between wild type, mdx/utrn +/+ and +/- mice. Significantly higher densities 





The percentage of fibrotic/necrotic tissue was assessed in all mouse strains for the tibialis 
anterior, triceps and quadriceps on H&E stained complete cross sections obtained from the middle 
part of the muscle. The proportion of fibrosis, necrosis, connective tissue and freshly regenerated 
tissue was determined with a color deconvolution plugin of Image J as described previously (van 
Putten et al. 2010). Wild type mice had significantly less fibrotic/necrotic tissue (~2%) than the 
dystrophic mouse strains, for which the histopathological severity did not significantly differ 
between the strains and varied between 8% and 13% for the different muscles (Fig. 4A–C). Only 
for the quadriceps, a significant difference (P<0.05) between mice with 1 and 0 utrophin alleles 
was observed.  
Fiber size distribution, fiber density and the percentage of centralized nuclei was 
determined on the middle section of the tibialis anterior stained for laminin and DAPI. Pictures 
were automatically analyzed with Mayachitra Imago which segmented the image and defined 
fiber area based on the number of pixels within an object and centralized nuclei based on the 
maximum intensity of fibers (Fig. 4D and E). The percentage of centrally nucleated fibers was 2% 
in wild type mice, while it was over 50% in the dystrophic mouse strains. A clear trend was 
observed, in which the number of utrophin alleles of the mice correlated to the number of 
centrally nucleated fibers, which reached significance when comparing mice with two or zero 
utrophin alleles. In line with this trend, we also observed a higher number of small regenerated 
fibers (<1000 μm2) in the more severely affected mdx/utrn +/- and -/- mice. No hypertrophic fibers 
were observed for the mdx/utrn -/- mice, while they were present in the sections of the mdx/utrn 
+/- mice and to a bigger extent in mdx/utrn +/+ mice. The fiber size distribution of the mdx/utrn +/+ 
mice matched that of the wild type mice more than those of the mdx/utrn +/- and -/- mice. Fiber 
density (number of fibers per μm2) was determined for all mice by dividing the total number of 
fibers by the total area of the whole cross section. We observed no significant difference between 
any of the mouse strains (Fig. 4F). Since mdx mice are known to have hypertrophic muscle and 
we observed that mdx/utrn +/- mice also have hypertrophic muscle to some extent, their muscle 
mass to body weight (muscle mass divided by body weight) of the quadriceps and gastrocnemius 
was compared (n = 4–6). Muscle mass to body weight ratio of mdx/utrn +/+ mice (quadriceps mean 
0.0080, SD 0.0009 and gastrocnemius mean 0.0062, SD 0.0006) did not significantly differ from 
that of mdx/utrn +/- mice (quadriceps mean 0.0081, SD 0.0016 and gastrocnemius mean 0.0062, SD 
0.0011) as was previously reported (Deconinck et al. 1997b). It should be noted, however, that the 
mdx/utrn +/- mice were significantly heavier than the mdx/utrn +/+ mice.  
To qualitatively assess the effect of expression of one, two or zero utrophin alleles in 
mdx mice on the morphology of NMJs, the diaphragm of two mice per genotype was stained with 
Alexa Fluor 488 α-bungarotoxin and viewed with fluorescence microscopy (Fig. 5). NMJs of wild 
type mice generally had continuous branches of acetylcholine receptor while most synapses of 
the dystrophic mouse strains showed discontinuous, more punctuate staining (Ferretti et al. 
2011;Ghedini et al. 2008;Grady et al. 1997b;Lyons and Slater 1991). This punctuate pattern was 
observed to more or less equal extent in all dystrophic genotypes, the current quantitative 










Fig. 5. Diaphragm NMJs stained with Alexa Fluor 488 α-bungarotoxin, which labels acetylcholine receptors. 
Representative pictures of synapses of two different mice per genotype. Clear distinctions in morphology are visible 
between wild type and dystrophic mice. The majority of wild type synapses are intact and show continuous 
acetylcholine receptor area branches that are arranged in an elliptical manner. Most synapses of the dystrophic 
mouse strains had a more disorganized, punctuate structure with discontinuous branches, with apparent qualitative 






The expression of some potential biomarker genes known to be involved in different pathological 
processes was determined in the quadriceps of mice of the four strains that underwent the 
functional test regime. For each gene, expression was upregulated in the three dystrophic mouse 
strains compared to wild type levels (Fig. 6). In concordance with the histological analysis, no 
significant difference was observed between mdx/utrn +/+ and +/- mice, although a trend of higher 
levels in the mdx/utrn +/- mice was found. The mdx/utrn -/- levels were increased or comparable to 
mdx/utrn +/- levels. As the mdx/utrn -/- mice were younger than the other strains (8–9 weeks 
versus 16 weeks) due to their premature death, we also checked the expression levels in the 
gastrocnemius of 6 week old mice for the four strains, to exclude that the observed differences 
were age related. Also in these young mice, a significant lower expression was found in wild type 
mice than in the dystrophic mouse strains. Between the dystrophic mice, a clear disease severity-
related trend was observed for all genes, except for Col1a1, with the mdx/utrn -/- mice showing 
the highest levels, followed by mdx/utrn +/- and mdx/utrn +/+ mice. For Lgals3 and Myh3 the 
difference between mdx/utrn +/+ and -/- mice reached significance.  
 
Fig. 6. Biomarker gene expression in 16 and 6 weeks old mice. (A and B) Expression of genes involved in regeneration 
(Myog, Myh3), inflammation (Lgals3, Cd68) and fibrosis (Col1a1, Lox) was elevated in 16 weeks old mdx/utrn +/- mice 
compared to the other mouse strains. Note that the mdx/utrn -/- mice were sacrificed between the age of 6 and 9 
weeks as a consequence of their severe phenotype. (C and D) For all genes in the age-matched mice, the expression 
level was the highest in mdx/utrn -/- mice, followed by the mdx/utrn +/- and the +/+ mice. Expression values shown 
have been normalized with Gapdh expression and are shown relative to wildtype values. 




Pre-clinical research on DMD pathology and the development of potential therapies has primarily 
made use of the mdx mouse, which resembles the genetic defect found in DMD patients 
(Willmann et al. 2009). Unfortunately, since the mdx mouse’s functional ability and lifespan is 
only slightly reduced and none of the skeletal muscles except the diaphragm show severe 
histopathology, the mouse does not resemble the pathology observed in DMD patients. One of 
the underlying causes of the improved phenotype is upregulation of utrophin which is less 
pronounced in patients than it is in mdx mice. The mdx/utrn -/- mouse more closely resembles the 
natural history of the disease with their short life span, kyphosis and walking difficulties 
(Deconinck et al. 1997b). Unfortunately, their fragility and limited life expectancy prevents long 
term treatment studies in these mice. With pre-clinical research focusing on the effect of 
potential therapeutic compounds on functional performance and fiber integrity, a mouse model 
more severely affected than the mdx mouse, but with a longer lifespan than the mdx/utrn -/- 
mouse would be very helpful.  
In this study, we tested how mono-allelic expression of utrophin affects muscle 
function, histopathology and disease progression. Mdx mice with two, one or zero utrophin 
alleles were subjected to a 12 week functional test regime. The performance of mdx/utrn +/- mice 
in the functional tests was as bad as that of mdx/utrn -/- mice and significantly worse than that of 
mdx/utrn +/+ and wild type mice for rotarod and two and four limb hanging wire tests. Since the 
performance of the mdx/utrn +/+ mice closely matched that of wild type mice, assessing functional 
improvement in mdx/utrn +/+ mice upon treatment is challenging. Using the functionally more 
hampered mdx/ utrn +/- mouse would enable better monitoring of functional improvement upon 
treatment. Only grip strength did not differ between mdx/utrn +/- and +/+ mice. Performance of 
mdx/utrn +/+ mice matched that of C57BL/10ScSnJ-DMDmdx/J mice (i.e. mdx mice on a pure 
BL10 background) tested with the same functional test regime (van Putten et al. 2010). An 
exception was the rotarod performance where C57BL/10ScSnJ-DMDmdx/J mice peaked at an age 
of 7 weeks, while mdx/utrn +/+ mice did not. This might result from the difference in background 
between the two strains, an observation which has been described previously for grip strength 
performance of two wild type strains (Connolly et al. 2001). For the four limb hanging wire test, 
mdx/utrn -/- mice even outperformed the mdx/utrn +/- mice, but this is caused by the survival of 
only the mouse which performed best in this test, while the mice that did not perform well died 
earlier. The bad functional performance of the mdx/utrn -/- mice is in line with previous findings 
of lower twitch and tetanus force, which is observed to a lower extent in mdx/utrn +/+ mice 
(Deconinck et al. 1998). No differences in CK levels between the dystrophic strains were observed 
over time but levels were significantly elevated for the dystrophic mouse strains compared to 
wild type as expected. When strains are compared for over half a year, mdx/utrn +/- mice have 
significantly higher CK levels than mdx mice (Tanganyika–de Winter et al., submitted for 
publication).  
Histopathology did not differ in severity between the three dystrophic mouse strains at 
an age of 4 months. This is in concordance with Zhou et al., who observed no difference in 
Collagen III immunostaining in quadriceps between mdx and mdx/utrn +/- mice aged 3 months 
(Zhou et al. 2008). Histopathology is known to increase in severity over time, as indicated by 
more pronounced fibrosis in 6 months old mdx/utrn +/- compared to mdx mice. The mdx/utrn  
-/- mice did have a significantly lower percentage of fibrotic/necrotic tissue in the quadriceps than 
the mdx/utrn +/- mice. The number of centrally nucleated fibers was increased in the mdx/utrn +/- 
and -/- compared to the mdx/utrn +/+ and wild type mice. The significant difference observed 




The high number of fibers with central nuclei observed in the mdx/utrn +/- and -/- mice nicely 
overlaps with that of small regenerated fibers in these mice. This indicates that the regeneration 
can still keep up in these more severe mice, which is in contrast to DMD patients, which usually 
have a lower regenerative capacity. Fiber density was significantly higher in mdx/utrn -/- 
compared to mdx/utrn +/+ and +/- mice, which corresponds to their high number of regenerated 
and low number of hypertrophic fibers. No significant difference was found between mdx/utrn +/+ 
and +/- mice, although fiber density was slightly lower in mdx/utrn +/+ mice. This slight difference 
is caused by the large proportion of hypertrophic fibers of the mdx/utrn +/+ that exceeded that of 
mdx/utrn +/- and wild type mice. On the other hand, the proportion of small regenerated fibers of 
mdx/utrn +/- exceeded that of mdx/utrn +/+ and wild type mice. Hypertrophy was not observed in 
the mdx/utrn -/- mice, which might be due to their short lifespan, during which damaged fibers 
are continuously replaced by newly regenerated fibers. Muscle mass to body weight ratio showed 
no significant difference between mdx/utrn +/+ and +/- mice. Previously, a similar comparison has 
been made between mdx and mdx/utrn -/- mice, for which no significant difference was found too 
(Deconinck et al. 1997b). However, one should keep in mind that mdx/utrn +/- and -/- mice are 
much heavier and lighter than mdx/utrn +/+ mice, respectively. This indicates that the capacity for 
hypertrophy appears to be unaffected by either partial or total utrophin deficiency. The 
differences observed in central nucleation and muscle fiber size probably also account to some 
degree for the reduced performance in the mdx/utrn +/- and -/- mice, which have been described 
previously for mdx/utrn -/- mice (Grady et al. 1997b).  
We also analyzed whether the bad motor performance observed in the mdx/utrn +/- mice 
might be partly caused by fatigability resulting from loss of acetylcholine receptors at the NMJ 
due to the mono-allelic utrophin expression. In mdx mice, the NMJ is remodelled in both its pre- 
and postsynaptic components due to continuous cycles of re- and degeneration (Ferretti et al. 
2011;Lyons and Slater 1991). Previous studies in utrn -/- and +/- mice, that do not have a behavioral 
or skeletal muscle phenotype, revealed that the overall structure of their NMJs is qualitatively 
normal (Deconinck et al. 1997a;Grady et al. 1997a). NMJs of mdx/utrn -/- mice do not qualitatively 
differ from those of mdx mice, although in these mice re- and degeneration is more pronounced 
(Grady et al. 1997b;Rafael et al. 2000). We showed with α-bungarotoxin staining of the 
diaphragm that neuromuscular synapses of the mdx/utrn +/+, +/- and -/- mice have more punctuate, 
discontinuous acetylcholine receptor area, while synapses of wild type mice generally have an 
area of continuous branches. Although our quantitative analysis does not allow for detection of 
subtle distinctions between the strains, we at least can conclude that massive acetylcholine 
receptor loss at the NMJ does not underlie muscle weakness of mdx/utrn +/- mice. To elucidate 
whether NMJ dysfunction contributes to fatigability of mdx/utrn -/- mice more detailed 
(physiological) investigation is needed.  
Expression levels of genes involved in regeneration, inflammation and fibrosis were 
tested in mice which underwent the functional test regime and were sacrificed at an age of 16 
weeks as well as in non-exercised 6 weeks old mice. For the older mice, a less pronounced trend 
was observed, which might be caused by the age difference of mdx/utrn -/- mice and the other 
strains. To test this, expression was also assessed in young mice, revealing that for all genes this 
was higher in mdx/utrn -/- mice compared to age-matched mdx/utrn +/- and +/+ or C57BL/10ScSnJ 
mice. The expression of the mdx/utrn +/- mice was higher than that of the mdx/utrn +/+ mice for all 
genes, although no significant difference was found. Given that the fibrosis of mdx/utrn +/- mice 
worsens after 6 months we anticipate larger difference at later ages. However, this was beyond 
the scope of this study.  
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Additional factors that might result in bad motor function of the mdx/utrn +/- mice are 
i.e. behavioral, force transmission and respiratory function related. Motor function tests 
performed in this study are not a reflection of a sole neuromuscular defect, such as fatigue or 
strength, but an integrated result of the whole body performance. As such, outcomes are also 
influenced by behavioral and coordination components, which might be altered in dystrophic 
mice to certain extents since both dystrophin and utrophin are expressed in the central nervous 
system, although expression does not overlap (Knuesel et al. 2000). Mdx mice suffer from 
behavioral abnormalities, however for mdx/utrn -/- mice this is unknown, because behavioral 
studies are hampered by their immobility and poor survival. Mice lacking one or two utrophin 
alleles in the presence of dystrophin at least show no behavioral abnormalities (Deconinck et al. 
1997a;Grady et al. 1997a).  
To determine whether individual muscles suffer from fatigue or loss of strength, 
experiments assessing e.g. specific forces and resistance to eccentric contractions should be 
performed. Mdx mice have decreased specific forces and resistance to eccentric contractions 
(Consolino and Brooks 2004;Deconinck et al. 1998;Dellorusso et al. 2001). To which extent the 
overall performance of the mdx/utrn +/- mice is affected by reduced muscle forces needs special 
attention and should be monitored aside motor function tests. In addition, the structure of the 
myotendinous junction, which is involved in force transmission from myofibrils across the 
muscle membrane to the extracellular matrix, might also play a role. The number of foldings in 
this structure is reduced in mdx mice, but to a greater extent in mdx/utrn -/- mice (Deconinck et 
al. 1997b). Future studies should address this in the mdx/utrn +/- mice. Finally, decreased 
respiratory function disables functional performance as well. A recent paper indicates that 
respiratory function in older (6 months) mdx/utrn +/- mice is impaired compared to mdx mice, 
while no difference is found at the age of 3 months (Huang et al. 2011). The mice used in this 
study might already experience respiratory impairment resulting in a lower functional 
performance. To which extent respiratory function disabled mdx/utrn +/- mice in their 
performance needs to be further elucidated.  
In conclusion, our findings indicate that mdx/utrn +/- mice have significantly impaired 
functional performance compared to mdx/utrn +/+ mice. Mdx/utrn +/- mice have a high life 
expectancy and develop a more severe histopathology when aging, which is already initiated at 4 
months, based on the increased mRNA muscle pathology biomarkers. This makes the mdx/utrn +/- 
mouse a better study subject to determine the benefits of potential therapeutic compounds than 
the mdx/utrn -/- and mdx/utrn +/+ mouse.  
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To identify serum biomarkers that allow monitoring of disease progression and treatment effects 
in Duchenne muscular dystrophy (DMD) patients, levels of matrix metalloproteinase-9 (MMP-9), 
tissue inhibitors of metalloproteinase-1 (TIMP-1) and osteopontin (OPN) were determined in 63 
DMD patients on corticosteroid therapy. These proteins were selected for their role in the 
pathogenesis of muscular dystrophy. Levels of MMP-9 and TIMP-1 were significantly higher in 
sera of DMD patients compared to healthy controls, whereas the OPN levels showed no 
significant difference. MMP-9 levels were also observed to be significantly higher in older, 
nonambulant patients, compared to ambulant patients. Longitudinal data from a smaller cohort of 
DMD patients followed up for over 4 years showed that MMP-9, but not TIMP-1 increased 
significantly with age. Hence, MMP-9 is a potential DMD biomarker for disease progression. 




Clinical biomarkers can be used to diagnose, monitor aetiology and progression of diseases and 
guide therapeutic decisions (Rifai et al. 2006). The serum biomarker currently used primarily as a 
first diagnostic hint for Duchenne muscular dystrophy (DMD), is creatine kinase (CK), where 
high levels of CK reflect muscle damage and/or disease. There are, however, several drawbacks to 
the CK test: levels may fall when disease progresses, probably due to the loss of muscle tissue 
(Emery and Muntoni 2003), and CK levels are also increased in normal individuals due to 
exercise, exertion or trauma to the skeletal muscle. Other available tests to monitor the 
progression of DMD pathology have limitations as well. Muscle biopsies have diagnostic value, 
but are laborious and invasive, and provide only local information on muscle quality, which may 
not be reflective for the state of all muscles. Muscle strength assessments are less of a burden to 
the patient and have prognostic applications, but are subject to extensive intra- and inter-patient 
variability (Mazzone et al. 2009). As such, there is no single test that can be used for diagnosis, 
prognosis, the recognition and/or prediction of potential complications and response to treatment. 
However, it might be feasible to achieve this with a group of serum biomarkers. Considering the 
various clinical treatments and trials currently ongoing for DMD (Angelini 2007;Bushby et al. 
2009;Malik et al. 2010;van Deutekom et al. 2007), the identification of serum biomarkers to assess 
the effect of these treatments would be invaluable, since functional improvement cannot be 
expected within the short treatment periods in early phase clinical trials, and monitoring through 
repetitive muscle biopsies is not feasible for longer trials.  
Based on recent literature findings on the pathophysiology of dystrophinopathy in both 
men and mice (dystrophin deficient mouse, mdx) via gene expression analyses (Li et al. 
2009;Pescatori et al. 2007;Turk et al. 2005;Vetrone et al. 2009), we selected several potential 
serum biomarkers for DMD: matrix metalloproteinase 9 (MMP-9), tissue inhibitor of 
metalloproteinase (TIMP-1) and osteopontin (OPN). MMP-9 is associated with the degradation or 
remodeling of the extracellular matrix and is either secreted or present as a trans-membrane 
proenzyme. It has recently been demonstrated that Mmp9 gene expression is increased in mdx 
mice and inhibition of Mmp9 reduces skeletal muscle damage, inflammation, necrosis and fibrosis 
(Li et al. 2009). This implies that the absence of MMP-9 in mdx mice reduces the effects of 
dystrophin deficiency in the skeletal muscle. The proteolytic activity of MMP-9 is modulated by 
TIMPs and it has been postulated that the maintenance of the balance between MMP-9 and 
TIMPs is essential to maintain tissue integrity (Raffetto and Khalil 2008). Gene expression 
analysis of mdx and DMD muscles showed an upregulation of the TIMP-1 gene (Li et al. 
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2009;Malik et al. 2010), suggesting it is worthwhile to include TIMP-1 in our biomarker study. 
OPN, a phosphorylated glycoprotein of the bone, is also expressed in immune cells, skin and 
blood vessels. The functions of OPN include formation of collagen fibrils during tissue 
remodelling, promotion of macrophage and neutrophil migration, angiogenesis and wound 
healing (Vetrone et al. 2009). A recent study revealed that mdx mice have high OPN serum 
concentrations, while absence of the OPN encoding Spp1 gene in mice reduced neutrophils and 
decreased TGF-β levels resulting in reduced fibrosis in mdx mice (Vetrone et al. 2009). 
Interestingly, studies on gene expression profiles of DMD muscles at various stages of the disease 
also demonstrated significant upregulation of SPP1 (Haslett et al. 2002;Pegoraro et al. 
2011;Pescatori et al. 2007;Turk et al. 2006).  
The three selected biomarkers are suggested to have a role either in inflammation, 
fibrosis, or extracellular matrix degradation, which are key events in the pathogenesis of DMD. 
We hypothesize that these biomarkers will be elevated in the DMD sera since DMD muscle fibres 
are leaky and continuously degenerating. Furthermore, as these markers are indicative for the 
disease pathophysiology, we suggest that they have potential as prognostic biomarkers. Our study 
examined serum levels of the selected biomarkers in mdx mice and in sera of corticosteroid 
treated DMD patients. The animal and patient studies reinforced each other, as mouse studies are 
better controlled but cannot be directly extrapolated to humans. Based on comparisons with 
control samples and correlations with other patient information, we suggest that MMP-9 and 
TIMP-1 in combination can be used as potential biomarkers for monitoring disease progression in 
DMD. 
 
Materials and methods 
Mice 
Four week old C57BL/10ScSnJ (wt) (N = 5) and C57BL/10ScSn-mdx/J (mdx) (N = 6) females were 
subjected to forced exercise consisting of three times a week horizontal treadmill running at 12 
m/min for 30 min for duration of 12 weeks to augment the severity of disease (De Luca et al. 
2008). Blood was collected at the age of 8 and 14 weeks via the tail vein, allowed to clot at room 
temperature for 10 min and then spun at 1700 g for 10 min at 4 °C before pipetting the serum for 
storage at -80 °C, prior to use. For CK determination blood from the tail vein was collected in a 
Minicollect tube (0.8 ml Lithium Heparin Sep, Greiner bio-one, Austria). All mice were sacrificed 
at the age of 16 weeks by cervical dislocation. The quadriceps muscle was isolated, snap frozen in 
isopenthane, cooled in liquid nitrogen and stored at -80 °C. Quadriceps muscles from 
nonexercised mdx mice were used as controls for the gene expression studies. All experiments 
were approved by the Institutional Animal Experimental Commission (DEC) at LUMC. 
 
Study participants 
Sixty-three male patients with a molecular diagnosis of DMD were recruited for this study from 
the clinic population of the muscle service in Newcastle upon Tyne (mean age 13.1 years, age 
range between 2.9 and 31.2 years). As shown in Table 1, 34 of the patients were ambulant, with a 
mean age of 8.7 years and 29 were nonambulant, with a mean age of 18.1 years. Other clinical 
information such as duration of corticosteroid therapy and North Star Ambulatory Assessment 
(NSAA) scores were also available for these patients. Patients were on corticosteroid therapy for 
an average of 3.2 years and the mean NSAA score (available only for 29 ambulant patients) was 
23/34.  
Nine of the boys were followed up in a longitudinal study involving blood sampling at 
various time intervals (Garrood et al. 2009). They were on corticosteroid therapy, commenced at 
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a dose of 0.75 mg/kg/day of prednisolone as per international guidelines (Manzur et al. 2008). 
Child D8 was on deflazacort prior to and for the duration of the study due to unacceptable side 
effects from prednisolone (Table 2). The characteristics of the nine boys are summarised in Table 
2, as the type of mutation, age of the boys, duration of corticosteroid treatment and the North 
Star Ambulatory Scores (NSAA) were also documented.  
As part of the study four adult males (age range, 29.6–5.3 years; mean 32.4 years) and 12 
healthy male children (age range, 6.25–1.9 years; mean 8.2 years) were recruited as controls. The 
healthy adult males (N = 4) were working at the Institute of Human Genetics when recruited. 
The control children were attending the Royal Victoria Infirmary, Newcastle upon Tyne for 
venepuncture for renal isotope imaging after a urinary tract infection. Any child with an 
abnormal renal isotope investigation was subsequently excluded from the study. Informed 
consent was taken from the parents after a further discussion of the study with both parents and 
child. The control children had no significant medical disorders and were not on any systemic 
medication. All elements of the human study received a favourable opinion from the local 
Research Ethics Committee prior to commencement.  
 
 
Human serum samples  
Blood was taken from DMD and control groups by the following method: 3–5 ml of venous blood 
(obtained prior to radioisotope injection for the child controls) was drawn and placed in BD-
Chapter 4  
 
 94 
Vacutainer (367694) tubes. The blood was allowed to clot at room temperature for 10 min and 
then placed in a refrigerator at 4 °C before further spinning at 2800 g at room temperature for 10 
min. The serum supernatant was carefully removed and aliquoted for storage at -80 °C pending 
use. 
 
RNA isolation and RT-PCR analysis 
Total RNA of the quadriceps was isolated in Magna Lyser Green Beads tubes (Roche diagnostics 
Ltd., UK) using RNA-Bee (Tel-Test, Bio-Connect, Huissen, The Netherlands) and purified with 
the NucleoSpin RNA II kit (Bioke, The Netherlands). The RNA concentration was measured on a 
Nanodrop (Nanodrop Technologies, DE, USA) and integrity was checked with a lab-on-chip total 
RNA nano assay on a labchip assay (Agilent, The Netherlands). cDNA was generated and gene 
expression levels were determined for Mmp9, Timp1 and Spp1 (primer sequences available on 
request) by Syber Green based Real Time qPCR (95 °C 10 s, 60 °C 30 s, 72 °C 20 s, 45 cycles) on 
the Roche Lightcycler 480. Gapdh was used as a reference gene, since the expression of this gene 
did not differ between different muscles or over time. The Cp values were obtained with the 
second derivative maximum method and analysed with genex (http://www.gene-
quantification.com/download.html).  
 
Determination of MMP-9, TIMP-1 and OPN levels in mice and human serum samples 
Levels of MMP-9, TIMP-1 and OPN were determined using commercially available 
immunoassays kits. To determine levels in mouse serum, the mouse MMP-9 (total) immunoassay 
kit (catalogue number MMPT90) and mouse TIMP-1 immunoassay (catalogue number MTM100) 
were purchased from R&D systems (Abingdon, United Kingdom), while the mouse OPN kit (code 
number 27351) was purchased from IBL (Hamburg, Germany). The immunoassay kits for 
detection in human serum were the Human MMP-9 (total) immunoassay kit (catalogue number 
DMP900), the Human TIMP-1 immunoassay kit (catalogue number DTM100) and the Human 
OPN immunoassay kit (catalogue number DOST00) all purchased from R&D systems. These kits 
used the quantitative sandwich enzyme immunoassay technique where only free, unbound forms 




Statistical analyses were performed using the Statistical Package for the Social Sciences (SPSS), 
version 17. All data sets were subjected to normality testing using the Kolmogorov–Smirnov 
method. For comparisons between means the Student’s t-test (two-tailed) was applied. 
Additionally, data on the independent study groups (DMD and controls) were presented using 
descriptive statistics in which the median value and interquartile range (IQR, the statistical 
dispersion of the middle 50% of the data) were calculated to show the distribution of the 
biomarker levels for each group. Pearson’s Correlation was used for correlation studies and data 
were analysed with a 95% confidence interval and P<0.05 was considered significant and P<0.01 
was considered highly significant. For the longitudinal DMD group, the statistical package from 
R2.9.2 was used and the linear mixed-effects model (lme4, version 0.99937538) was applied to 
determine the relationship of each biomarker with age and duration of corticosteroid therapy. 
The fixed and random effects used in this model were as follows: for fixed it was age and duration 
of corticosteroid therapy and for random, it was the patient. 
 




Gene expression analysis of Mmp9, Timp1 and Spp1 in mouse quadriceps 
As we had begun our study by selecting candidate biomarkers from mdx gene expression data, we 
first confirmed whether these mRNA expression changes were also present in the mice used in 
our study. Whereas previously reported studies on these biomarkers used sedentary mice (Li et al. 
2009;Vetrone et al. 2009), the mdx and wt mice used for serum collection were subject to exercise 
to augment the severity of the disease. We therefore compared the gene expression of Mmp9, 
Timp1 and Spp1 (coding for OPN) between the study mice groups (exercised mdx and exercised 
wt) and nonexercised mice (mdx) using qPCR analysis. Fig. 1a, b and c show the gene expression 
data of Mmp9, Timp1 and Spp1, respectively, from the quadriceps of 16 week old, exercised mdx 
and mdx compared to exercised wt. We observed no significant difference between the 
expression of these genes in the exercised mdx and mdx group. There was, however, a significant 
difference between exercised wt and mdx. Although gene expression in exercised mdx was much 
higher than in exercised wt mice, this difference was not significant due to a higher standard 
deviation (SD) observed in the exercised mdx group compared to the exercised wt and mdx group. 
 
Fig. 1. Gene expression analysis of (a) Mmp9, (b) 
Timp1 and (c) Spp1 in exercised wt, exercised mdx and 
mdx. The bar charts show the mean levels of gene 
expression for each biomarker and the error bars 
indicate the standard deviation. One way ANOVA was 
used to determine differences between groups and the 
Student’s t-test was applied to determine significant 
differences between two groups, where P<0.01 is 
considered highly significant, and P<0.05 is significant. 




Mouse serum levels of MMP-9, TIMP-1 and OPN 
We then assessed serum from 8 and 14 week old exercised mdx and exercised wt mice. At the age 
of 8 weeks, a highly significant difference was observed in the serum MMP-9 levels between 
exercised wt and exercised mdx mice. The serum MMP-9 levels in exercised mdx mice were 
twofold higher than in exercised wt mice, with mean levels of 41.8 ng/ml ± 10.5 (level ± SD) for 
exercised wt mice and 86.52 ng/ml ± 21.07 for exercised mdx mice (Fig. 2a). At the age of 14 
weeks, levels of MMP-9 were still elevated in exercised mdx mice (mean = 62.53 ng/ml ± 39.4),  




Fig. 2. Serum levels of (a) MMP-9, (b) TIMP-1, (c) OPN and (d) CK in exercised wt and exercised mdx at 8 and 14 
weeks. The bar charts show the mean serum levels of each biomarker and the error bars indicate the standard 
deviation. One way ANOVA was used to determine differences between groups and the Student’s t-test was applied 
to determine significant difference between two groups, where P<0.01 is considered highly significant, and P<0.05 is 
significant. The number of mice per group is five for wt and six for mdx. 
 
however this difference was not significant when compared to exercised wt mice at the similar 
age group (mean = 37.85 ng/ml ± 3.50). There were no significant differences in the serum levels 
at the different time points for either exercised wt or exercised mdx mice. However in exercised 
mdx mice, a drop in serum levels of MMP-9 was noted between 8 and 14 weeks. 
The levels of TIMP-1 at 8 weeks were 3-fold higher in exercised mdx mice (mean = 6.9 
ng/ml ± 1.32) compared to exercised wt mice (mean = 2.22 ng/ml ± 0.91), and this difference was 
significant (P<0.01) (Fig. 2b). Although a difference was observed in the TIMP-1 levels in 14 
week old mice, where exercised mdx mice (mean = 7.25 ng/ml ± 1.55) had higher levels than 
exercised wt mice (mean = 4.78 ng/ml ± 2.62), this difference was not significant. There was also 
no significant difference in the levels of TIMP-1 between 8 and 14 weeks for both strains.  
Serum OPN levels were found to be higher (P<0.05) in 8 week old exercised mdx mice 
(mean = 3.44 ng/ml ± 0.54) compared to exercised wt mice (mean = 2.62 ng/ml ± 0.59) (Fig. 2c). At 
14 weeks, the levels were similar for exercised mdx (mean = 2.53 ng/ml ± 0.73) and exercised wt 
mice (mean = 2.36 ng/ml ± 0.91).  
CK levels were also determined for the 8 and 14 weeks groups (Fig. 2d) and significant 
differences were observed between exercised wt and exercised mdx for mice at both age groups. 
At 8 weeks, the CK levels for exercised wt were lower (mean = 142 U/L ± 100) than the CK levels 
for exercised mdx (mean = 3900 U/L ± 1631). At 14 weeks, this difference is smaller but still 
significant as the CK levels for exercised wt were 230 U/L ± 102 whereas they were 4773U/L ± 
4024 for exercised mdx.  




Fig. 3. Serum levels of (a) MMP-9, (b) TIMP-1, (c) OPN 
in DMD and control samples. The median levels are 
indicated by the horizontal lines bisecting the box plot, 
which shows the interquartile range. The upper and 
lower limit of the bars show the maximum and 
minimum values considered while the extreme values 
are indicated by ○. Student’s t-test was applied to  





Serum levels of MMP-9, TIMP-1, and OPN in DMD and control samples 
We measured the serum levels of MMP-9, TIMP-1 and OPN in serum samples of 63 DMD boys 
and 16 control subjects (12 age-matched boys and 4 adult men) and statistically compared the 
levels with Students t-test. The 12 boys and 4 adults in the healthy control group were grouped 
together since there were no differences between biomarker levels in young and adult subjects 
(data not shown). As shown in Fig. 3a, serum MMP-9 levels were significantly higher in DMD 
(median level = 1185.34 ng/ml, IQR = 966.56) compared to control samples (median level = 73.22 
ng/ml, IQR = 121.00) (P<0.001). Similarly, serum TIMP-1 (Fig. 3b) levels were significantly 
higher in DMD (median levels = 245.55 ng/ml, IQR = 69.57) compared to control groups (median 
level = 164.77 ng/ml, IQR = 62.45) (P<0.01). The serum OPN levels, however, were not 
significantly different between DMD (median levels = 41.24 ng/ml, IQR = 33.74) and control 
groups (median level = 44.19 ng/ml, IQR = 30.69) (Fig. 3c). 
Further stratification of the DMD samples into ambulant and nonambulant groups (Fig. 
4) showed significantly higher levels for nonambulant compared to ambulant for MMP-9 
(ambulant group median levels = 927.89, IQR = 885.60; nonambulant group median levels = 
1328.45, IQR = 822.95), while both groups were significantly increased compared to the control 
group. By contrast, similar levels were observed in ambulant and nonambulant groups for TIMP-
1, which were both significantly higher than in the control group (Fig. 4b). OPN levels were 
similar for all three groups (Fig. 4c).  




Fig. 4. Serum levels of (a) MMP-9, (b) TIMP-1, (c) 
OPN in nonambulant, ambulant and control samples. 
The median levels are indicated by the horizontal 
lines bisecting the box plot, which shows the 
interquartile range. The upper and lower limit of the 
bars show the maximum and minimum values 
considered while the extreme values are indicated by 
○. One way ANOVA was used to determine 
differences between groups and the Student’s t-test 
was applied to determine significant difference 
between two groups. 
 
 
Correlation between levels of MMP-9, TIMP-1, OPN, age, steroid treatment and NSAA 
scores in DMD and control groups  
Pearson correlation analysis was applied to determine the correlation coefficient between the 
three biomarker levels with other patient characteristics (age, years on steroid treatment and 
NSAA scores) in the independent DMD patient cohort (as observed from Table 3). MMP-9 levels 
were positively correlated with age and duration of corticosteroid therapy (P<0.01). There were 
however, no significant correlations observed between levels of MMP-9 and TIMP-1, OPN or the 
functional scores, NSAA (ambulant boys only). There was a significant positive correlation 
between age and duration of corticosteroid therapy (P<0.05) and although there was negative 
correlation (correlation coefficient of -0.241) between age and the NSAA scores, the effect was 
not significant. Age dependent trends were not observed for TIMP-1 and OPN. Serum OPN 
showed negative correlation with NSAA scores (correlation coefficient of -0.309), however this 
effect was not significant. In the control group, no significant correlation was observed between 
any of the variables (age, serum MMP-9, TIMP-1 and OPN levels). 
 




Fig. 5. Serum levels of (a) MMP-9, (b) TIMP-1, (c) 
OPN for the longitudinal DMD patient cohort. The 
mean serum levels of nine DMD patients were 
plotted over 2, 3 or 4 time points depending on 
patient sample availability. The time points are 











Longitudinal analysis of MMP-9, TIMP-1 and OPN in DMD patients 
As nine patients were followed up longitudinally, there was an opportunity to determine serum 
levels of these biomarkers over time for the same group of patients. Fig. 4 shows the biomarker 
levels of the individual DMD patients followed up between two and four and a half years. The 
levels of MMP-9 (Fig. 5a) increased with age whereas the levels of TIMP-1 (Fig. 5b) did not 
demonstrate a consistent increase with age. Interestingly, the levels of OPN (Fig. 5c) seemed to 
decrease with age. To determine whether age and duration of corticosteroid therapy had an effect 
on biomarker levels, the linear mixed-effects model analysis was applied to the longitudinal data. 
We observed that MMP-9 shows a significant linear relationship with age (t-stat = 2.17, P<0.01) 
but duration of corticosteroid therapy does not significantly contribute to this relationship (t-stat 
= 0.63, P=0.53). OPN levels show a significant linear and negative relationship with age (t-stat = -
2.77, P<0.01) and the duration of corticosteroid therapy does not contribute significantly to this 
relationship (t-stat = 1.7, P=0.1).  
 




The potential biomarkers explored in this study, were initially hinted at by recent findings in 
mdx mouse experiments. Gene expression analysis of mdx muscle showed that the Timp1 gene 
and the Spp1 gene (which encodes OPN) were significantly upregulated compared to muscles of 
healthy mice (Turk et al. 2005), while other studies have shown that both MMP-9 and OPN were 
elevated in serum of the mdx mouse compared to wild-type (Li et al. 2009;Vetrone et al. 2009). 
MMP-9, TIMP-1 and OPN are known to have a role as pro inflammatory markers (Castellano et 
al. 2008;Sun et al. 2006) and in the absence of dystrophin in mouse models, MMP-9 and OPN 
have been shown to have an effect in extra cellular matrix degeneration, inflammation and 
subsequent degeneration and regeneration of muscle fibres leading to fibrosis (Li et al. 
2009;Vetrone et al. 2009). Data from our 8 week old exercised mice confirmed the findings of 
these previous studies. TIMP-1 levels remained elevated in 14 week old exercised mdx mice, but 
MMP-9 and OPN levels appeared to decrease with age. These latter observations were not in 
agreement with previous reports (Li et al. 2009;Vetrone et al. 2009), possibly as a consequence of 
the exercise regimen we used with our mdx mice. To examine whether our results differed 
because mice used in our study were subjected to forced exercise from the age of 4 weeks until 
time of blood sampling (8 weeks and 14 weeks) and sacrifice (16 weeks), we examined the gene 
expression of these three biomarkers in exercised mdx and nonexercised mdx mice. No significant 
differences in gene expression were observed between the exercised and nonexercised group for 
any of the biomarkers. We did however observe that inter mouse variation was higher in the 
exercised mdx group compared to the mdx and exercised wt. It has been suggested that the 
beneficial or deleterious effect of exercise on dystrophic muscles depends on the age of the animal 
at the start of exercise, the severity of pathology, the intensity, and the duration and type of 
training (Carter et al. 2002). Although in this study these parameters were similar in the exercised 
mdx group, the severity of the dystrophy for each mouse may be more variable, which could 
contribute to the higher variation seen in this group.  
Our results in humans are in line with the mouse data: levels of MMP-9 and TIMP-1 are 
higher in DMD compared to controls. We also observed that MMP-9 levels were significantly 
higher in older, nonambulant patients compared to the younger, ambulant patients, suggesting 
that there is an increase in MMP-9 levels with disease progression. Results of the longitudinal 
study supported this observation as levels of MMP-9 increased with age for individual patients. 
While this study reports on both MMP-9 and TIMP-1 levels in serum of DMD patients, gene 
expression analysis on DMD muscle tissue has indicated a role for elevated TIMP1 and MMP2 in 
extra cellular matrix modelling at early stages of disease development (Pescatori et al. 2007), 
which makes it likely that MMP-9 and TIMP-1 are derived from dystrophic muscles. An earlier 
study to detect inflammatory proteins in muscles of symptomatic DMD patients (5–12 years) and 
pre-symptomatic patients (infants) showed that the transforming growth factor (TGF)-β pathway 
was activated in the symptomatic group (Chen et al. 2005). The study by Li et al. 2009 suggested 
that MMP-9 increased TGF-β levels, which in turn exacerbated muscle degeneration in 
dystrophic mice (Li et al. 2009). A recent study comparing plasma levels and muscle expression of 
TGF-β and TIMP-1 in DMD, congenital muscular dystrophy (CMD) and Becker muscular 
dystrophy (BMD) showed that these markers were markedly elevated in DMD and CMD 
compared to the less severe BMD (Sun et al. 2010). Our data on serum levels of MMP-9 and 
TIMP-1 confirmed the findings of earlier studies on the pathogenesis of DMD.  
The Pearson correlation analysis also confirmed a significant positive correlation 
between MMP-9 levels, age and duration of corticosteroid treatment in the 63 DMD patients. 
While the positive correlation between age and MMP-9 levels reflected the observation seen in 
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the nonambulant and ambulant patients, the correlation between MMP-9 levels and duration of 
corticosteroid therapy needs further analysis. The patient cohort in our study was limited by the 
number of patients who were steroid naïve, and for patients that were on corticosteroid therapy, 
age and duration of treatment was confounded, making it difficult to discriminate between 
disease progression due to age and effects of steroid treatment. From the limited studies available 
on MMP-9 levels and corticosteroid therapy, one study on serum levels of patients with Graves 
ophthalmology and another on gene expression of MMP-9 in a murine model showed that MMP-
9 levels were lowered after corticosteroid therapy (De Paiva et al. 2006;Mysliwiec et al. 2007) 
while another study of asthmatic patients on corticosteroid therapy suggests that MMP-9 levels 
do not differ in steroid sensitive or resistant patients (Goleva et al. 2007). There was however one 
study which showed a short term increase in MMP-9 levels in patients with multiple sclerosis on 
a high dose of intra-venous methyl-prednisolone (1000 mg/day), where MMP-9 levels were noted 
to be significantly elevated at day 10 before returning to pre-treatment levels at day 20 (Mirowska 
et al. 2004). In our study, the positive correlation between age and MMP-9 was further 
strengthened by the results of the linear mixed-effects analysis in the longitudinal DMD cohort as 
there was a significant and positive linear relationship between MMP-9 levels and age i.e. disease 
progression, and the duration of steroid treatment did not contribute significantly to this 
relationship. Thus, based on our findings and information available from the above mentioned 
literature, we suggest that elevated MMP-9 levels are due to disease progression rather than the 
effect of corticosteroid treatment.  
Although we observed TIMP-1 levels to be significantly higher in DMD compared to 
controls, there was no significant difference in levels between ambulant and nonambulant groups 
or a significant correlation with age. However, due to the recent findings that plasma TIMP-1 
levels are lower in less severe BMD compared to DMD (Sun et al. 2010), the reports that ratio of 
MMP-9 and TIMP-1 reflected the balance of pro and anti-inflammatory cytokines (Wu et al. 
2008), and our own observation that TIMP-1 levels remained elevated in DMD patients, we 
suggest it is still useful to assess the potential of TIMP-1 as a biomarker in larger and independent 
cohorts from other clinical centres. OPN levels showed no significant difference between DMD 
and control samples or between ambulant and nonambulant groups. There was however a 
significant linear but negative relationship in the longitudinal cohort for OPN and age. A recent 
study on DMD patients with the less common G allele of the rs28357094 SPP1 promoter, which 
was associated to decreased OPN mRNA expression levels, suggested that less SPP1 leads to more 
muscle weakness, with lower grip strength and earlier age for loss of ambulance (Pegoraro et al. 
2011). As serum OPN levels were not reported in that study, it would be of future interest to 
know whether blood OPN levels were lowered in the DMD patients carrying the less common G 
allele.  
Current clinical trials on exon skipping and stop codon read-through (Aartsma-Rus and 
van Ommen 2010) include CK as a serum biomarker to study the effectiveness of treatment. 
While decreasing CK levels can be a positive prognostic indicator in some diseases (myocardiac 
infarction for example), in DMD patients the role of CK as a prognostic biomarker is questionable. 
CK levels are markedly increased before signs and symptoms of DMD are observed, confirming 
the useful diagnostic application at a very early stage of the disease. However as mentioned earlier 
(Emery and Muntoni 2003), declining CK levels in DMD are associated to decrease in ambulatory 
skills and disease progression. We suggest that MMP-9 and TIMP-1 levels are potentially more 
useful biomarkers for response to therapy, since they do not show this decreasing trend, probably 
as a consequence of the continued inflammatory response in DMD patients, even after substantial 
muscle degeneration. Effective therapy should reduce the degeneration-induced inflammatory 
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response. Future studies have to confirm whether MMP-9 and TIMP-1 indeed decrease after 
dystrophin restoration, and therefore are useful as biomarkers to monitor therapeutic responses.  
Due to their role in inflammation, cell migration, angiogenesis and fibrosis (Brunner et 
al. 2010;Wu et al. 2008), elevated levels of MMP-9 and TIMP-1 are not specific to DMD or 
muscle diseases. These markers have been investigated for their role in cancers (breast, bladder 
and pancreas), cardiovascular diseases and in preeclampsia. In breast cancer for example, MMP-9 
is used as a marker for diagnosis and prognosis, early detection and risk assessment, but also as an 
indicator of tumour recurrence, metastatic spread, and response to primary and adjuvant therapy 
(Wu et al. 2008). In coronary artery disease, the ratio of MMP-9/TIMP-1 in serum was suggested 
to be useful for progression of disease as it is reflective of the balance between circulating pro and 
anti inflammatory cytokines (Brunner et al. 2010). Hence, their diagnostic value for DMD perse 
may be limited. However, based on our study in mice and humans, we suggest to further evaluate 
MMP-9 and TIMP-1 as valuable biomarkers in DMD for the monitoring of disease progression 
and therapy efficacy. 
 
Acknowledgements 
This work was supported by the Dutch Organisation for Scientific Research (Medical council 
ZON-MW), the BIO-NMD Grant (EC, 7th FP, proposal# 241665; www.bio-nmd.eu) and the 
Centre for Medical Systems Biology within the framework of the Netherlands Genomics 
Initiative (NGI)/Netherlands Organisation for Scientific Research (NWO). The MRC Centre for 
Neuromuscular Diseases Biobank Newcastle is a partner of EuroBioBank (www.eurobiobank.org) 
and TREAT-NMD (EC, 6th FP, proposal# 036825). We wish to thank Dr Michelle Eagle and 








The effects of low levels of dystrophin  
on mouse muscle function  
and pathology 
 
M. van Putten, M. Hulsker, V.D. Nadarajah,  
S.H. van Heiningen, E. van Huizen, M. van Iterson,  
P. Admiraal, T. Messemaker, J.T. den Dunnen,  
P.A.C. ’t Hoen, A.M. Aartsma-Rus 
 








Duchenne muscular dystrophy (DMD) is a severe progressive muscular disorder caused by 
reading frame disrupting mutations in the DMD gene, preventing the synthesis of functional 
dystrophin. As dystrophin provides muscle fiber stability during contractions, dystrophin 
negative fibers are prone to exercise-induced damage. Upon exhaustion of the regenerative 
capacity, fibers will be replaced by fibrotic and fat tissue resulting in a progressive loss of function 
eventually leading to death in the early thirties. With several promising approaches for the 
treatment of DMD aiming at dystrophin restoration in clinical trials, there is an increasing need 
to determine more precisely which dystrophin levels are sufficient to restore muscle fiber 
integrity, protect against muscle damage and improve muscle function. To address this we 
generated a new mouse model (mdx-Xist∆hs) with varying, low dystrophin levels (3–47%, mean 
22.7%, stdev 12.1, n = 24) due to skewed X-inactivation. Longitudinal sections revealed that 
within individual fibers, some nuclei did and some did not express dystrophin, resulting in a 
random, mosaic pattern of dystrophin expression within fibers. Mdx-Xist∆hs, mdx and wild type 
females underwent a 12 week functional test regime consisting of different tests to assess muscle 
function at base line, or after chronic treadmill running exercise. Overall, mdx-Xist∆hs mice with 
3–14% dystrophin outperformed mdx mice in the functional tests. Improved histopathology was 
observed in mice with 15–29% dystrophin and these levels also resulted in normalized expression 
of pro-inflammatory biomarker genes, while for other parameters >30% of dystrophin was 
needed. Chronic exercise clearly worsened pathology, which needed dystrophin levels >20% for 
protection. Based on these findings, we conclude that while even dystrophin levels below 15% 
can improve pathology and performance, levels of >20% are needed to fully protect muscle fibers 
from exercise-induced damage. 
 
Introduction 
Duchenne Muscular Dystrophy (DMD) is an X-linked recessive disorder affecting 1:3500 new 
born boys. It is characterized by muscle fiber wasting, functional impairment and eventual death 
due to respiratory and heart failure. The underlying causes are frame-shifting and nonsense 
mutations in the DMD gene, resulting in the absence of functional dystrophin protein. Intact 
dystrophin anchors the intracellular cytoskeleton to the extracellular matrix and thereby prevents 
membrane damage during muscle contraction (Aartsma-Rus et al. 2006;Hoffman et al. 1987). An 
allelic, less severe form of the disease, Becker muscular dystrophy (BMD) is caused by mutations 
that maintain the open reading frame and allow synthesis of internally deleted, partially 
functional dystrophin proteins (Hoffman et al. 1988;Monaco et al. 1988).  
There is no cure for DMD, but many potential therapeutic compounds currently tested 
in clinical trials aim at restoration of (a BMD like) dystrophin (Aartsma-Rus et al. 2010;Cirak et 
al. 2011;Goemans et al. 2011;Hirawat et al. 2007;Kinali et al. 2009;Malik et al. 2010;Mendell et al. 
2010;Ogata et al. 2000;Pegoraro et al. 1995;Schmidt-Achert et al. 1993;van Deutekom et al. 2007). 
These trials at best resulted in the synthesis of low levels of dystrophin protein. However, it is not 
yet known how these levels will affect disease pathology, and which levels are needed to 
maintain muscle fiber integrity, to prevent against exercise-induced damage, or to improve 
muscle function. In addition, it is as yet unknown whether low dystrophin levels will stabilize 
and/or delay disease progression (Aartsma-Rus et al. 2010). In perspective of further optimization 
of currently tested potential therapeutic compounds, detailed studies in this direction are 
necessary.  
Early studies primarily involved female DMD carriers, heterozygous mdx mice and 




express dystrophin in approximately 50% of the fibers (when seen in a transverse cross section) 
due to random X-inactivation early in life (Pegoraro et al. 1995;Schmidt-Achert et al. 1993). 
During life, the proportion of dystrophin positive fibers increases due to positive selection. It 
appears that this is sufficient to maintain skeletal muscle function and fiber integrity in both 
human and mice. Although skeletal muscles appear to escape damage, human carriers are at risk 
for DMD-associated dilated cardiomyopathy (Ogata et al. 2000), while no heart failure is observed 
in heterozygous mdx mice (Bostick et al. 2008;Tanaka et al. 1990). Nevertheless, symptomatic 
carriers have been described, often expressing less than 50% of normal dystrophin levels due to 
either gross chromosomal rearrangements (Boyd et al. 1986), or unfortunate skewed X-
inactivation in which the degree of skewedness correlated with disease severity (Azofeifa et al. 
1995;Lupski et al. 1991;Pegoraro et al. 1995;Soltanzadeh et al. 2010). In addition, BMD patients 
generally have lower levels of dystrophin and these levels seem to correlate with disease severity, 
where levels <10% are observed in very severe patients and levels >20% in moderate/mild 
patients (Hoffman et al. 1988;Hoffman et al. 1989). Based on a case study involving one patient, it 
appears that dystrophin levels as low as 30% can be sufficient to largely prevent a muscle 
phenotype (Neri et al. 2007). The amount of revertant fibers has also been reported to correlate 
positively with disease severity (Nicholson et al. 1993). However, reports on BMD and skewed X-
inactivation cases involve low numbers of patients and detailed analysis (e.g. assessment of 
dystrophin levels in various muscles) is not possible for obvious reasons. Thus, there is an 
increasing need for a mouse model expressing low levels of dystrophin to allow the detailed study 
of the effects of low dystrophin levels on disease pathology.  
So far, several attempts have been made to achieve this. Unfortunately, each had 
limitations. First, transgenic mice expressing low levels of full-length or truncated dystrophin of 
murine or human origin have been generated to test whether this results in a less severe 
phenotype (Phelps et al. 1995;Rafael et al. 1994). However, from the 13 mouse lines generated, 
only two expressed dystrophin levels lower than 50% of wild type in both the quadriceps and 
diaphragm. The other lines had higher dystrophin levels or a combination of both higher and 
lower levels than wild type. From the two potential lines, one expressed low dystrophin levels 
(15% quadriceps and <5% diaphragm), while the other line expressed higher dystrophin levels 
(40% quadriceps and 20% diaphragm), thus allowing detailed analysis of only two different 
dystrophin levels. Dunant et al. generated mdx mice in which dystrophin expression was driven 
by a 1.35-kb MCK promoter resulting in abundant expression in fast-twitch muscles (~50%) and 
very low expression in slow-twitch fibers. The heart did not express dystrophin at all (Dunant et 
al. 2003). The fiber type specific dystrophin expression makes this model less suitable for detailed 
analysis. In another study, Stillwell et al. generated chimeric mice expressing various dystrophin 
levels depending on the amount of wild type cells incorporated in mdx blastocytes. Mice 
expressed dystrophin in skeletal muscles in a very high (60–100%) or low (<5%) manner (Stillwell 
et al. 2009). This, combined with the fact that this method is extremely labour intensive, makes 
this approach less favourable for extended studies. The final model known to express low 
dystrophin levels is the mdx3cv mouse. Studies in the mdx3cv mouse revealed that even ~5% of 
dystrophin increased specific tetanic force and partly prevented against eccentric contractions 
induced damage in young but not in old mice. However, it was insufficient to prevent 
histopathology, since severity did not differ from dystrophin negative mdx4cv mice (Li et al. 2008). 
Although mdx3cv mice are easy to generate, dystrophin levels do not exceed 5%, making studies 
on the effect of higher dystrophin levels e.g. 20–30% impossible.  
Taken together, these models give an indication that <50% dystrophin is sufficient for 
improvement of many pathological aspects, however, they are not ideal to assess the effects of low 
                                                         Effects of low dystrophin levels on pathology 
 
 109 
dystrophin levels on disease pathology in detail. Our study describes a mouse model expressing 
low dystrophin levels, based on non-random X-inactivation. In mammals, X-inactivation is 
regulated by the X-inactivation center in which Xist is the key player (Brockdorff et al. 
1991;Senner and Brockdorff 2009). Mutations in the Xist promoter can skew the randomness of 
X-inactivation resulting in preferential inactivation (60–90%) of the X-chromosome containing 
the mutated Xist gene (Newall et al. 2001). Here, non-dystrophic female Xist∆hs mice with a 
mutation in the Xist promoter were crossed with dystrophic mdx males. This resulted in female 
mdx-Xist∆hs mice in which the X-chromosome containing the wild type dystrophin is 
preferentially inactivated, leading to a wide range of low dystrophin levels in individual mice 
(Figure 1). Within individual muscle fibers of these pups, a mosaic pattern of dystrophin 
expression was observed, in which nuclei either did or did not express dystrophin. Experiments 
revealed that low dystrophin levels have a beneficial effect on muscle integrity, histology, 
function and serum biomarkers in a dose dependent manner.  
 
Materials and methods 
Ethics statement 
All experiments were approved by and performed following the guidelines of the Dier 
Experimenten Commissie (Animal Experimental Commission) of the Leiden University Medical 
Center (Permit Numbers: 08096 and 09136). Effort was put in minimizing the amount of distress 
caused to the animals as much as possible.  
 
Animal care  
All studied mouse strains were bred at the animal facility of the LUMC where they were housed 
in individually ventilated cages with 12-h light-dark cycles. The Xist∆hs model (Newall et al. 2001) 
was a kind gift from Prof Brockdorff (MRC Clinical Sciences Centre London, UK, current 
affiliation Department of Biochemistry, University of Oxford, UK). Mice were given standard 
chow and water ad libitum and were weighed two times a week. Breeding pairs of mdx 
(C57BL/10ScSn-mdx/J) males and Xist∆hs females gave birth to mdx-Xist∆hs females (Figure 1A). 
Genotyping was performed on DNA obtained from tail tips by PCR analysis to confirm the 
mutation in the Dmd and Xist gene (primers and PCR conditions on request). 
 
Functional test regimes 
To test the functional abilities of the different mouse strains over time, a group of 5 mdx, 24 mdx-
Xist∆hs (0–15% dys n = 9, 15–30% dys n = 9 and >30% n = 6, as assessed by Western blot of 
quadriceps muscles at the end of the study) and 5 Xist∆hs females underwent a functional test 
regime consisting of four different functional tests starting at four weeks of age, as described 
previously (van Putten et al. 2010). Plasma creatine kinase (CK) levels were determined once a 
week at the beginning of the functional test regime. Mice were sacrificed by cervical dislocation 
after 12 weeks of testing and muscles were isolated.  
To determine whether functional test performances could be influenced by chronic 
treadmill exercise, 6 mdx, 7 mdx-Xist∆hs and 5C57BL/10ScSnJ four week old females had to run 30 
minutes on a horizontal treadmill at 12 m/min, directly followed by either fore limb grip 
strength, rotarod running or the two limb hanging wire test three times a week for 12 weeks. CK 
levels were determined two times a week; on Mondays before exercise and on Fridays directly 
after the two limb hanging wire test. At the age of 8 and 14 weeks additional blood was collected 




determined in parallel research that these correlate with disease severity (Nadarajah et al. 2011). 
After the 12 week chronic exercise protocol, mice were forced to run a final time on the 
horizontal treadmill for 30 minutes at 12 m/min. Evans blue dye (5 μg/μl) was applied 
intravenously (5 μl/gram of body weight) 20–30 minutes after this exercise. Twenty four hours 
after the injection, mice were sacrificed by cervical dislocation and muscles were isolated. 
Standardized operating procedures from the TREAT-NMD network were implemented for grip 
strength, both hanging wire tests and treadmill running (http://www.treat-nmd.eu/resources/ 
research-resources/dmd-sops/). 
 
Fore limb grip strength test 
Fore limb grip strength was assessed by means of a grip strength meter (Columbus Instruments, 
USA). Mice were tested five times, with three consecutive measurements per trial (15 in total), 
and a two minute interval between trials. The three highest measured values were averaged to 
calculate the absolute strength, which was divided by the body weight in grams.  
 
Rotarod 
Mice were placed on the Rotarod (Ugo Basile, Italy) that accelerated from 5 to 45 rotations per 
minute within 15 seconds. The test session ended when a mouse ran for 500 seconds without 
falling. Mice that fell off before 500 seconds were given a maximum of two more tries. The 
longest running time was used for analysis. 
 
Two limb hanging wire test 
Mice were suspended above a metal cloth hanger secured above cage and released a few seconds 
after instinctively grasping the wire with the fore limbs. Depending on the functional ability of 
the mouse, 2–4 limbs and the tail were used during a 10 minute hanging session. Mice that fell 
down before the 10 minute time limit were given two more tries. The longest hanging time was 
used for further analysis. 
 
Four limb hanging wire test 
The start position of this test was with all limbs. To this end, mice were placed on a grid, which 
was then turned upside down above a cage filled with bedding. The session ended after a hanging 
time of 10 minutes was achieved or otherwise after three sessions. The longest hanging time was 
used for further analysis. 
 
Blood CK, MMP-9, TIMP-1 and OPN level analysis 
For CK determination, blood was collected via a small cut at the end of the tail in a Minicollect 
tube (0.8 ml Lithium Heparin Sep, Greiner bio-one, Austria). Plasma CK levels were determined 
with Reflotron CK test strips in the Reflotron plus machine (Roche diagnostics Ltd, UK) at the 
day of collection.  
To detect MMP-9, TIMP-1 and OPN levels, blood was collected via the tail and allowed 
to clot at room temperature for 10 minutes before spinning (1700 g for 10 minutes at 4°C). The 
serum supernatant was carefully aspirated and stored at -80°C, before use. To determine serum 
biomarker levels in mouse, the mouse MMP-9 (total) immunoassay kit (catalog number 
MMPT90) and mouse TIMP-1 immunoassay kit (catalog number MTM100) were purchased from 
R&D systems (Abingdon, United Kingdom), while the mouse OPN kit (code number 7351) was 
purchased from IBL (Hamburg, Germany). Experiments were performed as per manufacturer’s 
protocol. 




For all 16 week-old mice the quadriceps, gastrocnemius, tibialis nterior, triceps, biceps, 
diaphragm and heart were dissected and snap frozen in 2-methylbutane (Sigma Aldrich, the 
Netherlands) cooled in liquid nitrogen. Cross-sections of 8 μm were cut on Superfrost Plus slides 
(Thermo Fishes Scientific, Menzel-Gläser, Germany) with a Shandon cryotome (Thermo Fisher 
Scientific Co., USA) along the entire length of the muscle with an interval of 240 μm between the 
sections. The excess tissue between the sections was collected in MagNa Lyser Green Beads tubes 
(Roche diagnostics Ltd, UK) for total RNA and protein isolation.  
To determine the percentage of fibrotic/necrotic fibers, sections of the quadriceps were 
stained with Harris Haematoxylin and Eosin (H&E) (Sigma Aldrich, the Netherlands) and 
examined with a light microscope (Leica DM LB, Leica Microsystems, the Netherlands) at a 5 
times magnification and images were captured with a Leica DC500 camera and Leica IM50 
software (Leica Microsystems, the Netherlands) from the entire middle section of the muscle. 
Analysis was performed in a double-blinded manner, by two independent researchers on stitched 
pictures with the color deconvolution plugin of the ImageJ software (Rasband, W.S., ImageJ, U. S. 
National Institutes of Health, Bethesda, Maryland, USA, http://rsb.info.nih.gov/ij/, 1997–2008) as 
described previously (van Putten et al. 2010). Quadriceps, tibialis anterior, diaphragm and heart 
sections were stained with dystrophin (C-20, dilution 1:50, Santa Cruz, Germany) and donkey-
anti-goat Alexa 488 (dilution 1:1000, Invitrogen, the Netherlands) and mounted with Vectashield 
mounting medium including DAPI (Vector Labs, Germany). The percentage of dystrophin 
positive fibers was manually and independently counted by two persons in a blinded manner for 
the quadriceps, stained with dystrophin and laminin (ab11575, dilution 1:50 Abcam, UK) where 
donkey-anti-goat Alexa 488 and donkey-anti-rabbit Alexa 594 (dilution 1:1000, Invitrogen, the 
Netherlands) were respectively used as a secondary antibody. To determine the dystrophin 
expression per nucleus, longitudinal sections of the quadriceps were cut and stained with 
dystrophin, spectrin (dilution 1:200, Thermo Scientific, USA) and DAPI. Co-localization of 
dystrophin with nNOS (H-299, dilution 1:50, Santa Cruz, Germany) and β-dystroglycan (NCL b-
DG, dilution 1:50, Novocastra, UK) was determined in the quadriceps. The donkey-anti-rabbit 
Alexa 488 (dilution 1:1000, Invitrogen, the Netherlands) and MOM kit (Vector Laboratories, UK) 
were used as secondary antibody respectively.  
Fiber size and the percentage of centrally nucleated fibers were determined with 
Mayachitra Imago 1 (http://www.mayachitra.om/imago/) on five randomly captured images of 
the quadriceps stained with laminin and DAPI (van Putten et al. manuscript in preparation). 
Fibers were segmented based on intensity differences between the membrane and the cytoplasm. 
The cross sectional area of each segmented fiber was computed by the software.  Centrally 
nucleated fibers were identified based on the maximum intensity of the cytoplasm which is 
higher in fibers with a centralized nucleus than without. The percentage of Evans blue dye 
positive fibers was manually counted in a blinded manner for the quadriceps of all mice which 
were subjected to the chronic treadmill exercise. All fluorescent stained sections were examined 
with a fluorescent microscope (Leica DM RA2) at a 16 times magnification and six images were 
randomly captured with a Leica DC350FX snapshot camera.  
 
Western blot analysis 
Muscles were homogenized in treatment buffer (100 mM Tris- HCl pH 6.8 and 25% SDS) using 
MagNa Lyser green beads tubes in the MagNa Lyser (Roche Diagnostics, the Netherlands). 
Protein concentration was determined using the BCA protein assay kit (Thermoscientific, USA), 




to contain 75 mM Tris-HCl pH 6.8, 15% SDS, 5% β-mercaptoethanol, 20% glycerol and 0.001% 
bromophenol blue. Samples were boiled for 5 minutes and 50 μg was loaded on a hand-made 4–
7% gradient polyacrylamide gel and run overnight at 4°C. The gel was blotted to nitrocellulose 
BA83 (Whatman, Schleicher & Schuell, Germany) for 6 hours at 4°C. The blot was blocked with 
5% non-fat dried milk (Campina Melkunie, the Netherlands) in Tris Buffered Saline (TBS) plus 
0.05% Tween20 followed by an overnight incubation with NCL-DYS1 (dilution 1:125, 
Novacastra, UK) or MANCHO3 (dilution 1:50,Tebu-bio, the Netherlands) in TBS plus 0.05% 
Tween20 to detect dystrophin and utrophin respectively. Myosin (MF20 dilution 1:20000, 
Developmental Studies Hybridoma Bank, University of Iowa, Iowa City) was used as a loading 
control. The fluorescent IRDye 800CW goat anti-mouse IgG (dilution 1:5000 for dystrophin and 
utrophin, dilution 1:10000 for myosin, Li-Cor, USA) was used as a secondary antibody. Blots were 
visualized and quantified with the Odyssey system and software (Li-Cor, USA) as described 
previously (Heemskerk et al. 2009). For each sample, 2–9 technical replicates were performed. A 
standard deviation of 15% was allowed between the replicates. RT-qPCR analysis Total RNA was 
isolated with RNA-Bee (Tel-Test, Bio-Connect, the Netherlands) and purified with the 
NucleoSpin RNA II kit including a DNAse digestion (Bioke, the Netherlands) according to the 
manufacturer’s instructions. The RNA concentration was measured on a Nanodrop (Nanodrop 
Technologies, USA) and integrity was checked with a total RNA nano chip assay on a labchip 
assay (Agilent, the Netherlands). cDNA was synthesized with random hexamer primers and gene 
expression levels were determined by Sybr Green based Real Time qPCR (95°C 10 sec, 60°C 30 
sec, 72°C 20 sec. 45 cycles followed by melting curve determination) on the Roche Lightcycler 
480 (Roche diagnostics Ltd, UK). Expression of genes involved in inflammation (Lgals3,Cd68), 
fibrosis (Tnnt2, Itgb2, Timp-1, Nox2, Lox, Nox4, Mmp9, Spp1)regeneration (Myog, Bgn, eMHC, 
Ctsk, Thymosinβ), heart function (Nppa, Serca2a, Cdnk1a) and exercise (Glut4, Pgc1α) were 
analysed. Gapdh was used as a reference gene, since the expression of this gene did not differ 
between different muscles or over time. Primer efficiencies were determined with LinREgPCR 
version 11.1 (Raymackers et al. 2003). The Cp values were obtained with the second derivative 
maximum method and analysed. 
 
Statistics 
Statistical analyses were performed with statistical software in R (version R2.11.1). Mdx-Xist∆hs 
mice were divided in three groups by k-means clustering, based on the median level of 
dystrophin quantified by Western blot data (n =2–9). Figures 2, 5 and 6 summarize the data, i.e. 
showing the mean and standard deviation per genotype and age. To overcome applying separate 
tests for each age between genotypes, which suffers from multiple testing and ignores the age 
trend, we applied an analysis of covariance (ANCOVA) to the data. ANCOVA was applied to 
temporal functional performance, body weight and CK level data with age as continuous and 
genotype as a categorical variable. In choosing the appropriate model we applied the principle of 
parsimony. Given the application of tests for several different variables, we considered P<0.01 as 
significant.  
The two-tailed homoscedastic Student’s t-test was conducted for comparison of the 
single time point histological, serum biomarker and gene expression data. P<0.05 was considered 








Mdx-Xist∆hs mice express varying levels of dystrophin  
To study whether low dystrophin levels reduce the dystrophic pathology of mdx mice, mdx-
Xist∆hs mice carrying a wide range of low dystrophin levels based on non-random X-inactivation 
were bred (Figure 1A). For each mdx-Xist∆hs mouse, dystrophin levels in the quadriceps muscle 
were quantified by Western blot (Figure 1B). These varied between 3–47% of wild type levels 
(mean 22.7, stdev 12.1, n = 24) (Figure 1C), which correlated well (R = 0.97) with the percentages 
of dystrophin positive fibers in cross sections of the same muscle, as assessed by blinded manual 
counting (Figure 1D). Dystrophin levels of individual muscles differed (assessed in n = 6 mdx-
Xist∆hs mice), with the tibialis anterior and biceps expressing slightly higher levels than the 
quadriceps, gastrocnemius and triceps. Lowest dystrophin levels were found in the diaphragm and 
heart (Figure S1A–B). The dystrophin level of the quadriceps was used to group the mice. 
Longitudinal sections of the quadriceps revealed that dystrophin expression along a single whole 
fiber was patchy, with nuclei either expressing dystrophin or not (Figure 1E). This indicates that 
dystrophin proteins cannot freely diffuse along the muscle fiber and that nuclei where the normal 
DMD gene is not inactivated serve only certain regional domains in the muscle fiber. Transverse 
cross sections of several skeletal muscles and heart revealed that dystrophin positive fibers were 
most often grouped together and that these small groups were spread over the muscle (Figure 
S1C).  
Dystrophin is part of a larger complex of dystrophin-glycoprotein associated proteins, 
such as β-dystroglycan and nNOS. As expected, dystrophin positive fibers of the mdx-Xist∆hs mice 
were also positive for β-dystroglycan and nNOS (Figure S2A). In absence of dystrophin, the 
homolog utrophin can partly take over its function. Muscles of adult mdx mice have significantly 
higher utrophin levels than those of adult C57BL/10ScSnJ, as utrophin is overexpressed in the 
absence of dystrophin (van Putten et al. 2012b). We assessed how dystrophin expression 
influences utrophin expression for six mdx-Xist∆hs mice expressing various levels of dystrophin. In 
mdx-Xist∆hs mice with very low dystrophin levels (<15%), utrophin levels were increased as 
confirmed by Western blot (Figure S2B, lane 2 and 6). In contrast, mdx-Xist∆hs mice with 
intermediate dystrophin levels (>15%) had low utrophin levels (lanes 1, 3–5). We did not observe 
a decrease in utrophin intensity in dystrophin positive fibers analyzed by immunohistology (data 
not shown). 
 
Dystrophin level dependent improvement in muscle function 
To determine the effect of low dystrophin levels on functional performance, Xist∆hs, mdx and 
mdx-Xist∆hs mice were subjected to a functional test regime consisting of four functional tests per 
week for 12 weeks, during which also body weight and creatine kinase (CK) levels were 
monitored. After sacrificing, quadriceps muscles were isolated and dystrophin levels were 
determined by Western blot. K-means clustering was used to divide mdx-Xist∆hs mice into three 
groups in an unbiased way. This resulted in the following division: <15%, 15–30% and >30% 
dystrophin. Mdx mice were significantly (P<0.001) heavier at the end of the functional test 
regime than the other mouse strains (mean weight 26, 24.5 and 18.2 gram for mdx, mdx-Xist∆hs 
and Xist∆hs, respectively). An increased weight compared to wild type has been described before 
for mdx mice (Spurney et al. 2009). Xist∆hs mice had a stable body weight from week 11 onwards, 
while the other models showed a mild increase overtime. The body weights of the mdx-Xist∆hs 
mice from the three dystrophin level groups were very similar and fell in between mdx and 










Figure 1. Mdx-Xist∆hs mice. A. To breed mice with low dystrophin levels, female Xist∆hs mice, carrying a mutation in 
the Xist promoter which coordinates X-inactivation, were crossed with dystrophin negative mdx males. During 
embryogenesis, the maternal X-chromosome encoding a functional dystrophin gene will be preferentially (60–90%) 
inactivated as a result of the mutated Xist promoter. The Xist∆hs mice were a kind gift from N. Brockdorff (MRC 
Clinical Sciences Center, London, UK, current affiliation Department of Biochemistry, University of Oxford, UK). B. 
Picture of a representative Western blot. The percentage of dystrophin was determined for the quadriceps of all mdx-
Xist∆hs mice by Western blot (2–9 technical replicates per mouse). The percentage of individual mice was determined 
using a concentration curve made from wild type samples. Myosin was used as a loading control. C. Skewed X-
inactivation resulted in dystrophin levels of 3–47% (mean 22.7, stdev 12.1, n = 24) (as determined by Western blot) in 
the female mdx-Xist∆hs offspring. Each bar represents the dystrophin level of an individual mouse. The dystrophin 
levels of the individual mice belonging to the three dystrophin groups can be appreciated from this graph. D. 
Dystrophin levels determined by Western blot and manual counting of dystrophin positive fibers demonstrate a 
strong correlation (R = 0.97). E. Longitudinal sections of a quadriceps stained with dystrophin (green) and spectrin 
(red). From the pictures it can be appreciated that dystrophin expression is not homogeneously expressed across the 
fiber but rather confined to certain nuclear domains. 












Figure 2. Body weight, CK levels and functional performance of the mouse models. A. Normalization towards wild 
type levels was observed for bodyweight of the mdx-Xist∆hs mice. At the end of the functional test regime mdx mice 
were significantly heavier (P<0.001) than the other mice. B. CK levels of mdx and mdx-Xist∆hs mice with low 
dystrophin levels were both significantly (P<0.001) higher compared to the levels of mdx-Xist∆hs mice with >30% 
dystrophin and Xist∆hs mice. C. Four limb hanging wire performance was comparable for the Xist∆hs and mdx-Xist∆hs 
mice, while mdx mice performed significantly (P<0.001) worse. D. The best performance on the two limb hanging 
wire test was obtained for the Xist∆hs, mdx-Xist∆hs with <15% and 15–30% while the mdx and mdx-Xist∆hs with >30% 
dystrophin performed significantly (P<0.001) worse. Bad performance of mdx-Xist∆hs with >30% was due to the bad 
performance of one individual mouse. E. Normalized fore limb grip strength was significantly (P<0.001) higher in the 
Xist∆hs mice compared to the other strains and all the mdx-Xist∆hs mice were significantly (P<0.001) stronger than the 
mdx mice. F. No difference in rotarod running was observed, except for the mdx-Xist∆hs mice with 15–30% 




 CK levels are a measure for muscle condition and are <500 U/L in healthy mice. CK 
levels of the Xist∆hs mice never exceeded this threshold and were, averaging 270 U/L, significantly 
(P<0.001) lower than levels of the other mouse strains. Mdx mice had the highest CK levels 
(average 2700 U/L). When analyzed over the complete time course, these were significantly 
(P<0.001, linear regression) higher than those of mdx-Xist∆hs mice with >30% dystrophin (average 
1570 U/L). CK levels of mice with 15–30% dystrophin generally fell between those with <15% 
and >30%, showing a clear correlation between CK and dystrophin levels. CK levels of mice with 
<15% of dystrophin were similar to mdx suggesting that these dystrophin levels were not enough 
to decrease CK levels (Figure 2B).  
In the four limb hanging wire test, mdx mice performed significantly (P<0.001) worse 
compared to all the other groups (Figure 2C). Xist∆hs mice were able to hang for the maximum 
period of time for the entire testing period of 12 weeks, whereas all mdx-Xist∆hs mice performed 
nearly as well as Xist∆hs mice. Also in the two limb hanging wire test, Xist∆hs and mdx-Xist∆hs mice 
significantly (P<0.001) outperformed mdx mice and were able to hang for the maximum allowed 
time. Performance of mdx-Xist∆hs mice with >30% dystrophin dropped from an age of 9 weeks 
compared to the other mdx-Xist∆hs mice, but this was due to the poor performance of a single 
mouse. Generally, the decreased performance was more pronounced in mdx mice (Figure 2D). 
The normalized fore limb grip strength measured for Xist∆hs mice (7.9) was significantly (P<0.001) 
higher than that of mdx and mdx-Xist∆hs mice (Figure 2E). Strength was improved towards wild 
type levels in all mdx-Xist∆hs mice (6.5) and significantly (P<0.001) lower in mdx mice (5.9). 
Rotarod performance was significantly (P<0.001) better in the mdx-Xist∆hs mice with 15–30% 
dystrophin compared to all the other groups (Figure 2F). Unfortunately, we observed a high inter 
group variation, which makes drawing conclusions difficult for this test. Based on these analyses, 
even the lowest levels of dystrophin analyzed (between 3 and 14%), appear sufficient to improve 
hanging times and grip strength.  
 
Dystrophin dependent improvement of histopathology and restoration of gene 
expression 
After sacrificing the animals, the quadriceps, heart and diaphragm were dissected and 
cryosections were made. To determine fiber size and the percentage of centralized nuclei, the 
quadriceps of all mice was stained with laminin and DAPI. Five pictures were randomly captured 
of the middle section of the muscle and analysed with Mayachitra Imago (Figure 3A and B). 
Regenerating fibers (<1000 μm2) and hypertrophic fibers (>6000 μm2) were predominantly found 
in the mdx mice (50% and 4.8%, respectively), whereas smaller proportions were observed for the 
Xist∆hs mice (20% and 0.9%, respectively) and a dystrophin level dependent normalization 
towards the wild type fiber size distribution was observed for mdx-Xist∆hs mice. The percentage of 
centralized nucleated fibers was significantly higher (P<0.01) in mdx (51%) compared to Xist∆hs 
mice (2%). More than 15% of dystrophin was sufficient to significantly (P<0.01) reduce the 
amount of centralized nuclei by 40%, whereas dystrophin levels above 30% caused a reduction of 
around 60%.  
To determine the percentage of fibrotic/necrotic fibers, sections of the quadriceps, 
diaphragm and heart were stained with haematoxylin & eosin. For all muscles quantified, except 
heart, the percentage of fibrosis was significantly higher (P<0.001) in mdx mice compared to 
Xist∆hs mice. In the quadriceps of mdx-Xist∆hs mice of the different groups no significant 
differences was observed, although there appears to be a dystrophin-dependent trend towards 
lower levels of fibrosis in the mice with moderate levels of dystrophin (Figure 3C).  
 




Figure 3. Muscle fiber size, degree of central nucleation and percentage of fibrotic/necrotic tissue. A. Regenerating 
and hypertrophic fibers were mainly observed in the mdx mice. A dystrophin level depend trend towards wild type 
distribution was observed for mdx-Xist∆hs mice where <15% dystrophin already resulted in improvement. B. 
Dystrophin levels between 15–30% and >30% resulted in a reduction of the percentage of centralized nuclei of 40% 
and 60% respectively. C. The quadriceps of all mice was significantly more severely affected compared to Xist∆hs mice. 
D. The diaphragm was the most severely affected muscle with on average 20% fibrotic/necrotic tissue in mdx mice. 
All mice were significantly more severely affected compared to Xist∆hs mice. Mdx-Xist∆hs mice with >30% dystrophin 
had less fibrotic/necrotic tissue than mdx and mdx-Xist∆hs mice with <15% dystrophin, but this difference was only 
significant between both mdx-Xist∆hs groups. # indicates a significant difference of that bar with all the other groups. 
Single asterisks indicate a P<0.05 and double asterisks indicate a P<0.01.  
 
The diaphragm was the most severely affected muscle examined, with fibrotic/necrotic tissue 
percentages of 20% in both mdx and mdx-Xist∆hs mice with <15% dystrophin compared to 8% in 
Xist∆hs mice. Again, there was a dystrophin-level dependent pattern of reduced fibrotic tissue 
which reached significance (P<0.05) in mice with >30% dystrophin (Figure 3D). Fibrosis/necrosis 
levels in heart were below 5% in all mice, which is expected, as fibrosis in heart generally is 
observed in older mice (data not shown) (van Erp et al. 2010).  
To determine whether low levels of dystrophin were able to normalize the expression of 
genes known to be involved in inflammation, fibrosis, regeneration and heart function RT-qPCR 
was performed on mRNA of the quadriceps, diaphragm and heart of all mice (Turk et al. 2005). 
The expression of most genes was significantly (P<0.01) elevated in mdx mice compared to Xist∆hs 
mice in the three muscles, and most often normalized in a dystrophin level dependent manner in 
the mdx-Xist∆hs mice (Figure 4). Notably, in the diaphragm, mRNA levels of the biomarkers for 
muscle regeneration (Tnnt2, Bgn) decreased in mice with <15% dystrophin, while biomarkers for 
inflammation (Lgals3, Cd68) only decreased in mice with >30% dystrophin. Biomarkers for 
fibrosis (Timp-1, Nox2) decreased in mice with <15% and >15% dystrophin, respectively. No 
difference in expression of heart function genes was observed, except for Nppa, which is due to 








Figure 4. Expression of several genes involved in disease pathology. A and B. For most biomarkers a clear dystrophin 
level dependent restoration of gene expression levels was observed in the mdx-Xist∆hs mice, where intermediate 
dystrophin levels resulted in low expression of genes involved in disease pathology. For some genes, dystrophin levels 
<15% were enough to reduce gene expression while for other genes >30% was necessary. C. In the heart, even 
dystrophin levels of <15% decreased expression of fibrotic biomarkers like Timp-1. Since the mice were young, no 
difference in expression levels in heart function was observed, except for Nppa. Double asterisks indicate a P<0.01.  
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Dystrophin level dependent protection against exercise induced muscle damage 
To determine the protective effect of low dystrophin levels on muscle integrity during chronic 
exercise, mice were forced to run three times a week on a horizontal treadmill. This was directly 
followed by a functional test to assess the influence of muscle fatigue on performance. We tested 
seven mdx-Xist∆hs mice which had an average dystrophin level of 21% (2%–45% median 25.8), six 
mdx and five C57BL/10ScSnJ females (the wild type sub-strain from which the mdx mouse was 
derived).  
CK levels were assessed on Mondays before exercise (Figure 5B) and on Fridays directly 
after exercise (Figure 5C). For mdx and mdx-Xist∆hs mice CK levels increased significantly 
(P<0.01) upon exercise (4150 U/L before versus 11170 U/L after for mdx and 2070 U/L before 
versus 8850 U/L after for mdx-Xist∆hs), whereas this was not observed for the wild type mice (250 
U/L before versus 291 U/L after) (Figure 5A). CK levels of the mdx-Xist∆hs mice were significantly 
(P<0.05) lower compared to mdx, both before and after exercise. Wild type mice had significantly 
(P<0.01) lower CK levels than those of mdx and mdx-Xist∆hs mice. Mdx-Xist∆hs mice gained 
significantly (P<0.01) less weight over time than mdx mice, as they had a higher body weight at 
the start, but a similar body weight at the end of the test regime (data not shown). Wild type mice 
were significantly (P<0.01) less heavy than mdx mice, but did not significantly differ in weight 
from the mdx-Xist∆hs mice.  
At an age of 8 and 14 weeks, serum levels of matrix metalloproteinase-9 (MMP-9), tissue 
inhibitors of matrix metalloproteinase-1 (TIMP-1) and osteopontin (OPN) were assessed. These 
markers have been identified as potential biomarkers to monitor disease progression in DMD 
patients (Nadarajah et al. 2011). For MMP-9, 8 week old mdx mice had significantly (P<0.05) 
higher levels when compared to wild type and mdx-Xist∆hs mice (Figure 5D). 
 
 
Figure 5. Serum and plasma biomarkers assessed before and directly after treadmill running. A. CK levels assessed 
before and directly after treadmill running. CK levels collected before exercise were significantly (P<0.01) lower than 
those collected directly after exercise in mdx-Xist∆hs and mdx mice. This exercise induced increase was absent in wild 
type mice. B. CK levels determined before exercise were significantly (P<0.01) elevated in mdx and mdx-Xist∆hs mice 
compared to wild type, but this was less pronounced for the mdx-Xist∆hs mice as mdx mice had significantly (P<0.05) 
higher CK levels. C. Plasma collected directly after exercise contained extremely high CK levels, in both mdx and 
mdx-Xist∆hs mice but not in wild type mice. D. Serum levels of MMP-9 were elevated in mdx mice compared to 
Xist∆hs mice at both 8 and 14 weeks of age, while levels were normalized in mdx-Xist∆hs mice. E. TIMP-1 levels were 
elevated in serum of both mdx and mdx-Xist∆hs mice. In wild type mice we found an age related increase of the serum 
TIMP-1 level. Interestingly, at the age of 8 weeks, levels of mdx-Xist∆hs mice were significantly lower than those of 
mdx mice. F. Mdx mice had significantly elevated OPN levels compared to both wild type and mdx-Xist∆hs at 8 weeks 





Figure 6. Functional performance 
measured directly after treadmill 
exercise. A. Longest hanging 
time with the two limb hanging 
test was achieved by wild type 
and mdx-Xist∆hs mice which both 
performed significantly (P<0.001) 
better than mdx mice. B. Fore 
limb grip strength of mdx-Xist∆hs 
mice was significantly (P<0.001) 
better than that of mdx mice. C. 
Wild type mice outperformed 
mdx and mdx-Xist∆hs mice on the 
rotarod, while no significant 
difference was observed between 
mdx and mdx-Xist∆hs mice. 
Average dystrophin level of 
mdx-Xist∆hs mice was 21% (2%–





















No significant difference was observed between mdx-Xist∆hs and wild type mice. TIMP-1 levels 
were significantly (P<0.05) elevated in both mdx and mdx-Xist∆hs mice compared to wild type 
mice at the age of 8 and 14 weeks (Figure 5E). Interestingly, a significant (P<0.05) difference was 
also observed between mdx and mdx-Xist∆hs mice aged 8 weeks. OPN levels were significantly 
(P<0.05) elevated in mdx compared to both wild type and mdx-Xist∆hs at 8 weeks. This difference 
was not observed at 14 weeks of age (Figure 5F).  
The chronic treadmill exercise protocol was completed by all mice without any 
problems. However, we later found that fibrosis was much worse in these exercised mice and that 
the low dystrophin levels were not enough to prevent worsening of the muscle’s condition (see 
below). Directly after treadmill exercise, mice were subjected to two limb hanging wire test, fore 
limb grip strength or rotarod (Figure 6). For the two limb hanging wire test, the hanging time of 
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mdx mice decreased over time, and was significantly (P<0.001) lower than those of the mdx-
Xist∆hs and wild type mice. The hanging time of the mdx-Xist∆hs and wild type mice did not differ 
significantly. Performance of the grip strength was consistently lower for the mdx mice (5.8) than 
for the other groups (mdx-Xist∆hs 6.3 and wild type 6.4). Wild type mice performed well at the 
start of the functional test regime, but their strength slightly decreased over time. Grip strength 
of mdx and mdx-Xist∆hs mice followed the same curve, and mdx-Xist∆hs mice performed 
significantly (P<0.001) better than mdx mice. Rotarod running time was significantly (P<0.001) 
higher in the wild type mice with an average running time of 430 seconds, which was generally 
130 seconds longer than that of both dystrophic mouse strains. The performance of mdx and 
mdx-Xist∆hs mice did not significantly differ for this test. 
 
Low dystrophin levels did not fully prevent exercise induced pathology 
The effect of the chronic exercise regime on histopathology was assessed by measuring the 
percentage of fibrotic/necrotic tissue for the quadriceps. On average, 18% of the quadriceps of the 
mdx mice consisted of fibrotic/necrotic tissue, compared to less than 5% for wild type mice. Mdx-
Xist∆hs mice had slightly more healthy tissue than mdx mice (Figure 7A). When compared to 
fibrosis observed in mice which underwent the functional test regime without treadmill running, 
histopathology was much worse. At the end of the chronic exercise regime, Evans blue dye was 
injected intravenously and the percentage of Evans blue dye positive fibers was manually counted 
for the quadriceps of all mice. Hardly any Evans blue dye positive fibers were detected in wild 
type muscle (0.41%), while both in mdx and mdx-Xist∆hs mice 11.11% and 9.23% of positive fibers 
were found. This suggests that while low dystrophin levels are sufficient to improve muscle 
function and muscle fiber integrity in the absence of chronic exercise, they apparently are not 
sufficient to protect against fiber damage induced by the chronic treadmill exercise regime.  
The expression of some fibrosis, inflammation and regeneration biomarkers was assessed 
for the quadriceps. For most genes, mdx and mdx-Xist∆hs mice had significantly (P<0.05) increased 
expression when compared to wild type levels. However, between mdx and mdx-Xist∆hs mice no 
difference in expression was observed indicating that the dystrophin levels in these mice were not 
sufficient to prevent pathology induced by chronic exercise (Figure 7B). In addition, we were able 
to confirm the differences observed in serum for MMP-9, TIMP-1 and OPN (Spp1) on gene 
expression level.  
 
 
Figure 7. Exercise induced histopathology and biomarker gene expression. A. Wild type mice were less severely 
affected than mdx and mdx-Xist∆hs mice. Due to high variation between individual mdx mice, the difference between 
mdx and wild type mice was not significant. Mdx-Xist∆hs mice had slightly less fibrotic tissue than mdx mice. B. No 
difference in expression of genes involved in disease pathology was found between mdx and mdx-Xist∆hs mice. Both 
mouse strains did differ significantly from wild type mice, of which the expression levels were low. Single and double 
asterisks indicate a P<0.05 and P<0.01, respectively. # Indicates a significant difference from all other groups, average 





With several potential therapeutic compounds being tested in clinical settings for DMD, there is 
an increasing need to gain detailed knowledge about which levels of dystrophin are of therapeutic 
value and which and/or how low dystrophin levels affect the different pathological pathways. 
This would help the optimization phase of pre-clinical research on therapeutic approaches aiming 
at dystrophin restoration. It will also facilitate providing patients and parents who are candidates 
to participate in clinical trials for these approaches with realistic expectations.  
Several attempts to generate mice expressing low dystrophin levels have been 
undertaken previously, unfortunately without success since none of these strains expressed a 
wide variety of low dystrophin levels in the most interesting range. With no accessibility to a 
good model, current knowledge and rough estimations are based on human female DMD carriers, 
heterozygous mdx mice, generated transgenic mice expressing lower levels of full-length or 
truncated dystrophin of murine or human origin and antisense oligonucleotide (AON) treated 
mdx mice.  
In this paper, we describe the easy to generate mdx-Xist∆hs mouse model, which 
facilitates assessment of the effects of different dystrophin levels on muscle performance and 
integrity. Mice with very low (<15%), low (15–30%) and moderate dystrophin (>30%) levels 
showed a dystrophin level dependent reduction of the homolog utrophin. All mdx-Xist∆hs mice 
had a normalized body weight and outperformed mdx mice in both hanging wire tests and in the 
grip strength test, indicating that even low dystrophin levels (<15%) can bring about improved 
performance in this mouse model. The improved functional performance observed is in 
concordance with that previously described in mdx3cv mice and AON treated mice expressing low 
levels of dystrophin (Li et al. 2008;Sharp et al. 2011). Although, ~5% of dystrophin in the mdx3cv 
mice resulted in increased specific tetanic force and partly resistance to eccentric contractions in 
young, but not in old mice, histopathology was not different from dystrophin negative mdx4cv 
mice. This again is in line with our observation in mdx-Xist∆hs mice expressing <15% dystrophin, 
were we also found no histopathological improvements, while we did find improvements on 
motor function. Dystrophin levels >30% reduced CK levels significantly while for lower 
percentages only a non-significant trend was found. Also for the expression of pro-inflammatory 
biomarkers and histopathology, a dystrophin level dependent improvement was observed where 
for some genes >15% of dystrophin led to improvement while for other genes >30% dystrophin 
was needed. In chronically exercised mice with ~20% dystrophin, normalization towards wild 
type levels was observed for three different disease serum markers (CK, MMP-9 and TIMP-1). 
This confirms findings that MMP-9 and TIMP-1 are useful serum biomarkers to monitor disease 
pathology in DMD patients’ serum (Nadarajah et al. 2011). Even after treadmill exercise the mdx-
Xist∆hs mice performed significantly better than the mdx mice for the two limb hanging wire test 
and grip strength. However, the levels of fibrosis and Evans blue dye uptake were similar for 
mdx-Xist∆hs mice and mdx mice, indicating that ~20% of dystrophin is not sufficient to protect 
against forced exercise induced damage. Thus, while even dystrophin levels below 15% can 
improve pathology and performance, levels of >20% are needed to fully protect muscle fibers 
from exercise- induced damage.  
The fact that most of our observations concur with those of other studies conducted in 
transgenic mice and AON treated mice confirms the usefulness of the mdx-Xist∆hs mouse as a 
dystrophic mouse strain. It should be noted that the mdx-Xist∆hs mouse expresses dystrophin in a 
random manner where nuclei either express wild type levels of dystrophin or no dystrophin at 
all. This is similar to the pattern what is expected for cell therapy, gene therapy and to what is 
observed in transverse cross sections after phosphorodiamidate morpholino oligomer (PMO) 
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administration (Cirak et al. 2011), but different from that of 2’-O-methyl phosphorothioate 
(2OMePS) (Goemans et al. 2011) or gentamicin administration (Malik et al. 2010), which result in 
a more evenly low dystrophin expression in nearly all fibers. With detailed knowledge lacking 
regarding the migration properties of AONs and dystrophin over the membrane, it is unknown 
whether the mosaic pattern seen in longitudinal cross sections of mdx-Xist∆hs mice could be 
expected upon PMO administration. The effect of differences in distribution of dystrophin has 
never been studied in great detail; i.e. whether 20% of dystrophin in all muscles is better than 
100% dystrophin in 20% of muscle fibers. Previously, Phelps et al. showed that mice expressing 
dystrophin 10-fold greater than wild type levels in a mosaic manner had 34% of centralized 
nuclei, while mice expressing similar amounts uniformly only had 7% of central nuclei. More 
detailed studies especially in mice expressing low dystrophin levels are needed and could easily be 
conducted using our mouse model and comparing them to 2OMePS or gentamicin treated mdx 
mice (Phelps et al. 1995). Using the mdx-Xist∆hs mouse as study object is favored above treated 
mdx mice since no expensive treatment is needed to achieve a range of low dystrophin levels. 
Notably, we observed variation in pathology for mice with similar levels of dystrophin. This 
phenomenon is also anticipated for patients currently in clinical trials aiming at dystrophin 
restoration. Our mouse model will allow extended studies to elucidate this discrepancy.  
In summary, the Gaussian distribution of low dystrophin levels obtained in the mdx-
Xist∆hs mouse and the ease of generating large numbers of mice, make it a good mouse model for 
more detailed research on the effect of low levels of dystrophin on several aspects of DMD 
pathology and effects of future treatment strategies for dystrophinopathies. 
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Figure S1 Dystrophin expression in mdx-Xist∆hs mice. A. Example of a Western blot of some skeletal muscles and 
heart. In order to determine the expression levels of the different muscles, a concentration curve was made of wild 
type samples from the corresponding muscle. Myosin was used as a loading control. B. Relative dystrophin levels of 
skeletal muscles compared to these of the quadriceps. Dystrophin levels of six mdx-Xist∆hs mice, with dystrophin 
levels of <15%, 15–30% and >30%, were assessed for skeletal muscles and heart by Western blot. Levels are expressed 
relative to the quadriceps. Those of gastrocnemius and triceps were similar to quadriceps levels, while those of the 
tibialis anterior and the biceps were slightly higher. Low levels were observed for the diaphragm and heart. qua: 
quadriceps, gas: gastrocnemius, ta: tibialis anterior, tri: triceps, bi: biceps, dia: diaphragm, ha: heart. C. Small groups of 
dystrophin positive fibers were randomly distributed over the muscles. Representative pictures of mdx-Xist∆hs mice 
with 8 and 23% dystrophin. 

















Figure S2 Dystrophin co-localisation with β-dystroglycan and nNOS in mdx-Xist∆hs mice. A. Dystrophin co- localises 
with β-dystroglycan (top) and nNOS (bottom). B. For mdx-Xist∆hs mice dystrophin levels previously determined on 
several Western blots (representative blot shown in Figure 1B) were compared to utrophin levels. The relative level 
of utrophin nicely correlated to that of dystrophin. Mice with intermediate dystrophin levels had decreased utrophin 
levels (lane 2 and 6) while mice with low dystrophin levels had higher utrophin levels (lane 1, 3–5). Mdx/utrn mice 
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Abstract 
Aim: Duchenne muscular dystrophy is a muscular dystrophy caused by mutations that prevent 
synthesis of functional dystrophin. All patients develop dilated cardiomyopathy. Promising 
therapeutic approaches are underway that successfully restore dystrophin expression in skeletal 
muscle. However, their efficiency in heart is limited. Improved quality and function of only 
skeletal muscle potentially accelerates the development of cardiomyopathy. Our study aimed to 
elucidate which dystrophin levels in heart are required to prevent or delay cardiomyopathy in 
mice. 
Methods and Results: Heart function and pathology assessed with magnetic resonance imaging, 
histology and gene expression analysis were compared between 2, 6 and 10-month-old mdx-
Xist∆hs mice, expressing low dystrophin levels (3-15%) based on skewed X-inactivation, 
dystrophin-negative mdx mice, and wild type mice of corresponding genetic backgrounds.  
Mdx mice developed severe dilated cardiomyopathy and hypertrophy, whereas the 
onset of heart pathology was delayed and function greatly improved in mdx-Xist∆hs mice. The 
ejection fraction, the most severely affected parameter for both ventricles, correlated to 
dystrophin expression and the percentage of fibrosis. Fibrosis was reduced from 9.8% in mdx to 
5.4% in mdx-Xist∆hs mice. Additionally, expression of genes involved in heart pathology 
normalized towards wild type levels in older mdx-Xist∆hs mice.  
Conclusions: These data suggest that mosaic expression of 3-15% dystrophin in heart is sufficient 
to delay the onset and ameliorate cardiomyopathy in mice. 
 
Introduction 
Duchenne muscular dystrophy (DMD) is the most common inherited neuromuscular disorder. It 
is characterized by severe and progressive muscle wasting and affects 1 in 3500 newborn boys. In 
DMD patients, the synthesis of functional dystrophin proteins is prevented by mutations in the 
DMD gene, located on the X-chromosome (Muntoni et al. 2003). Dystrophin is part of the 
dystrophin-associated protein complex, which links the actin cytoskeleton to the extracellular 
matrix and stabilizes the sarcolemma during muscle contractions (Blake et al. 2002). In DMD 
patients, this link is absent, making fibers vulnerable to exercise-induced damage, leading to 
repeated cycles of de- and regeneration. Upon exhaustion of the regenerative capacity, fibers are 
replaced by fibrotic and fat tissue, resulting in loss of ambulation in the second decade of life. Pre-
clinical cardiac involvement is sometimes already observed in young patients (aged <6 years) and 
its frequency increases with age. Later in life, it progresses into clinically relevant 
cardiomyopathy affecting 40% of 10-year-old patients (Nigro et al. 1990). Old patients are 
dependent on assisted ventilation and at that stage the vast majority suffers from dilated and 
hypertrophic cardiomyopathy of the left ventricle, while the right ventricle and atrium remain 
unaffected (Connuck et al. 2008;van Bockel et al. 2009). Eventually, patients die of heart or 
respiratory failure in their third or fourth decade (Gulati et al. 2005).  
Becker muscular dystrophy (BMD) is a milder form of muscular dystrophy, caused by 
in-frame mutations in the DMD gene, which result in reduced expression of dystrophin and/or 
internally truncated, but partly functional dystrophin. The skeletal muscle pathology is less 
severe than in DMD patients, and patients usually remain ambulant until later in life. However, 
in 70% of the BMD patients a more severe cardiomyopathy is observed at time of clinical 
presentation accounting for 50% of deaths (Connuck et al. 2008;Yilmaz et al. 2008;Kaspar et al. 
2009). Especially BMD patients with very mildly affected skeletal muscles can develop severe 
cardiomyopathy (Melacini et al. 1996). Dilated cardiomyopathy is also found in DMD and BMD 




muscle weakness, whereas 23% have dilated cardiomyopathy or left-ventricular dilation 
(Hoogerwaard et al. 1999).  
There is no cure for DMD, but several potential therapies aiming at dystrophin 
restoration are under investigation in clinical trials (Bowles et al. 2012;Malik et al. 2010;Skuk et 
al. 2007), with antisense-mediated exon skipping being closest to clinical application (Goemans et 
al. 2011;Cirak et al. 2011). Unfortunately, the efficiency of targeting the heart seems less than for 
skeletal muscle for the exon skipping approaches currently tested in clinical trials (Alter et al. 
2006;Bostick et al. 2009;Townsend et al. 2008;Heemskerk et al. 2010;Heemskerk et al. 
2009;Malerba et al. 2011;Wu et al. 2011). Eventually, this might result in partial dystrophin 
restoration in skeletal muscle accompanied by improved function, but without restoration in the 
heart. Given that both BMD patients and DMD/BMD carriers exhibit more pronounced 
cardiomyopathy than DMD patients, increased physical activity is likely to put a larger workload 
on the heart, thereby potentially exacerbating the development of cardiomyopathy.  
The most commonly used mouse model for DMD, the mdx mouse, also suffers from 
dilated cardiomyopathy. In non-treated mdx mice, increased activity (e.g. voluntary wheel 
running), accelerates the progression of dilated cardiomyopathy (Jearawiriyapaisarn et al. 
2010;Quinlan et al. 2004;Spurney et al. 2008;Costas et al. 2010). In line with this, skeletal muscle 
restricted dystrophin restoration improves voluntary activities thereby increasing the workload of 
the heart and exacerbating heart pathology (Malerba et al. 2011;Townsend et al. 2008). By 
contrast, it has been shown that high dystrophin levels in skeletal muscles and diaphragm only, 
improve heart function in mdx mice (Crisp et al. 2011).  
To study which dystrophin levels are needed to prevent or delay the onset of heart 
failure, we assessed heart function and pathology over time in mdx-Xist∆hs mice. These mice 
originate from crossing Xist∆hs females (expressing intact dystrophin but carrying a mutation in 
the promoter of the Xist gene which coordinates X-inactivation (Newall et al. 2001)), with 
dystrophic mdx males. In the female offspring (mdx-Xist∆hs), the X-chromosome expressing the 
mutated Xist gene, but intact dystrophin, is preferentially inactivated, resulting in expression of 
varying, low dystrophin levels in skeletal muscle and heart (van Putten et al. 2012a). We show 
that dystrophin levels of 3-15% in heart are sufficient to delay the onset of dilated 
cardiomyopathy and reduce the severity of pathology in mdx mice.  
 
Material and methods  
Animal care 
Breeding pairs of mdx (C57BL/10ScSn-mdx/J) males and Xist∆hs females gave birth to mdx-Xist∆hs 
females (van Putten et al. 2012a). The Xist∆hs model (Newall et al. 2001) was a kind gift from prof. 
Dr. Brockdorff (MRC Clinical Sciences Centre London, UK, current affiliation Department of 
Biochemistry, University of Oxford, UK). Genotyping was performed on DNA obtained from tail 
tips by PCR analysis. Mice were housed in individually ventilated cages with 12-h light-dark 
cycles and had ad libitum access to standard chow and water. All experiments were approved by 
the Animal Experimental Commission (DEC) of the LUMC and conforms with the Directive 
2010/63/EU of the European Parliament. 
 
MRI heart function analysis 
MRI analysis was performed at the Faculty of Science of the University of Leiden to which the 
mice were transported a week before analysis to acclimatize. Mice were anaesthetized by 
inhalation of 2% isoflurane in a 1:1 mixture of pure oxygen and air. Mice were scanned in a 
vertical 9.4T magnet with 89 mm bore size, equipped with a 1 T/m gradient system (Bruker 
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BioSpin, Germany), using a quadrature birdcage coil (inner diameter 3 cm). Image acquisition was 
done with Bruker Paravision 5.0 software and took ~30 min including animal setup. A 
retrospectively-gated Intragate sequence was used with flip angle 10°; repetition time 8.5 ms; 
echo time 1.86 ms; field-of-view 2.56x2.56 cm2; matrix 192x192; in-plane resolution 133 μm. We 
made 8-9 short-axis slices of the heart of 1 mm thick and 200 repetitions per slice. The navigator 
echo was placed in-slice. Images were reconstructed to 18 frames per heart cycle. Respiration rate 
was monitored with a respiratory pad and kept constant at 50-80 respirations per minute. Six of 
the 135 mice scanned were not used for analysis as the angle of the scan was incorrect.  
MASS for MICE software (developed at the LUMC, Division of Image Processing 
(LKEB)) was used for image analysis (van der Geest and Reiber 1999). For each picture, 
endocardial and epicardial contours of both ventricles were drawn manually. The end diastolic 
and systolic phase was computed by the software and a maximum mass difference of 10% was 
accepted. When this criteria was met, End Diastolic and Systolic Volume (EDV and ESV, 
respectively) were determined and based on these values Stroke Volume (SV = EDV-ESV), 
Ejection Fraction (EF = (SV/EDV)*100%) and Cardiac Output (CO = SV*heart rate) were 
calculated automatically.   
 
Serum biomarker level analysis 
For analysis of cardiac Troponin I and N-terminal Pro Brain Natriuretic Peptide levels, blood 
(~1mL) was drawn from the anaesthetised mouse via the eye after which it was sacrificed by 
cervical dislocation. Blood was collected in a non-coated eppendorf tube, allowed to clot at room 
temperature for 10 min and stored on ice. Samples were centrifuged at 1700 g for 10 min at 4°C 
and stored at -80°C. Levels of cardiac Troponin I and NT-proBNP were measured using the High 
Sensitive Mouse Cardiac Troponin-I ELISA Kit (Life Diagnostics, USA) and the ELISA Kit for NT-
proBNP (Uscn Life Science Inc, China) respectively.  
 
Histological examination 
Tissues were snap frozen in 2-methylbutane (Sigma Aldrich, the Netherlands) cooled in liquid 
nitrogen. Sections of 8 μm were made on Superfrost Plus slides (Thermo Fishes Scientific, 
Menzel-Gläser, Germany) with a Shandon cryotome (Thermo Fisher Scientific Co., USA) along 
the entire length of the heart with an interval of 240 μm between the sections. Excess tissue was 
used for protein and RNA isolation. Sections were stained with goat-anti-Collagen type 1 
(dilution 1:100, 1310-01 Southern Biotech, USA), donkey-anti-goat Alexa594 (dilution 1:1000, 
Invitrogen, the Netherlands) and DAPI. A fluorescent microscope (Leica DM RA2) was used to 
examine the sections at a 16 times magnification and images covering the entire heart were 
captured with a Leica DC350FX snapshot camera. The percentage of fibrotic tissue was assessed 
with ImageJ software (Rasband W.S., ImageJ, U.S. National Institutes of Health, USA, 
http://rsb.info.nih.gov/ij/, 1997-2008).     
 
Dystrophin determination by western blot 
Heart and diaphragm muscles were homogenized and dystrophin levels quantified by western 
blotting using the Odyssey system as described previously (van Putten et al. 2012a). The lowest 







Gene expression analysis with qPCR 
Total RNA was isolated with TRIzole (Invitrogen, the Netherlands) in MagNA Lyser Green Beads 
tubes (Roche diagnostics Ltd, UK) and purified with the NucleoSpin RNA II kit (Bioke, the 
Netherlands). RNA integrity and concentration was determined with a total RNA nano-chip 
assay on a labchip bioanalyzer (Agilent, the Netherlands). Random hexamer primers were used 
for cDNA synthesis and gene expression was determined by Sybr Green based Real Time qPCR 
(95°C 10 sec, 60°C 30 sec, 72°C 20 sec for 45 cycli followed by melting curve analysis) on the 
Roche Lightcycler 480 (Roche diagnostics Ltd, UK). Gapdh was used as a reference gene. The Cp 
values were obtained with the second derivative maximum method and primer efficiencies and 
gene expression was determined with LinREgPCR version 11.1 (Ramakers et al. 2003). The 
expression of C57BL/10ScSnJ mice was set to one.  
 
Statistics 
Statistical analyses were performed using SPSS 17.0.2. (SPSS, Inc., Chicago, IL, USA). Heart 
function was compared over time with the two-way analysis of variance (ANOVA). In case of 
significance (P<0.05), a LSD correction for multiple testing was applied. Correlations for the 10-
month-old mdx-Xist∆hs mice were tested with the Spearman correlation test. Values of P<0.05 
were considered significant. The one-way ANOVA was conducted for comparison of the 




Low dystrophin levels in heart prevent the age-dependent decline of heart function    
To determine whether low dystrophin levels can prevent or delay the onset of dilated 
cardiomyopathy, heart function was determined by MRI in groups of female mdx (no 
dystrophin), mdx-Xist∆hs (low dystrophin), C57BL/10ScSnJ (wild type control) and Xist∆hs (wild 
type control) mice aged 2, 6 and 10 months. We chose a cross-sectional design to allow post-
mortem histological validation. To assess the correlation between dystrophin levels and heart 
function in individual mice, 27 mdx-Xist∆hs mice were scanned per time point, while 6 mice were 
scanned for the control groups. Dystrophin levels in the heart of mdx-Xist∆hs mice varied between 
3-15% and were similar for the different age groups (2 months; 3-13.8%, 6 months; 3-14.9%, 10 
months; 3-12.1%) as assessed by western blot (Figure 1A-B). MRI scans were positioned on the 
left ventricle and the ejection fraction (EF), stroke volume (SV), end diastolic volume (EDV), 
cardiac output (CO) and end systolic mass of both ventricles were assessed.  
Overall, the heart function of the two wild type strains was largely comparable, but 
differed slightly, probably due to differences in the genetic background. In mdx mice, heart 
function of both ventricles deteriorated with age, most evidently for the EF and SV, while it 
remained constant in both wild type models (Figure 1C-F, Table 1), as reported previously 
(Verhaart et al. 2011). Expression of 3-15% dystrophin in heart prevented EF and SV to drop in 
mdx-Xist∆hs mice as levels remained stable over time and were higher than mdx mice from the age 
of 6 months onwards (P<0.05). The EF and SV of mdx-Xist∆hs mice were similar to levels of the 
wild type stains at 6 months, and for the left ventricle only lower than 10-month-old Xist∆hs mice 
(P<0.05). The EDV and CO of both ventricles did not differ between the mouse models. 
End systolic mass of both ventricles increased with age in all mice. However, the left 
ventricular mass of mdx mice was greater than that of all other mice regardless of their age 
(P<0.01), indicative of hypertrophy of the heart. In contrast, the expression of <15% dystrophin 
in mdx-Xist∆hs mice hearts completely prevented hypertrophy.  




Figure 1. Dystrophin levels and heart function of mdx-Xist∆hs mice. (A) Dystrophin levels were assessed by western 
blot for all mdx-Xist∆hs mice, as shown in the representative blot. Myosin was used as a loading control. M=marker. 
(B) Dystrophin levels are plotted in the box plot. The line dissecting the box resembles the median, outer bars of the 
box resemble the lower and upper quartile. The bars show maximum and minimum values considered excepting 
outliers (indicated by ○). Dystrophin levels varied between 3-15%, n = 81 and no increment was observed in older 
animals. (C-F) The EF and SV of both ventricles remained stable in wild type mice, but declined in mdx mice, which 
was prevented in the mdx-Xist∆hs mice. LV=left ventricle, RV=right ventricle. Bars represent mean values and the 
standard deviation. Asterisks indicate a difference of P<0.05. 
 
The right ventricular mass did not differ between mdx and C57BL/10ScSnJ mice, but was higher 
than that of mdx-Xist∆hs and Xist∆hs mice (P<0.01), which were comparable. This indicates that 
hypertrophy was restricted to the left ventricle. Heart rate increased in mdx mice with age 
(P<0.001), but remained stable over time for the other models. Heart rate of 2 months old Xist∆hs 
mice was higher than that of both mdx and mdx-Xist∆hs mice (P<0.01). In old mdx mice, heart rate 
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Dystrophin levels of 10-month-old mdx-Xist∆hs mice correlated with the EF of both ventricles 
(left R=0.464 P=0.019, right R=0.471 P=0.017), which was also the most severely affected 
parameter in mdx mice (Figure 2A-B). As heart function has been described to normalize by 
dystrophin expression in the diaphragm (Crisp et al. 2011), we also assessed this for 10-month-old 
mdx-Xist∆hs mice. Dystrophin levels of the diaphragm varied between 1.5-38% (mean = 11.5% 
stdev = 8.8) and did not correlate to dystrophin levels in heart (R=0.04 P=0.849). Dystrophin 
levels in the diaphragm only correlated with the EDV of the right ventricle (R=0.492 P=0.017), 
however, the EDV did not differ between any of the models. We hypothesized that the combined 
presence of dystrophin in heart and diaphragm might have a cumulative beneficial effect on heart 
function (Figure 2C-D). To elucidate this, we grouped the EF of 10-month-old mdx-Xist∆hs mice 
based on their dystrophin levels in heart and diaphragm into the following groups; mice with 
<4% dystrophin in heart and >4% in diaphragm (heart; median 3.0% stdev = 0.29, diaphragm; 
median 8.67% stdev = 3.07, n = 7), >4% dystrophin in heart and <4% in diaphragm (heart; median 
7.64% stdev = 1.13, diaphragm; median 2.63% stdev = 0.88, n = 5) and >4% dystrophin in heart 
and diaphragm (heart; median 6.31% stdev = 3.04, diaphragm; median 15.23% stdev = 9.31, n = 
13) (there were no mice with <4% dystrophin in both heart and diaphragm). The EF of both 
ventricles of mice expressing <4% dystrophin in heart and >4% in diaphragm was as low as age-
matched mdx mice. The EF of mice expressing >4% dystrophin in heart and <4% or >4% in 
diaphragm was higher than in mdx mice (P<0.05). This indicates that expression of >4% 
dystrophin in heart only improves EF of both ventricles, while expression of >4% (but less than 




Figure 2. Correlation between dystrophin expression and heart function. (A-B) Dystrophin levels of the heart 
correlated to EF of both ventricles in 10-month-old mdx-Xist∆hs mice (left R=0.464 P=0.019 and right R=0.471 
P=0.017). (C-D) <4% dystrophin in heart did not restore EF despite dystrophin expression in the diaphragm. EF levels 
were improved in mice expressing >4% dystrophin in heart regardless of expression levels in the diaphragm. H=heart, 





We also assessed levels of potential serum biomarkers for heart failure; cardiac Troponin I and N-
Terminal Pro Brain Natriuretic Peptide (NT-proBNP). Detectable concentrations of cardiac 
Troponin I were observed for some mice for all models and at all ages, but were slightly more 
often found in serum of dystrophic mice (Figure 3A). Cardiac Troponin I levels did not differ 
between mdx and mdx-Xist∆hs mice, nor did they correlate to heart dystrophin levels (R=0.004 
P=0.986). Levels did correlate to CO and SV of the right ventricle (R= -0.535 P= 0.015 and R= -
0.483 P=0.031 respectively). NT-proBNP levels were undetectable in any of the mouse models at 
any age.  
 
Low dystrophin levels reduce fibrosis   
Transverse cross-sections of the heart were stained with Collagen type I, to determine the 
percentage of fibrotic tissue (see Supplementary Figure 1 for representative examples). No fibrosis 
was detected in 2-month-old mice, whereas levels were elevated in 6-month-old mdx and mdx-
Xist∆hs compared to wild type mice (2.4% and 3.4% vs 2%, Table 2). Due to high individual 
variation only the increment of the mdx-Xist∆hs mice reached significance (P<0.05). Fibrosis was 
most prominent in 10-month-old mdx mice, while its formation was partly prevented in mdx-
Xist∆hs mice (9.8% vs 5.4%, P<0.01), although levels were still higher than wild type (P<0.01). 
Dystrophin levels in the mdx-Xist∆hs hearts did not correlate with fibrosis (R= -0.234 P=0.240, 
Figure 3B). Fibrosis negatively correlated to the EF of both ventricles (left R= -0.512 P=0.009, 
right R= -0.594 P=0.002) (Figure 3C-D). This concurs with the above described correlation 
between the EF of both ventricles and dystrophin levels Heart mass did not correlate with fibrosis 
(left R= 0.253 P= 0.222, right R= 0.285 P=0.167).  
 
 
Figure 3. Cardiac Troponin I levels and correlation between fibrosis, dystrophin expression and heart function. Bars 
represent mean values and the standard deviation. (A) Serum cardiac Troponin I levels exceeded the detection 
threshold of 0.2 ng/μl in some samples from all models. Levels did not differ between models or correlate to 
dystrophin expression in the heart (R=0.004 P=0.986). (B) Scatter plot of the percentage of fibrosis versus dystrophin 
levels of the heart of 10-month-old mice. Although mdx-Xist∆hs mice had less fibrosis than mdx mice, dystrophin 
levels did not correlated to fibrosis (R= -0.234 P=0.240). (C-D) Fibrosis levels of 10-month-old mdx-Xist∆hs mice 
negatively correlated to EF of both ventricles (left R= -0.512 P=0.009, right R= -0.594 P=0.002). 










Concurring with histopathological and functional data, expression levels of 2-month-old 
dystrophic mice were not elevated except for Ctgf, which was increased in mdx-Xist∆hs compared 
to C57BL/10ScSnJ mice. With age, expression of several genes increased in mdx mice, but to a 
lesser extent in mdx-Xist∆hs mice. In 6-month-old mdx mice, expression of Nppa was elevated. 
Gene expression of 10-month-old mdx mice was greatly increased, while levels of mdx-Xist∆hs 
mice fell between those of mdx and wild type mice for most genes. By contrast, levels of Serca2a 
dropped in mdx mice, but were similar for mdx-Xist∆hs and C57BL/10ScSnJ mice.   
 
Discussion 
Potential therapeutic strategies for DMD are currently tested in clinical trials and encouraging 
results have been published for dystrophin restoration in skeletal muscles (Cirak et al. 
2011;Goemans et al. 2011). Unfortunately, the heart seems to be a less efficient target as several 
therapeutic approaches fail to restore dystrophin expression in this organ or are less efficient in 
heart than skeletal muscle (Bowles et al. 2012;Cirak et al. 2011;Goemans et al. 2011;Malik et al. 
2010;Skuk et al. 2007). Studies in mdx mice suggest that functional improvement in skeletal 
muscles may worsen cardiomyopathy (Malerba et al. 2011;Townsend et al. 2008). It is, however, 
unknown whether low dystrophin levels can preserve function and prevent or delay heart 
pathology.  
  We used skewed X-inactivation as a tool to generate mice with low dystrophin levels in 
heart and skeletal muscles. Heart function of mdx mice progressively declines with age, resulting 
in severe dilation of both ventricles in 10-month-old mice (Quinlan et al. 2004;Spurney et al. 
2008;Verhaart et al. 2011;Zhang et al. 2008). With age, they develop severe fibrosis and 
upregulate genes involved in pathology and function, whereas this remains stable in wild type 
mice (Au et al. 2011;Li et al. 2009). Interestingly, expression of 3-15% dystrophin in 10-month-
old mdx-Xist∆hs mice ameliorates the age-dependent loss of heart function and pathology, as heart 
function parameters, fibrosis and gene expression partly normalize towards wild type levels. 
Whereas EF and SV are affected already in mdx mice aged 6 months, this is observed later (10 
months) and to a lesser extent in mdx-Xist∆hs mice.  
  It was hypothesized that the combined expression of dystrophin in heart and diaphragm 
might cumulatively improve heart function, as others observed beneficial effects of dystrophin 
expression in diaphragm on heart function (Crisp et al. 2011). Expression of >4% dystrophin in 
diaphragm does not improve heart function (EF, the most affected parameter) in mdx-Xist∆hs 
mice, whereas similar levels in heart do. Expression of >4% dystrophin in both heart and 
diaphragm does not further improve heart function indicating that the cumulative beneficial 
effect of dystrophin expression in diaphragm on heart function is limited. The discrepancy 
between our findings and those reported by Crisp et al. might be caused by the low dystrophin 
levels in diaphragm in this study compared to the high dystrophin levels in their study. This 
suggests that for a protective effect on heart function probably high dystrophin levels in 
diaphragm are needed.  
  Dystrophin levels of the mdx-Xist∆hs mice do not correlate with fibrosis, whereas, 
fibrosis correlates to the EF of both ventricles, which is in concordance with literature (Li et al. 
2009). It should be stressed that mdx-Xist∆hs mice also express low dystrophin levels in skeletal 
muscle leading to improved muscle quality and function, which has been reported to increase the 
workload for the heart, thereby potentially worsening cardiomyopathy. Whether 3-15% 
dystrophin in heart is still protective when forced strenuous exercise is applied remains to be 
elucidated. Hearts of mdx mice are hypertrophic from the age of 2 months onwards, a 
pathological feature which is not observed in any of the mdx-Xist∆hs mice. Our finding (assessing 
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the mass of the entire ventricle) concurs with the report of Costas et al. (assessing ventricular wall 
thickness (Costas et al. 2010)), but is in contrast with work from others  who observe hypertrophy 
from 6 months onwards (measuring heart to body weight ratios) (Bia et al. 1999;Quinlan et al. 
2004). The difference in age of onset might be caused by differences in sensitivity of the 
quantification methods used.  
  The applicability of cardiac Troponin I and NT-proBNP as biomarkers for heart failure 
was also assessed. Cardiac Troponin I has previously been used for detection of cardiac infarcts 
and was reported to be a useful marker for heart function in DMD and BMD patients (Matsumura 
et al. 2007). Additionally, cardiac Troponin I levels of idebenone treated mdx mice have been 
reported to normalize towards wild type levels (Buyse et al. 2009). Unexpectedly, serum cardiac 
Troponin I values observed in our study did not correspond with those obtained by Buyse et al. 
However, personal communication revealed that their values were in the in pg/ml range instead 
of the published ng/ml, making their observations fall in the same range as ours. Although heart 
function of mdx mice is severely impaired, serum cardiac Troponin I levels barely exceeds the 
detection threshold of the kit. Thus, we feel the usefulness of cardiac Troponin I as a biomarker 
for cardiomyopathy in dystrophic mouse models is limited. Based on literature, the applicability 
of NT-proBNP is questionable as well, as positive and negative correlations with heart function in 
DMD and BMD patients have been published (van Bockel et al. 2009;Schade van Westrum et al. 
2006). In our hands, NT-proBNP levels are undetectable even in 10-month-old mdx mice. 
Therefore we propose this marker not suitable for the assessment of heart failure in mdx mice 
younger than 10 months. 
Our study is partly limited by the fact that scans only entirely cover the left ventricle, 
while the top part of the right ventricle is not scanned. At initiation of this study, our primary 
focus was the left ventricle, but with interesting findings published on the right ventricle 
meanwhile, we also analysed MRI data available for the right ventricle. All scans were analysed 
in the same manner and up to exactly the same height in the right ventricle to ensure 
comparability. However, the top part of the right ventricle was not scanned and analysed, which 
resulted in a lower CO for the right compared to the left ventricle. It may also be the reason that 
we observe a more severe phenotype for the left than the right ventricle, while others have 
reported the opposite (Crisp et al. 2011;Verhaart et al. 2011).  
In summary, we have shown that expression of 3-15% dystrophin not only delays the 
onset of cardiomyopathy, but also largely ameliorates its severity in 10-month-old mdx mice. 
These observations suggest that treatments restoring only low dystrophin levels in the heart of 
DMD patients may have benefits on heart function.  
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Supplementary Figure 1. Representative pictures of fibrosis in the heart. Mean dystrophin levels are indicated for 
each model and the percentage of fibrosis is given for each picture. No fibrosis was evident in any of the models aged 
2 months, nor in wild type mice regardless of their age. From 6 months onwards, increased levels of fibrosis were 
observed in mdx and mdx-Xist∆hs mice. Ten months old mdx mice had extensive areas of fibrosis, covering ~10% of 
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Duchenne muscular dystrophy is a severe muscle wasting disorder caused by the lack of 
functional dystrophin. There is no cure, but several clinical trials are underway aimed at restoring 
the synthesis of functional dystrophin. The dystrophin levels needed for improvement of muscle 
pathology, function and overall vitality are unknown. Here, we describe the mdx/utrn-/-/Xist∆hs 
mouse model, which expresses a range of low dystrophin levels depending on the degree of 
skewing of X-inactivation in a utrophin negative background. Mdx/utrn-/- mice develop severe 
muscle weakness, kyphosis, respiratory and heart failure and premature death closely resembling 
DMD pathology. We show that dystrophin levels below 4% already greatly improve survival and 
motor function in these animals. In mice expressing more than 4% dystrophin, histopathology is 
ameliorated as well. This suggests that the dystrophin levels needed to benefit vitality and 




Duchenne muscular dystrophy (DMD) is the most common inherited neuromuscular disorder. It 
is caused by mutations which disrupt the reading frame of the DMD gene located on the X-
chromosome. These mutations result in a premature stop codon, which prevents the synthesis of 
functional dystrophin (Hoffman et al. 1987). Dystrophin provides muscle fiber stability during 
contraction by anchoring the extracellular matrix to actin filaments. When this connection is 
absent, fibers are vulnerable to exercise-induced damage and, upon exhaustion of the regenerative 
capacity, they will be replaced by fibrotic and fat tissue. The continuous loss of muscle tissue 
results in loss of ambulation generally in the second decade of the patient’s life. Due to improved 
care including corticosteroid treatment, spinal surgery and assisted ventilation, patients now 
survive till the third or forth decade in the Western world (Muntoni et al. 2003;Kohler et al. 
2009). Mutations that do not disrupt the reading frame are found in Becker muscular dystrophy 
patients (BMD). These patients express dystrophin of lower quantity and/or of different quality 
(generally internally deleted) that is partly functional, resulting in a milder phenotype.  
The mdx mouse is the most commonly used mouse model for basic and therapy research 
for DMD. It carries a nonsense/stop mutation in exon 23 of the mouse Dmd gene and 
consequently, like DMD patients, lacks functional dystrophin. The phenotype of this mouse is, 
however, less severe than that of DMD patients and the life span is nearly normal (Sicinski et al. 
1989;Stedman et al. 1991). This is likely due to a better regenerative capacity than human muscle, 
as suggested by the upregulation of muscle transcription factors. Also the dystrophin homologue 
utrophin, in the mouse, seems better capable of replacing dystrophin. Mdx/utrn-/- mice, lacking 
both dystrophin and utrophin, mimic the DMD patients’ phenotype more closely, since they are 
severely affected, develop kyphosis, show breathing difficulties and do not live beyond 3 months 
(Deconinck et al. 1997b, Grady et al. 1997a).  
There is no cure for DMD, but several therapeutic approaches, aiming to restore the 
expression of functional dystrophin, are currently under investigation in clinical trials (Goemans 
et al. 2011;Cirak et al. 2011;Bowles et al. 2011;Malik et al. 2010;Skuk et al. 2006). It is, however, 
unknown which dystrophin levels are needed to obtain a beneficial effect in DMD patients and 
whether correction of muscle function, histopathology and overall vitality require similar 
dystrophin levels.  
Previously, two attempts have been undertaken to elucidate this. The mdx3cv mice 
(expressing ~5% of truncated dystrophin lacking exon 65/66) were crossed into two different 




were as severely affected as mdx/utrn-/- mice and no increase in the 12-week life span was 
observed. By contrast, (Li et al. 2010) the other study reported mice with a median survival of 79 
weeks. Despite discrepancies between these models, their common drawback is that dystrophin 
expression is limited to <5% of a compromised dystrophin in the mdx3cv model, whereas 
expression of a broader range of a partially functional dystrophin is preferred.  
We here determined the effects of a broad range of low dystrophin levels against an 
utrn-/- background on muscle integrity, pathology, function and overall viability in the mdx/utrn-/-
/Xist∆hs mouse model. These mice have mutations in the Xist gene of one X-chromosome leading 
to skewed X-inactivation, combined with a defective dystrophin on the other X-chromosome, 
resulting in low dystrophin levels (Newall et al. 2001). Introducing low, but varying, dystrophin 
levels resulted in improvements in life span and pathology, ranging from that of severely affected 
mdx/utrn-/- to almost wild type mice. Dystrophin expression correlated with survival and severity 
of pathology: where <4% dystrophin already significantly improved life span and muscle 
function, levels of >4% dystrophin not only further improved this, but also protected muscles 
against damage. 
 
Materials and methods 
Animal care 
All mice participating in this study were bred at the animal facility at the LUMC where they were 
housed in groups in individually ventilated cages with 12-h light-dark cycles. Mice were given 
standard chow and water ad libitum. The generation of mdx/utrn-/-/Xist∆hs mice was performed in 
two steps. First, we crossed Xist∆hs females (Newall et al. 2001) with hDMD+/-utrn-/- males. The 
hDMD mouse has an intact and functional copy of the human dystrophin gene, which can 
functionally compensate for the lack of mouse dystrophin ('t Hoen et al. 2008). Offspring were 
genotyped, and utrn+/-/Xist∆hs mice lacking the hDMD gene were interbred to generate utrn-/-
/Xist∆hs mice. Utrn-/-/Xist∆hs males were then crossed with mdx/utrn+/- females, giving rise to 
female mdx/utrn-/-/Xist∆hs mice, which were used for experiments (Fig. 1A). The Xist∆hs mice were 
a kind gift from Prof. Brockdorff (MRC Clinical Sciences Centre London, UK, current affiliation 
Department of Biochemistry, University of Oxford, UK). Genotyping was performed on DNA 
obtained from ear biopsies by PCR analysis (primers and PCR conditions available on request). 
All experiments were approved by the Animal Experimental Committee (DEC) of the LUMC. 
Mice that became too severely affected (body weight drop of >15% within two days) were 
sacrificed. All mice used in the study were females, except for the mdx/utrn-/- mice of which both 
genders were used. 
 
Determination of functional performance  
To assess forelimb grip strength, mice were suspended above the grid of a strength meter 
(Columbus Instruments, USA), which they instinctively grasped and were then pulled backwards 
forcing release of the grid. Five measurements were made in a row and the average of the three 
highest measured values was divided by the body weight in grams and used for further analysis.  
 To determine running performance on the rotarod (Ugo Basile, Italy), mice were placed 
on the rotating tube, which accelerated from 5 to 45 rotations per min within 15 sec. Mice had to 
run for a maximum of 500 sec without falling. Individuals that fell off earlier were given two 
more tries. The longest running time was used for analysis. 
 The two limb hanging wire test was conducted with a metal cloth hanger that was 
secured above a cage filled with bedding. Mice had to grasp the wire with the two forelimbs and 
were then released. During the 10 min session, all limbs and the tail were used depending on the 
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functional ability of the mouse. Mice that were not able to hang for the maximum time were 
allowed two more tries. Maximum hanging time was used for analysis.  
 For the four limb hanging wire test, mice were placed on a grid, which was turned 
upside down above a cage filled with bedding, forcing mice to hang using four limbs from the 
start of the test onwards. The session ended when the mice had hung for 10 min or otherwise 
after three sessions. Maximum hanging time was used for analysis. When possible, standardized 
operating procedures from the TREAT-NMD network were implemented (http://www.treat-
nmd.eu/resources/research-resources/dmd-sops/). 
 
Blood biomarker analysis 
At the age of 8 and 14 weeks blood was collected via the tail to determine serum biomarker levels 
of matrix metallopeptidase-9 (MMP-9), tissue inhibitor of metalloproteinases-1 (TIMP-1) and 
vascular endothelial growth factor (VEGF) (Nadarajah et al. 2011;Saito et al. 2009). The mouse 
MMP-9 (total) immunoassay kit (catalog number MMPT90), mouse TIMP-1 immunoassay kit 
(catalog number MTM100) and mouse VEGF immunoassay kit (catalog number MMV00) were 
purchased from R&D systems (UK). Collected blood was allowed to clot at room temperature for 
10 min before centrifuging (1700 x g for 10 min at 4°C) and stored at -80°C, before use. Age and 
gender-matched C57BL/10ScSnJ (n = 4) and mdx/utrn-/- mice (n = 4) were used as controls.  
Plasma creatine kinase (CK) levels were determined in blood that was obtained via the 
tail and collected in a Minicollect tube (0.8ml Lithium Heparin Sep, Greiner bio-one, Austria). CK 
levels were determined with Reflotron CK test strips in the Reflotron plus machine (Roche 
diagnostics Ltd, UK).  
 
Heart function assessment  
Mice were transported to the Faculty of Science at the University of Leiden where they were 
housed for at least one week to acclimatize. Heart function was assessed by Magnetic Resonance 
Imaging (MRI) in a vertical 9.4T magnet with 89 mm bore size, equipped with a 1 T/m gradient 
system (Bruker BioSpin, Germany), using a quadrature birdcage coil with an inner diameter of 30 
mm. Mice were anesthetized by inhalation of 2% isoflurane in a 1:1 mixture of oxygen and air. 
Respiratory rate was monitored during the scan with a respiratory pad and kept between 50-80 
respirations per minute. Image acquisition was done with Bruker Paravision 5.0 software and 
took approximately 30 min per mouse including animal setup. A retrospectively-gated Intragate 
sequence was used with flip angle 10º; repetition time 8.5 ms; echo time 1.86 ms; field-of-view 
2.56x2.56 cm2; matrix 192x192; in-plane resolution 133 µm. We made 8-9 short-axis slices of the 
heart with a slice thickness of 1 mm and 200 repetitions per slice. The navigator echo was placed 
in-slice. Images were reconstructed to 18 frames per heart cycle. Scans were oriented on the left 
ventricle (Verhaart et al. 2011). Mice were sacrificed by cervical dislocation after completion of 
the scans. The scans were analyzed with MASS for MICE software (developed at the LUMC, 
Division of Image Processing (LKEB))(van der Geest et al. 1997;van der Geest and Reiber 1999). 
The endo and epicardial contours of both ventricles were drawn manually for each image. The 
end diastolic and systolic phase was computed by the software and a maximum mass difference of 
10% was accepted for both ventricles. When this criterion was met, end diastolic and systolic 
volume were determined and based on these values stroke volume (end diastolic volume – end 
systolic volume), ejection fraction (stroke volume/end diastolic volume*100%) and cardiac output 
(stroke volume*heart rate) were calculated automatically. One mdx/utrn-/-/Xist∆hs mouse was left 





Western blot analysis 
Protein was isolated from the quadriceps and heart in 1 ml buffer (1.25 M Tris-HCl pH 6.8, 20% 
(v/v) glycerol and 25% (w/v) SDS) in MagNA Lyser green beads in the MagNA Lyser (Roche 
Diagnostics, the Netherlands). The BCA protein assay kit (Thermoscientific, Il, USA) was used 
according to the manufacturer’s instructions to determine protein concentration. Subsequently, 
the protein solution was complemented with 5% (v/v) β-mercaptoethanol and 0.001% (w/v) 
bromophenol blue. The Trans-blot Turbo system (BioRad, the Netherlands) was used for Western 
blotting (Hulsker et al. manuscript in preparation). Samples (30 μg) were heated at 95°C for 5 min 
and 20 μl was loaded on 1.0 mm thick native PAGE Tris acetate (polyacrylamide) gels, with a 
linear resolving gel gradient of 3-8% (BioRad, the Netherlands). The gels were run on ice for 1 hr 
at 75 V (0.07 A) and 2 hrs at 150 V (0.12 A) in the running buffer (XT Tricine; BioRad; the 
Netherlands). When changing voltage, running buffer was refreshed to maintain pH. Proteins 
were blotted to membrane using the ready to use Trans-Blot Turbo transfer packs and the Trans-
Blot Turbo transfer system at 2.5 A (25 V) for 10 min. Membranes were blocked for 1 hr with 5% 
(w/v) non-fat dried milk (Campina Melkunie, the Netherlands) in TBS and washed three times 
with TBST for 10 min. Primary dystrophin antibody NCL-DYS1 (dilution 1:125 in TBS, 
Novacastra, UK) and loading control α-actinin (dilution 1:5000 in TBS, AB72592, Abcam) were 
incubated overnight at 4ºC. After the membranes were rinsed three times with TBS for 10 min, 
they were incubated for 1 hr with fluorescent IRDye 800CW goat-anti-mouse (dilution 1:5000, 
Li-Cor, NE, USA) and IRDye 650LT donkey-anti-rabbit (1:10,000, Li-Cor, NE, USA). Protein 
quantification was performed with the Odyssey system and software (Li-Cor, NE, USA). 
 
Histological examination 
After sacrifice, skeletal muscles and heart were dissected and snap frozen in 2-methylbutane 
(Sigma-Aldrich, The Netherlands) cooled in liquid nitrogen. For the quadriceps and heart, 
sections of 8 μm were cut along the entire length of the muscle with a Shandon cryotome 
(Thermo Fisher Scientific Co., Pittsburgh, PA, USA) with an interval of 240 μm between the 
sections. Sections of the quadriceps were stained with Harris Haematoxylin and Eosin (H&E), 
according to conventional histological procedures. From the middle section of the muscle, images 
covering the entire muscle were captured with a light microscope (Leica DM LB, Leica 
Microsystems, The Netherlands) and a Leica DC500 camera with Leica IM50 software (Leica 
Microsystems, The Netherlands) at a 5 times magnification. Blending and background correction 
was performed with Adobe Photoshop CS3 version 10.0.1. Freely available ImageJ software with 
the H&E colour deconvolution plugin (Rasband, W.S., ImageJ, U. S. National Institutes of Health, 
Bethesda, Maryland, USA, http://rsb.info.nih.gov/ij/) was used to determine the fibrotic/necrotic 
percentage of the entire cross-section by two individuals in a double blinded manner, as described 
previously (van Putten et al. 2010).  
Fiber size and the percentage of centralized nuclei were determined with Mayachitra 
Imago 1 (http://www.mayachitra.com/imago/) (van Putten et al. manuscript in preparation) on 
five randomly captured images of the quadriceps stained with dystrophin (dilution 1:50, C-20, 
Santa Cruz, Germany) and laminin (dilution 1:50, ab11575, Abcam, UK) where donkey-anti-goat 
Alexa 594 and donkey-anti-rabbit Alexa 488 (dilution 1:1000, Invitrogen, the Netherlands) were 
respectively used as a secondary antibody. Slides were mounted with Vectashield mounting 
medium including DAPI (Vector Labs, Germany).  
Cryosections of the heart were stained with goat-anti-Collagen type 1 (dilution 1:100, 
1310-01 Southern Biotech, USA), rabbit-anti-goat Alexa 594 (dilution 1:1000, Invitrogen, The 
Netherlands) and DAPI. Sections were examined with a Leica DM RA2 fluorescent microscope at 
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a 16 times magnification and images covering the entire heart were captured with a Leica 
DC350FX snapshot camera. The percentage of fibrosis was quantified with ImageJ software 
(Rasband, W.S., ImageJ, U. S. National Institutes of Health, Bethesda, Maryland, USA, 
http://rsb.info.nih.gov/ij/).     
Co-localization of dystrophin and β-dystroglycan was performed on a transverse cross-section of 
the quadriceps, stained with dystrophin (dilution 1:50, C-20, Santa Cruz, Germany) and β-
dystroglycan (dilution 1:50, NCL β-DG, Novocastra UK). The staining was completed with 
donkey-anti-rabbit Alexa 488 (dilution 1:1000, Invitrogen, the Netherlands) and Fluorescein 
Avidin solution of the MOM kit (Vector Laboratories, UK), respectively.  
 
RT-qPCR analysis 
For total RNA isolation, tissue was disrupted in MagNA Lyser Green Beads tubes (Roche 
diagnostics Ltd, UK) with Tripure isolation reagent (Roche diagnostics Ltd, USA). Isolation was 
performed with chloroform, and RNA precipitated with isopropanol. The NucleoSpin RNA II kit 
including a DNAse digestion (Bioke, the Netherlands) was used for RNA purification. RNA 
integrity and concentration was checked with a total RNA nano-chip assay on a labchip 
bioanalyzer (Agilent, The Netherlands) and used for cDNA synthesis with random hexamer 
primers. Expression of genes involved in regeneration (Myog, eMHC3), inflammation (Cd68, 
Lgals3), fibrosis (Lox, Timp-1, Nox4, Ctgf) and heart function (Serca2a, Nppa) was determined by 
Sybr Green based Real Time qPCR (95°C 10 sec, 60°C 30 sec, 72°C 20 sec, 45 cycles followed by 
melting curve analysis) on the Roche Lightcycler 480 (Roche diagnostics Ltd., UK). Gapdh was 
used as a reference gene, since the expression of this gene did not differ between different 
muscles and mouse strains or over time. Primer efficiencies were determined and analysis was 
performed with LinREgPCR version 11.1 (Ramakers et al. 2003).  
 
Statistics 
Statistical analyses were performed with statistical software in R (package 2.11.1) and SPSS 17.0.2. 
(SPSS, Inc., Chicago, IL, USA). Cox regression analysis was used to test for differences in survival 
between groups (Fig. 1C and 2D). Figures 1, 3, 5 and 7 summarize the data, i.e. showing the mean 
and standard error of the mean per genotype and age. We applied an analysis of covariance 
(ANCOVA) to the temporal functional performance and CK level data, to overcome applying 
separate tests for each age between genotypes as this suffers from multiple testing and ignores the 
age trend. Age was used as a continuous variable and genotype as a categorical variable. 
Comparisons between mdx/utrn-/- mice with the other strains were performed on data obtained 
between the age of 4 and 11 weeks, while for comparisons between the other strains, data from 
all ages was taken into account. In choosing the appropriate model we applied the principle of 
parsimony. Given the application of tests for several different variables, we considered P<0.01 as 
significant. A one-way ANOVA was used to analyze the serum biomarkers, the percentage of 
fibrosis, central nucleation and the gene expression data, followed by the Bonferroni post-hoc test 
in case of significance. For the fiber size distributions, the one-way ANOVA test was applied on 
the median of all fibers of each mouse and in case of significance (P<0.05) followed by a 
Bonferroni post hoc test. Spearman correlation was used to test for correlations. The heart 
function data were analyzed with the one-way ANOVA in case of significance (P<0.05) a LSD 







Low dystrophin levels improve muscle function  
Mdx/utrn-/-/Xist∆hs females were bred and used to study the potential of low dystrophin levels to 
improve motor function in the absence of utrophin (fig. 1A). Mdx/utrn-/-/Xist∆hs (n = 20) and 
mdx/utrn-/- (n = 9) mice underwent a functional test regime consisting of four different tests per 
week for a maximum of 12 weeks (van Putten et al. 2010). Mice were sacrificed when the burden 
of the phenotype was moderate/severe, or at completion of the functional test regime (aged 16 
weeks). Post mortem dystrophin levels of the quadriceps were determined by western blot. No 
dystrophin was observed for mdx/utrn-/- mice, while for mdx/utrn-/-/Xist∆hs mice levels varied 
between 3-16.2% (fig. 1B). In cross-sections of mdx/utrn-/-/Xist∆hs mice, dystrophin co-localized 
with β-dystroglycan, suggesting that the dystrophin-glycoprotein complex was restored (For a 
representative see picture fig. S1A). 
Mdx/utrn-/-/Xist∆hs mice were divided into two groups based on dystrophin levels either 
below or above the median dystrophin level observed (3.9%). Most strikingly, 14 out of 20 
mdx/utrn-/-/Xist∆hs mice survived the entire test period, while none of the mdx/utrn-/- mice did 
(P<0.0001, fig. 1C). Mice with >4% dystrophin outlived mice with <4% dystrophin (P<0.001). 
Creatine kinase (CK) levels reduced in a dystrophin level dependent manner (fig. 1D). 
Mice with >4% dystrophin had lower CK levels than mice with <4% dystrophin (average 2604 
U/L vs 3860 U/L, P<0.05), but levels did not completely normalize to wild type (<500 U/L, 
P<0.0001). 
Maximum times obtained in the two limb hanging wire test for mdx/utrn-/-/Xist∆hs mice 
were higher than those for mdx/utrn-/- mice (>4% 404 sec and <4% 298 sec, vs 71 sec for 
mdx/utrn-/-, P<0.0001, fig. 1E). Mice with >4% dystrophin outperformed mice with <4% 
dystrophin (P<0.01). However, performance was not completely restored to wild type (594 sec, 
P<0.0001). A similar pattern was obtained for the four limb hanging wire test, in which all 
mdx/utrn-/-/Xist∆hs mice outperformed mdx/utrn-/- mice (>4% 496 sec and <4% 407 sec, vs 163 sec 
for mdx/utrn-/-, P<0.01, fig. 1F). Expression of >4% dystrophin improved outcome over <4% 
dystrophin (P<0.001), but did not completely restore it to wild type (586 sec, P<0.001). 
Normalized forelimb grip strength of mdx/utrn-/-/Xist∆hs mice was greater than mdx/utrn-/- mice 
(>4% 59 grams and <4% 58 grams, vs 38 gram for mdx/utrn-/-, P<0.0001), and lower than wild 
type mice (79 grams, P<0.0001, fig. 1G). Mdx/utrn-/-/Xist∆hs mice outperformed mdx/utrn-/- mice 
on the rotarod (>4% 260 sec and <4% 222 sec, vs 51 sec for mdx/utrn-/-, P<0.0001, fig. 1H), but 
performance did not differ between them. In our experience, wild type mice (Xist∆hs and 
C57BL/10ScSnJ) do not perform well on the rotarod (van Putten et al. 2012a;van Putten et al. 
2012b). Xist∆hs mice ran longer than mdx/utrn-/- mice (183 sec vs 51 sec, P<0.0001), but shorter 
than mdx/utrn-/-/Xist∆hs mice. In summary, for all functional tests, <4% dystrophin already 
substantially improves motor function compared to mdx/utrn-/- mice, while >4% dystrophin 
further improves hanging performance. 
 
 




Fig. 1. Survival and functional performance of mdx/utrn-/-/Xist∆hs mice. (A). Mdx/utrn-/- females expressing low 
dystrophin levels due to skewed X-inactivation were bred by crossing utrn-/-/Xist∆hs males with mdx/utrn+/- females. 
(B). Mdx/utrn-/-/Xist∆hs mice were grouped based on dystrophin levels of the quadriceps, which varied between 3 and 
16.2%. (C). Levels <4% dystrophin increased life span in mdx/utrn-/-/Xist∆hs mice (P<0.0001), while all mdx/utrn-/- 
mice died prematurely. Expression of >4% dystrophin prevented premature death. (D). CK levels decreased in a 
dystrophin level dependent manner in mdx/utrn-/-/Xist∆hs mice, but did not completely normalize to wild type levels. 
(E). Mdx/utrn-/-/Xist∆hs mice outperformed mdx/utrn-/- mice in the two limb hanging wire test, but performed worse 
compared to wild type mice (P<0.0001). >4% dystrophin resulted in better hanging times than <4% dystrophin 
(P<0.01). (F). Mdx/utrn-/-/Xist∆hs mice hang longer compared to mdx/utrn-/- mice in the four limb hanging wire test. 
Expression of >4% dystrophin further increased performance (P<0.001), although it was worse than wild type mice 
(P<0.001). (G). Mdx/utrn-/-/Xist∆hs mice had a greater forelimb grip strength than mdx/utrn-/- mice (P<0.0001). (H). 
Rotarod running times of mdx/utrn-/-/Xist∆hs mice exceeded those of mdx/utrn-/- and wild type mice (P<0.0001). Data 






Fig. 2.  Long term survival of mdx/utrn-/-/Xist∆hs mice. (A). Mdx/utrn-/-/Xist∆hs mice significantly outlived mdx/utrn-/- 
mice, which all died prematurely, as at the age of 10 months, 26 out of 42 mice were still alive. Sixteen mice were 
sacrificed for analysis before the age of one year and six mice were allowed to life, of which four were still alive at the 
age of two years. (B). Mdx/utrn-/-/Xist∆hs mice could be discriminated into three phenotypically distinct groups based 
on disease severity. Severely affected mice developed similar symptoms as mdx/utrn-/- mice although at a much older 
age. Moderately affected mice developed malformations of the hips possibly combined with kyphosis, while mildly 
affected mice were similar to wild type mice. (C). Representative western blot of the quadriceps. The percentage of 
individual mice was assessed using a concentration curve made from wild type samples. (D). Dystrophin levels of the 
quadriceps ranged from 3-30.4%, which was used to divide mice into three groups. (E). Dystrophin expression 
correlated to the phenotype of the mice. (F). Dystrophin expression correlated to phenotypic appearance and life 
span (R=0.718 P<0.0001). Levels of <4% dystrophin improved life span, with 63% of these mice still alive at the age of 
6 months (P<0.01). Expression of higher dystrophin levels further improved life span. (G) Overview of the dystrophin 
levels of the quadriceps, clinical features, life span and cause of death of six mdx/utrn-/-/Xist∆hs mice that were kept 
alive. Data are represented as mean. 
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Dystrophin levels of <4% improve long term survival  
To more thoroughly investigate life span of mdx/utrn-/-/Xist∆hs mice, a longer survival study was 
performed in 42 mdx/utrn-/-/Xist∆hs and 6 mdx/utrn-/- mice. Several other aspects of skeletal muscle 
and heart function were assessed along with histopathology. Mdx/utrn-/- mice again became 
severely affected as they developed kyphosis, could not spread their hindlimbs and had 
difficulties moving and breathing, leading to death generally before the age of 12 weeks (fig. 2A). 
Disease severity of mdx/utrn-/-/Xist∆hs mice could be divided into three phenotypically distinct 
subgroups (fig. 2B). The first subgroup developed similar symptoms as mdx/utrn-/- mice, including 
severe muscle weakness, kyphosis and inability to spread their hindlimbs. Notably, these mice 
exhibited these pathological features at an older age than mdx/utrn-/- mice and had a similar 
appearance to wild type mice before onset. Mice of the second subgroup had a moderate 
phenotype; they developed malformations of the hips, leading to an unnatural way of walking 
(video available on request). This was observed either in presence or absence of kyphosis. The last 
subgroup exhibited a mild phenotype and appeared comparable to wild type mice. The age of 
death depended on the age at onset of pathology and the degree of severity. Generally, mice with 
a moderate or mild phenotype outlived those with a severe phenotype.  
 For each mouse studied, post mortem dystrophin levels of the quadriceps were 
determined by western blot (fig. 2C). Levels varied between 3-30.4% and were higher than those 
observed for animals sacrificed after 16 weeks. We attribute this to selection of dystrophin 
positive fibers over time (Danko et al. 1992;Karpati et al. 1990), or transcriptional rate exceeding 
protein turnover rate, causing accumulation of protein over time. Based on the dystrophin level, 
mice were divided into three groups (fig 2D). Mdx/utrn-/-/Xist∆hs mice belonging to the severe 
phenotype mostly had <4% dystrophin (fig 2E). Of these, 62% were still alive at the age of 6 
months, reflecting an improved life span compared to mdx/utrn-/- mice (P<0.01). Dystrophin 
levels between 4-15% generally resulted in a moderate or mild phenotype and increased survival 
compared to mdx/utrn-/- mice (P<0.0001). Of these mice 100% were still alive after 6 months and 
64% after 10 months (fig 2F). Notably, their life span was further improved over the mice with 
<4% dystrophin (P<0.01). All mice with 15-30% dystrophin survived until the age of 10 months 
after which they were sacrificed for analysis, extending their life span yet further than all other 
mice (P<0.05). The Spearman correlation test confirmed a very strong positive correlation 
between dystrophin expression and life span (R=0.718 P<0.0001). 
Six mdx/utrn-/-/Xist∆hs mice were kept alive (fig 2G). At the time of submission, one 
mouse aged 26 months, is still alive, looking similar to age-matched wild type mice. Three out of 
the five remaining mice died of non-muscle related causes, aged 17.5, 25 and 25.7 months and 
expressing >35% dystrophin. The other two mice died as a consequence of their muscular 
dystrophy aged 17 (fig. S1B) and 24.5 months (fig. S1C). These mice had a severe and moderate 
phenotype and expressed 3% and 27% dystrophin respectively.  
 
Low dystrophin levels improve muscle function and normalize serum biomarker levels  
During the survival study, all mice were subjected to two limb hanging wire and forelimb grip 
strength tests once every 6 weeks (van Putten et al. 2010). Hanging performance clearly depended 
on dystrophin expression. Mice with <4% dystrophin hung shorter than mice with 4-15% 
dystrophin (135 vs 369 sec, P<0.0001, fig 3A), while mice with 15-30% dystrophin hung even 
longer (499 sec, P<0.01). Forelimb grip strength of mice with <4% dystrophin was lower than that 
of mice with 4-15% dystrophin (55 grams vs 60 grams, P<0.05, fig. 3B), which were as strong as 







Fig. 3. Functional performance and plasma CK levels. (A). Two limb hanging wire performance was impaired in mice 
with <4% dystrophin compared to mice with 4-15% dystrophin (P<0.001), and mice expressing 15-30% dystrophin 
(P<0.001). (B). Mice with 4-15% dystrophin had a larger normalized forelimb grip strength than mice with <4% 
dystrophin (P<0.05). Strength did not further improve in mice with 15-30% dystrophin. (C). CK levels were elevated 
in mice with <4% dystrophin compared to mice with >4% dystrophin. For all mice, levels dropped over time and 
reached wild type levels from 30 weeks of age onwards. Data are represented as mean±SEM. 
 





Fig. 4. Serum levels of VEGF, MMP-9 and TIMP-1 at 8 and 14 weeks of age. (A). VEGF levels already decreased in 
mice with <4% dystrophin. (B). MMP-9 levels normalized in mice with <4% dystrophin. (C). TIMP-1 levels showed a 
clear dystrophin level dependent normalization. Already <4% dystrophin decreased levels compared to mdx/utrn-/- 
mice while >4% dystrophin resulted in further decrement. (D). The TIMP-1/MMP-9 ratio normalized to wild type 




Plasma CK levels, assessed every 6 weeks throughout the study, clearly fell in all mice over time. 
Mice with <4% dystrophin had higher CK levels than mice with 4-15% dystrophin (3251 vs 1785 
U/L, P<0.0001, fig. 3C). CK levels fell further in mice with 15-30% dystrophin, reaching wild type 
levels from 30 weeks onwards (554 U/L, P<0.0001).  
Serum levels of VEGF (angiogenesis (Saito et al. 2009)), MMP-9 and TIMP-1 (tissue 
integrity (Nadarajah et al. 2011;van Putten et al. 2012a)) were analyzed on a group of 20 
mdx/utrn-/-/Xist∆hs, 4 mdx/utrn-/- and 4 C57BL/10ScSnJ mice at the age of 8 and 14 weeks (fig. 4). 
Levels of all biomarkers were elevated in mdx/utrn-/- compared to wild type mice. At 8 weeks, 
VEGF levels were already decreased with < 4% dystrophin (P<0.05), whereas >4% dystrophin also 
normalized TIMP-1 and the TIMP-1/MMP-9 ratio to wild type levels. At 14 weeks, <4% 
dystrophin decreased VEGF and MMP-9 levels, whereas >4% dystrophin also normalized TIMP-1 
levels and the TIMP-1/MMP-9 ratio. At both ages, dystrophin expression significantly correlated 
to TIMP-1 levels (8 weeks R= -0.543 P=0.03, 14 weeks R= -0.599 P=0.03) and the TIMP-1/MMP-9 
ratio (8 weeks R= -0.659 P=0.005, 14 weeks R= -0.846 P<0.001). 
 
Low dystrophin levels improve muscle pathology 
A strong negative correlation was observed between dystrophin expression and the percentage of 
fibrosis and necrosis (R= -0.616 P<0.0001, fig. 5A). Mdx/utrn-/-/Xist∆hs mice with <4% dystrophin 
had more fibrosis and necrosis than mdx/utrn-/- mice (P<0.05). This is possibly due to the age 
difference of the two groups (6-9 weeks and 7-40 weeks). Levels of fibrosis and necrosis dropped 
in mice expressing >4% dystrophin (P<0.01) and did not differ from wild type levels.  
Fiber size distribution and the percentage of centrally nucleated fibers also normalized 
towards wild type levels in a dystrophin level dependent manner in mice expressing >4% 
dystrophin (fig. 5B-C). Dystrophin expression also correlated to the median of fiber surface area 
(R=0.779 P<0.0001) and central nucleation (R= -0.675, P<0.0001). 
Finally, we quantified the expression of some biomarker genes involved in 
inflammation (Cd68, Lgals3), fibrosis (Lox, Timp-1) and regeneration (eMHC3, Myog) for the 
quadriceps (fig. 5D-F). Although the high inter group variation only occasionally resulted in 
significant differences, there is a clear pattern, in line with the histological data, that gene 
expression of mdx/utrn-/-/Xist∆hs mice with <4% dystrophin is higher than mdx/utrn-/- mice, while 
>4% dystrophin results in a clear dystrophin level dependent normalization towards wild type 
levels. 
 
Dystrophin level dependent improvement of heart pathology 
At the age of 10 months, heart function of mdx/utrn-/-/Xist∆hs mice (n = 10) was analyzed with 
Magnetic Resonance Imaging and compared with age and gender-matched mdx, Xist∆hs and 
C57BL/10ScSnJ mice (n = 5). Dystrophin levels of the heart ranged from 2.5-49.2% (median = 
13.7, stdev = 17.3) and mice were divided into a low (2.5-10.9%, median = 4.3, stdev = 3.3), and 
high dystrophin level group (16.4-49.2%, median = 29.7, stdev = 14.3). Left ventricular ejection 
fraction of mice with low dystrophin levels was severely hampered, but improved in mice 
expressing higher dystrophin levels (P<0.05), although not to wild type levels (P<0.01, fig. 6). 
Also stroke volume was significantly decreased (P<0.05) in all mdx/utrn-/-/Xist∆hs mice. Right 
ventricular function was not affected in mdx/utrn-/-/Xist∆hs mice. Dystrophin expression correlated 









Fig. 5. Dystrophin levels and histopathology. Note that not all mice are of similar age; mdx/utrn-/- mice did not live 
beyond 12 weeks, while the age of mdx/utrn-/-/Xist∆hs mice ranges from 7 weeks to 1 year. Data of Xist∆hs mice are 
from 16 week old animals. (A). Dystrophin expression negatively correlated to the percentage of fibrotic/necrotic 
tissue (R= -0.518 P<0.002). Mice with <4% dystrophin had more fibrotic/necrotic tissue compared to mdx/utrn-/- mice 
(P<0.05). (B). Fiber size distribution of mice with <4% dystrophin was comparable to that of mdx/utrn-/- mice, 
whereas 4-15% dystrophin reduced the number of small recently regenerated fibers. Distribution pattern of mice 
with 15-30% dystrophin closely resembled that of wild type mice. (C). Central nucleation was comparable for 
mdx/utrn-/- mice and mice with <4% dystrophin. Higher dystrophin levels resulted in a drop (P<0.01) although levels 
were still considerably higher than wild type. (D-F). Expression levels of genes involved in inflammation (Lgals3, 
Cd68), regeneration (eMHC3, Myog) and fibrosis (Lox, Timp-1) were upregulated in mice with <4% dystrophin 
compared to mdx/utrn-/- mice, whereas a dystrophin level dependent normalization was observed for the other 








Fig. 6.  Heart function. (A-D). Heart function of the left ventricle (LV). Ejection fraction and stroke volume of 
mdx/utrn-/-/Xist∆hs mice with low dystrophin levels were severely hampered. This was restored by expression of high 
dystrophin levels, although not completely to wild type levels. (E-H). Heart function of the right ventricle (RV) was 
not affected in any of the mdx/utrn-/-/Xist∆hs mice. Ejection fraction of mdx mice was significantly (P<0.05) smaller 
than that of wild type strains and mice with high dystrophin levels.  
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Dystrophin expression also negatively correlated to the extent of fibrosis (R= -0.733 P<0.05). The 
extensive fibrosis in mice with low dystrophin levels was markedly reduced in mice with higher 
levels of dystrophin (P<0.05, fig. 7A and S1D) although still exceeding wild type (P<0.01).  
Expression of genes involved in inflammation, fibrosis and heart function was elevated 
in hearts of all dystrophic mice compared to wild type, except for Serca2a, of which levels are 
known to be down regulated in dystrophic mice (fig. 7B). In line with the histological data, gene 
expression levels of mice high dystrophin levels was normalized, although still exceeded wild 
type levels.  
 
Fig. 7.  Heart pathology. (A). The percentage of fibrotic tissue in mice with low dystrophin levels was higher than 
mice with higher dystrophin levels and mdx mice (P<0.05). Wild type mice had lower levels compared to dystrophic 
mice (P<0.01). (B). Expression of genes involved in heart pathology and function matched that found for 
histopathology. Gene expression of mdx/utrn-/-/Xist∆hs mice with low dystrophin levels was higher compared to those 
of mice with higher dystrophin levels, mdx and wild type mice. Single and double asterisks represent a P-value of 
<0.05 and <0.01 respectively. Data are represented as mean±SEM. 
 
Discussion 
Over the last couple of years, several therapeutic strategies for DMD have progressed into clinical 
trials, aiming to restore functional dystrophin (Cirak et al. 2011;Goemans et al. 2011;Malik et al. 
2010;Bowles et al. 2011;Skuk et al. 2006). Most likely, these strategies will not result in full 
restoration of dystrophin to healthy control levels. However, based on the mild disease of BMD 
patients and DMD/BMD carriers expressing low dystrophin levels, this is probably not necessary 
to provide benefit, 
Our study describes the mdx/utrn-/-/Xist∆hs mouse, which expresses a variety of low 
dystrophin levels in a utrophin negative background based on skewed X-inactivation. In these 
mice, <4% of the wild type dystrophin level already greatly improved life span and performance 
in functional tests. Higher dystrophin levels (4-15%) yet further increased survival and functional 
performance in hanging wire tests, but not in grip strength and rotarod running. This suggests 
that maintenance of vitality and functionality of the front and hind paw musculature requires less 
dystrophin than the larger limb and trunk muscles do.  
Over time, mdx/utrn-/-/Xist∆hs mice expressing <4% dystrophin develop severe 
pathology, with high levels of fibrosis, central nucleation and upregulation of genes involved in 
pathology . We attribute the fact that the pathology of mdx/utrn-/- mice was in fact less severe, to 
the lack of time to develop more severe muscle damage prior to their early death (van Putten et 
al. 2012b). Thus, while expression of <4% dystrophin allowed for a longer life span and improved 
muscle function, it could not yet prevent severe muscle damage. In contrast, expression of >4% 
dystrophin, besides further improving life span and muscle function, also protected muscles 




We also assessed the potential of several biomarkers to monitor disease progression over 
time. Although plasma CK levels decreased in a dystrophin dependent manner in mdx/utrn-/-
/Xist∆hs mice, they reached wild type levels after 30 weeks, hampering the usefulness of this 
biomarker. Both serum TIMP-1 levels and the TIMP-1/MMP-9 ratio correlated to dystrophin 
expression and showed a clear dystrophin level dependent normalization towards wild type 
levels. We therefore propose these as useful biomarkers to monitor therapeutic effects for 
dystrophin-restoring approaches in mice and possibly humans (Nadarajah et al. 2011). Although 
levels of MMP-9 and VEGF were elevated in mdx/utrn-/- compared to wild type mice, levels in 
mdx/utrn-/-/Xist∆hs mice were similar to, or lower than wild type mice. This implies that, at least in 
mice, MMP-9 and VEGF are less suitable serum biomarkers. 
 Ten-month-old mdx/utrn-/-/Xist∆hs mice expressing low dystrophin levels (median 4.3%) 
suffered from a more severe cardiomyopathy than mice expressing higher dystrophin levels 
(median 29.7%). This suggests that prolonged life span and functionality in these mice leads to a 
high workload for which the lower dystrophin levels in the heart can not entirely compensate. A 
small limitation of this experiment is that the scans only entirely covered the left ventricle, which 
was our main focus at initiation of the study. Interesting findings published on the right ventricle 
meanwhile encouraged us to also analyze this ventricle. Comparability was ensured by analyzing 
all scans in the same manner and exactly to the same height. However, as the top part of the right 
ventricle was not scanned and measured, this resulted in a lower cardiac output, and 
underestimation of end diastolic volume. This may also explain that in this study the left ventricle 
was more severely affected, while others have reported the opposite (Crisp et al. 2011;Verhaart et 
al. 2011).  
 It should be noted that mdx/utrn-/-/Xist∆hs mice have low dystrophin levels in a mosaic 
manner from birth onwards, protecting them during extensive cycles of regeneration and 
degeneration occurring early in life. Studies treating mdx/utrn-/- mice postnatally are limited to a 
starting age of at least 10 days (Goyenvalle et al. 2010;Goyenvalle et al. 2012;Kawano et al. 2008). 
Generally, dystrophin levels needed to improve life span exceeded 25% in these studies. We 
observe that 4-15% dystrophin not only greatly improves life span and muscle function, but also 
prevents histopathological damage. This indicates that, at least in mice, dystrophin restoration has 
larger protective effects when initialized very early after birth, or even before. Whether similar 
effects on disease pathology can also be expected for DMD patients is unknown.  
 To summarize, the mdx/utrn-/-/Xist∆hs mouse model described here expresses a range of 
low dystrophin levels in a utrophin negative background. Major improvement in life span and 
functional performance is obtained even with expression of <4% dystrophin, while further 
improvement in life span and performance as well as protection against muscle damage is 
achieved when >4% dystrophin is expressed. These data indicate that very low dystrophin levels, 
like they are currently generated in several therapeutic trials, may already have substantial 
beneficial effects in DMD patients, which is encouraging for therapies aiming at dystrophin 
restoration. Especially worth noting is the striking effect on survival. This is probably due to 
general effects on condition and resilience, which are not otherwise measurable so far. If this 
pertains to DMD in humans as well, extension of the life span may be amongst the main benefits 
of therapies currently in development. This puts special emphasis of the urgent need to develop 
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Fig. S1. Characterization of the mdx/utrn-/-/Xist∆hs mouse. (A). Transverse cross-section of the quadriceps stained with 
dystrophin that nicely co-localizes with β-dystroglycan, a member of the dystrophin-associated protein complex. (B). 
Mdx/utrn-/-/Xist∆hs mouse exhibiting severe kyphosis and malformations of the hips at the age of 17 months. Both 
phenotypical characteristics were developed later in life. This mouse was found dead at the age of 17 months, 
probably caused by respiratory or heart failure as body weight only slightly dropped in the week prior to death. This 
mouse expressed 3% dystrophin in the quadriceps. (C). Mdx/utrn-/-/Xist∆hs mouse exhibiting a minor degree of 
kyphosis and severe malformations of the hips at the age of 23.5 months, which was developed later in life. This 
mouse was sacrificed at the age of 24.5 months, after it slowly but progressively lost weight. The mouse expressed 
27% dystrophin in the quadriceps. (D). Representative pictures of a transverse cross-section of the heart stained with 
Collagen Type I from 10 months old mdx/utrn-/-/Xist∆hs mice with either <15% or >15% dystrophin, which resulted in 
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With several clinical trials ongoing aiming to restore dystrophin synthesis, more attention has 
been drawn to answering the most tempting question; how much dystrophin is needed to delay 
and/or prevent disease pathology and improve muscle function in DMD patients? The definite 
answer to this is rather complex as many factors need to be considered. This thesis covers many of 
these aspects, although several more still remain to be answered. 
 First of all, the amount of dystrophin needed depends on whether the newly 
synthesized dystrophin protein will be full-length, which might be achieved with e.g. stem cell 
therapy, or whether it is an internally truncated dystrophin obtained by e.g. gene therapy or 
AON-mediated exon skipping. In mice, full-length dystrophin is more effective than truncated 
dystrophin. Differences in efficacy between different truncated dystrophins are also expected, as 
the phenotype of BMD patients expressing different truncated dystrophin also varies between 
individuals.  
 Second, the way in which dystrophin will be expressed differs between the different 
types of treatment. Stem cell, PMO-mediated exon skipping and gene therapy result in 
dystrophin expression in a mosaic manner, whereas gentamycin administration and 2OMePS-
mediated exon skipping result in a more uniformly expressed dystrophin pattern. Additionally, 
although stem cell therapy results in fibers expressing dystrophin at wild type intensities, the 
other therapies will likely result in intensities that are significantly lower and that might differ 
from muscle to muscle. Both the type and levels of dystrophin expression largely influences its 
ability to protect fibers against pathology. Especially when dystrophin is expressed in a mosaic 
manner, the distribution of dystrophin within a fiber will probably largely influence its 
protective effect. Large dystrophin negative clusters might still be prone to injury and are likely 
to be replaced by either smaller dystrophin negative clusters or more homogenous dispersion. 
Nevertheless it seems that dystrophin positive fibers create a beneficial environment for 
dystrophin negative ones and thereby enhance their survival. There might however be a 
threshold to the number of dystrophin positive parts within a fiber needed to ensure such an 
environment. Interestingly, limited studies in mdx mice have shown that a uniform expression 
will probably protect fibers better than when similar amounts of total protein are expressed in a 
mosaic manner. Extensive studies addressing these issues are lacking. In the same line, it is also 
interesting to know how much dystrophin can migrate over the membrane away from its 
transcription side.  
The levels of dystrophin needed might also vary between different skeletal muscles. It is 
likely that slow fibers require less dystrophin than fast fibers to ensure protection against 
pathology. Likewise, muscles undergoing great workloads might be more demanding.  
So far, the heart appeared to be very challenging to target. Dystrophin restoration in 
skeletal muscle potentially results in higher activity levels in DMD patients, which subsequently 
increases the workload for the heart. As DMD patients already suffer from dilated 
cardiomyopathy this might worsen its progression. The few publications available on this topic 
showed that 50% of dystrophin is sufficient to prevent heart failure, but based on our study we 
know that levels <22% already improve heart function significantly. Others have shown that low 
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dystrophin levels in the diaphragm also partly prevent against heart failure in mice. With the 
studies described in this thesis and those performed by others more insight has been obtained 
regarding the protective effect of low dystrophin levels in several mouse models for DMD. So far, 
conclusions based on mouse studies show strong similarities with the limited amount of human 
case reports available and with results obtained from gentamycin upregulation. This indicates that 
results obtained in mice are probably useful in translation to conclusions with respect to the 
dystrophin levels needed in humans. It is however unknown which effect size in mice is needed 
(e.g. improvement of 30% in the hanging wire test) to obtain clinically relevant effects in DMD 
patients. It might be that specific improvements obtained with low dystrophin levels in mice do 
have a less benefit in the larger muscles of the human body. Undoubtedly, the timing of initiation 
of dystrophin expression will largely influence the efficacy of the therapy. Ongoing clinical trials 









Duchenne muscular dystrophy (DMD) is the most prevalent neuromuscular disorder, affecting 
1:4000 boys. The first symptoms, consisting of difficulties in running, climbing stairs and standing 
from the ground become apparent by the age of three. Loss of muscle fibers leads to wheelchair 
dependency from the age of 12 years onwards. Patients die due to respiratory and heart failure 
around the age of 30. Although symptomatic treatment has significantly improved life expectancy 
in the Western world, no therapy is available yet.  
DMD is caused by mutations in the DMD gene which encodes the protein dystrophin. 
Dystrophin forms a bridge between the sarcolemma and the extracellular matrix and provides 
stability to muscle fibers during contractions. In the absence of dystrophin, fibers are more prone 
to exercise-induced damage. This leads to continuous necrosis of muscle fibers which is 
compensated for by regeneration. Upon exhaustion of the regenerative capacity fibers are 
replaced by fibrotic and fat tissue, leading to a loss of muscle function.  
In healthy individuals the DMD gene transcribes dystrophin according to a reading 
frame in which three mRNA nucleotides contain information for one amino acid (THE DOG BIT 
THE CAT). Reading frame disrupting mutations, like those found in DMD patients, result in 
premature termination of protein synthesis (THE DOG BIT HEC AT). In-frame mutations result 
in transcription of a shortened, but functional protein as both begin and end regions are 
conserved (THE DOG BIT CAT). These mutations are present in Becker muscular dystrophy 
(BMD) patients, which express low levels of dystrophin that generally results in a milder 
phenotype.  
Using antisense oligonucleotides (AON) the disrupted reading frame in DMD patients 
can be restored, allowing synthesis of shorter but partly functional BMD-like dystrophin. At best, 
this and other clinical interventions result in the expression of low dystrophin levels. Fortunately, 
expression of wild type levels is not needed, as both humans and mice expressing ~50% of 
dystrophin do not show pathology. Even expression of ~30% of dystrophin has been found to 
result in a mild phenotype. Detailed studies on which levels of dystrophin are needed to increase 
muscle integrity, prevent muscle damage and improve muscle function have been performed in 
this thesis.  
 To do so we first had to set up good outcome measures. To assess motor 
function in mdx mice without interfering with the natural course of the disease a functional test 
regime consisting of four different functional tests was designed. In Chapter 2 we show that this 
type of exercise indeed did not interfere with disease pathology. Thereupon, we determined 
motor function in several mouse models for DMD (Chapter 3). We observed that motor function 
in mice that either did not express utrophin or in a monoallelic manner is significantly impaired 
compared to that of mdx mice. Additionally we identified MMP-9 and TIMP-1 as suitable serum 
biomarkers to monitor disease progression in both human and mouse samples (Chapter 4). Having 
good biomarkers is essential as patients need to be repeatedly treated with AONs whereas 
treatment efficacy cannot be determined on biopsies on a regular basis. 
These tools were further validated and used in two new innovative mouse models 
expressing low levels of dystrophin. The first model was generated by crossing mice with a 
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mutation in the Xist gene (Xist∆hs) with mdx mice. In female mdx-Xist∆hs embryos X-chromosomes 
that carried the mutated Xist gene but expressed intact dystrophin were preferably inactivated. 
This resulted in the expression of low dystrophin levels in a utrophin positive background 
(Chapter 5). We observed that dystrophin levels <15% already resulted in significantly improved 
muscle performance, while histopathology was largely prevented in mice expressing >15% 
dystrophin. Higher dystrophin levels (>22%) were needed to protect muscles from damage 
initiated by chronic treadmill exercise. So far, AON delivery to skeletal muscle is much easier to 
achieve than to the heart which appears to be a very difficult target. In mice, partly restored 
dystrophin expression in skeletal muscle increases voluntary activities thereby increasing the 
workload for the heart. The mdx-Xist∆hs mouse was used to study whether low dystrophin levels 
in heart can delay or prevent the onset of dilated cardiomyopathy (Chapter 6). Dystrophin levels 
between 3 and 21% already prevented the development of dilated cardiomyopathy in 10 months 
old dystrophic mice.  
Mdx mice are less severely affected than DMD patients due to over expression of the 
dystrophin homologue utrophin, which compensates for its absence. Mice lacking both proteins 
mimic the human phenotype and die before the age of 12 weeks. To determine the effect of low 
dystrophin levels in these mice mdx/utrn +/- mice were crossed with utrn -/- Xist∆hs mice (Chapter 
7). Again, based on skewed X-inactivation these mice expressed dystrophin levels <50%. In these 
mice, <10% dystrophin already significantly improved life expectancy and muscle function. To 
reduce histopathology >10% dystrophin was needed.  
 Based on these results it can be concluded that <10% dystrophin already improves the 
dystrophic phenotype to some extent, but >10% is needed to protect muscles from disease 
pathology. These findings are encouraging for ongoing and future clinical trails. 
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Samenvatting voor niet ingewijden 
 
 
Duchenne spierdystrofie (DMD) is de meest voorkomende neuromusculaire aandoening die 1 op 
de 4000 jongens treft. De eerste symptomen zijn zichtbaar vanaf het 3e levensjaar en omvatten 
moeite met rennen, traplopen en opstaan. Door verlies van spiervezels worden de jongens rond 
hun 12e rolstoelafhankelijk en overlijden ze rond hun 30e veelal als gevolg van ademhalings en 
hartfalen. Ondanks dat de levensverwachting in de Westerse wereld is gestegen door verbeterde 
zorg en in het bijzonder beademingsondersteuning, is er tot op heden geen therapie.  
DMD wordt veroorzaakt door mutaties in het DMD gen welke codeert voor het eiwit 
dystrofine. Dystrofine vormt een brug tussen het sarcolemma en de extracellulaire matrix en geef 
zo stabiliteit aan spiervezels tijdens contracties. In afwezigheid van dystrofine zijn deze 
vatbaarder voor schade tijdens beweging. Dit resulteert in een chronisch verlies van spiervezels 
wat tot op zekere hoogte wordt opgevangen door regeneratie. Wanneer de regeneratie capaciteit 
van de spier is uitgeput worden ze vervangen door bindweefsel en vet.  
In gezonde personen wordt het DMD gen afgeschreven volgens een leesraam waarbij 
elke drie mRNA bouwstenen de informatie bevatten voor één aminozuur (LEO EET EEN KIP). 
DMD patiënten hebben mutaties die het leesraam vertoren wat leidt tot een voortijdige stop van 
de eiwit synthese (LEO EET ENK IP). Mutaties waarbij het leesraam intact blijft, zoals die bij 
Becker spierdystrofie (BMD) patiënten, resulteren in de synthese van een kleiner maar 
functioneel eiwit gezien zowel het begin als eind van het eiwit aanwezig is (LEO EET KIP). BMD 
patiënten brengen kleine hoeveelheden dystrofine tot expressie en zijn daardoor minder ernstig 
aangedaan.  
In DMD patiënten kan met behulp van antisense oligonucleotiden (AON) het leesraam 
worden hersteld waardoor een korter maar deels functioneel Becker-achtig dystrofine wordt 
aangemaakt. Hoogstwaarschijnlijk zullen deze en andere klinische interventies niet resulteren in 
het herstel van dystrofine expressie op wild type niveau. Gelukkig is dat waarschijnlijk ook niet 
nodig gezien zowel mensen als muizen die ~50% dystrofine tot expressie brengen niet zijn 
aangedaan. Op basis van een case report is het bekend dat zelfs 30% dystrofine kan leiden tot een 
mild fenotype. Gedetailleerde studies naar welke hoeveelheden dystrofine leiden tot verbeterde 
spier integriteit, bescherming tegen spierschade en verbetering van spierfunctie zijn beschreven 
in dit proefschrift.  
Allereerst hebben we een functioneel test regime opgezet bestaande uit vier functionele 
testen om spierfunctie in mdx muizen te bepalen zonder daarbij het natuurlijk ziektebeloop te 
beïnvloeden (Hoofdstuk 2). Met behulp hiervan hebben we de spierfunctie van verschillende 
muismodellen voor DMD bepaald (Hoofdstuk 3). We zagen dat de spierfunctie van muizen die 
geen utrofine tot expressie brengen of op één allel een significant slechtere spierfunctie hebben in 
vergelijking tot mdx muizen. Daarnaast hebben we bewezen dat MMP-9 en TIMP-1 geschikte 
serum biomarkers zijn om het ziektebeloop in mens en muis te bepalen (Hoofdstuk 4). Gezien 
patiënten herhaaldelijk moeten worden behandeld met AONs en het effect van behandeling niet 




Zowel het functionele test regime als de serum biomarkers werden vervolgens 
gevalideerd en gebruikt in twee nieuwe innovatieve muis modellen die lage hoeveelheden 
dystrofine tot expressie brengen. Het eerste model werd gegenereerd door muizen met een 
mutatie in het Xist gen (Xist∆hs) te kruizen met mdx muizen. In de vrouwelijke mdx-Xist∆hs 
embryo’s werd voornamelijk het X-chromosoom geïnactiveerd dat het gemuteerde Xist gen 
bevatte, maar dat intact dystrofine tot expressie bracht. Dit resulteerde in expressie van een laag 
percentage dystrofine in een utrofine positieve achtergrond (Hoofdstuk 5). We zagen dat 
spierfunctie significant verbeterde in muizen met <15% dystrofine, terwijl histopathologie sterk 
afnam bij >15% dystrofine. Meer dystrofine (>22%) is nodig om spieren te beschermen tegen 
schade die wordt geïnduceerd door blootstelling aan rennen op een loopband op een chronische 
basis. Hoewel AONs succesvol opgenomen worden door skeletspieren blijkt het hart moeilijker te 
behandelen. Deels herstelde dystrofine expressie in skeletspieren verhoogt vrijwillige activiteit in 
muizen wat voor een grotere belasting voor het hart zorgt. In mdx-Xist∆hs muizen werd bepaald of 
lage hoeveelheden dystrofine in het hart het ontstaan van gedilateerde cardiomyopathie kan 
uitstellen of zelfs voorkomen (Hoofdstuk 6). Tussen de 3 en 21% dystrofine was al afdoende om 
gedilateerde cardiomyopathie te voorkomen op een leeftijd van 10 maanden.  
Mdx muizen zijn veel minder ernstig aangedaan dan DMD patiënten doordat zij de 
dystrofine homoloog utrofine tot overexpressie brengen, wat compenseert voor de afwezigheid 
van dystrofine. Muizen die beide eiwitten missen hebben een vergelijkbaar fenotype als DMD 
patiënten en sterven al voor ze de leeftijd van 12 weken bereiken. Om te bepalen wat het effect 
van lage hoeveelheden dystrofine in deze muizen is hebben we mdx/utrn +/- muizen gekruist met 
utrn -/- Xist∆hs muizen (Hoofdstuk 7). Ook bij deze muizen resulteert niet-random X-inactivatie in 
dystrofine levels van <50%. We observeerden dat <10% dystrofine levensverwachting en 
spierfunctie verbeterd in deze muizen. Om histopathologie te verbeteren was >10% dystrofine 
nodig.  
Gebaseerd op deze resultaten kan worden geconcludeerd dat <10% dystrofine het 
fenotype al tot op zekere hoogte verbeterd. Echter is >10% dystrofine noodzakelijk om spieren te 
beschermen tegen pathologie. Deze bevindingen zijn zeer bemoedigend voor gaande en 
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